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Abstract 
The last major study of causes of vision loss in 600 eyes with uveitis was published over 10 years ago 
and there have been many advances in treatment over this time. In this thesis I undertook a study of 
1594 patients (2593 eyes) with uveitis currently attending the clinic, 75% of whom were aged 
between 24 and 63 years. The type of uveitis, sight threatening complications that developed and 
treatment were followed from presentation to final follow up.  At presentation, 16% of eyes had 
BCVA ≤ 6/18 (e.g. 6/18-6/36) and 14% of affected eyes had BCVA 6/60 or worse. At one year follow-
up, we found 11% of eyes with vision loss to 6/18-6/36 and 8% of eyes with severe visual loss or 
blindness. In the group of eyes followed up for 10 years or more, 19% developed severe visual loss 
or blindness and 16% developed vision loss to 6/18-6/36. Chronic macular damage was the main 
cause of visual loss, accounting for both for visual impairment and for severe visual loss, accounting 
for 41% and 36% respectively. Cystoid macular oedema accounted for 29% in visual impairment and 
19% in severe visual loss or blindness. When classified by uveitis types, CMO was the main cause of 
vision loss in intermediate uveitis (38%), glaucoma was the leading cause in anterior uveitis (32%), 
and chronic macular damage accounted for 46.3% in panuveitis and 58.8% in posterior uveitis.  
Additionally, I looked at the outcome and subsequent impact on vision of ocular surgery for cataract, 
glaucoma and vitreo-retinal procedures. Visual prognosis after cataract surgery was favourable in 
anterior and intermediate uveitis. Eyes which underwent glaucoma surgery had vision stabilised or 
slightly improved over time. The mean log MAR BCVA prior to glaucoma surgery was 0.53+/- 60, and 
0.31+/- 49 at final follow-up visit. (P= 0.012). There was no statistically significant improvement in 
visual acuity in eyes which had undergone vitreo-retinal procedures. The mean logMAR BCVA were 
1.1+/-0.82 and 0.87+/-0.80 respectively pre-operative and at last post- op visit. (P=0.28)  
The 3rd main results chapter looks at patients presenting with retinal vasculitis who had ischemia 
and the long term outcome for these eyes. Of the 106 eyes which developed ischemia, 24% had 
vision loss to 6/18-6/36 at presentation, 23% of these had BCVA 6/60 or worse. Chronic macular 
damage was the main cause of visual impairment and accounted for 36%, macular ischemia 
accounted for 67% of severe visual loss or blindness. I found that in most eyes with ischemia, visual 
loss developed early in the first 5 years and do not worsen with time.  
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NPE: Non-pigmented ciliary epithelium. 
NVD: Neovascularisation disc. 
NVE: Neovascularisation elsewhere. 
OCT: Optical coherence tomography. 
OHT: Ocular hypertension. 
OS: Outer segment. 
OT: Ocular toxoplasmosis. 
oxLDL: Oxidized-low-density lipoprotein. 
P-ANCA: Perinuclear antineutrophil cytoplasmic antibodies. 
PAMPs: Pathogen-associated molecular patterns 
Panu: Panuveitis. 
PAS: Peripheral anterior synechiae. 
PBMC: Peripheral blood monocyte cells. 
PCNSL: Primary CNS lymphoma. 
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PCR: Polymerase chain reaction. 
PE: Pigmented ciliary epithelial layer. 
PIC:   Punctate Inner Choroidopathy. 
PMNs: Polymorphonuclear cells. 
PSCLO: Posterior subcapsular lens opacification. 
Pu: Posterior uveitis. 
RANTES: Regulated on action normal t-Expressed and secreted. 
RD: Retinal detachment. 
RFNL: Retinal fibre nerve layer. 
ROS: Rod outer segment. 
RPE: Retinal pigment epithelium. 
RPPP: Retinal pigment epithelial protective protein. 
SACE: Serum angiotensin Converting-Enzyme. 
SC: Serpiginous choroidopathy. 
SCE: Stiles-Crawford effect. 
SD-OCT: Spectral domain optical coherence tomography. 
SIJ: Sacroiliac joint. 
SLE: Systemic lupus erythematous. 
SO: Sympathetic ophthlamia. 
SOD: Superoxide dismutase. 
SpA: Spondyloarthritis. 
SUN: Standardization of uveitis nomenclature. 
TB: Tuberculosis. 
TCRs: T-Cell receptors. 
TD-OCT: Time domain optical coherence tomography.  
TIGR: Trabecular meshwork-inducible glucocorticoid response. 
TINU: Tubulointerstitial nephritis syndrome. 
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TLRs: Toll-like receptors. 
TM: Trabecular meshwork. 
TNF: Tumour necrosis factor. 
UBM: Ultrasound biomicroscopy. 
VA: Visual acuity. 
VEGF: Vascular endothelial growth factor. 
VMT: Vitreomacular traction syndrome. 
VKH: Vogt-Koyanagi-Harada syndrome. 
WDs: White dots syndromes. 
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Chapter 1: Introduction 
1.1 Anatomy of the eye 
 
The eyeball is not a simple sphere but can be viewed as the result of fusing a small portion of a small, 
strongly curved sphere with a large portion of a large, not so strongly curved sphere (Figure 1.1). The 
small piece, occupying about one-sixth of the whole, has a radius of 8 mm (0.3 inch); it is transparent 
and is called the cornea; the remainder, the scleral segment, is opaque and has a radius of 12 mm 
(0.5 inch). The ring where the two areas join is called the limbus. Thus, on looking directly into the 
eye from in front one sees the white sclera surrounding the cornea; because the latter is transparent 
one sees, instead of the cornea, a ring of tissue lying within the eye, the iris. The iris is the structure 
that determines the colour of the eye. The centre of this ring is called the pupil [1].   The 
dimensions of the eye are reasonably constant, varying among normal individuals by only a 
millimetre or two; the sagittal (vertical) diameter is about 24 mm (about one inch) and is usually less 
than the transverse diameter. At birth the sagittal diameter is about 16 to 17 mm (about 0.65 inch); 
it increases rapidly to about 22.5 to 23 mm (about 0.89 inch) by the age of three years; between 
three and 13 the globe attains its full size. The eye is made up of three coats, which enclose the 
optically clear aqueous humour, lens, and vitreous body (Fig.1.1). The outermost coat consists of the 
cornea and the sclera; the middle coat (the uvea) contains the main blood supply to the eye and 
consists, from the back forward, of the choroid, the ciliary body, and the iris. The innermost layer is 
the retina, lying on the choroid and receiving most of its nourishment from the vessels within the 
choroid, the remainder of its nourishment being derived from the retinal vessels that lie on its 
surface[1].  
 
Figure 1.1 Anatomy of the eye.
  Introduction 
 
 
25 
 The ciliary body and iris have a very thin covering, the ciliary epithelium and posterior 
epithelium of the iris, which is continuous with the retina. 
Within the cavities formed by this triple-layered coat there are the crystalline lens, suspended by 
fine transparent fibres-the suspensory ligament or zonule of Zinn-from the ciliary body; the aqueous 
humour, a clear fluid filling the spaces between the cornea and the lens and iris; and the vitreous 
body, a clear jelly filling the much larger cavity enclosed by the sclera, the ciliary body, and the lens. 
The anterior chamber of the eye is defined as the space between the cornea and the forward 
surfaces of the iris and lens, while the posterior chamber is the much smaller space between the 
rear surface of the iris and the ciliary body, zonule, and lens; the two chambers both contain 
aqueous humour and are in connection through the pupil. 
1.1.1 The uvea. 
 
 The uvea is the vascular tissue surrounding the eye, lying between the corneoscleral shell 
externally and the retina internally (Fig.1.1). It consists of three basic parts: the Iris, the ciliary body 
and the choroid [2].           The functions of 
the uvea include pupillary reactions, the formation of aqueous fluid and the supply of nutrition to 
the eye. It also plays an important role in the immunological defence mechanisms of the eye [3].   
The iris is made up of three layers. A compact arrangement of fibroblasts, melanocytes, and collagen 
constitute the anterior and most superficial layer which terminates at the iris root peripherally, 
except where spokelike extensions continue to Schwalbe’s line. The stroma (middle layer) consists of 
pigmented and nonpigmented cells in a loose extracellular matrix of collagen and 
mucoplysaccharides. It also contains a rich supply of blood vessels and nerves as well as the iris 
sphincter muscle. The dilator muscle made of smooth muscle fibres and the pigment epithelium 
composed of two layers apposed to each other apex to apex constitute the posterior layers of the 
iris [4]. 
The ciliary body extends from the iris anteriorly to the ora serrata posteriorly and is divided into two 
parts: The anterior portion (pars plicata or corona ciliaris) made of 70-80 meridional process that 
secrete aqueous and the posterior portion (pars plana or orbiculus ciliaris) measuring 3.5-4mm in 
length. The ciliary body contains two epithelial layers: the nonpigmented epithelium (NPE) which is 
the continuation of the neurosensory retina anteriorly, and the pigmented epithelium (PE) which is 
an extension of the retinal pigment epithelium. The NPE in the pars plana region is thought to be 
responsible of the acid mucopolyssaccharide component of vitreous, while it is responsible for the 
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secretion of aqueous in the anterior portion [5]. The capillaries within the ciliary process are 
fenestrated. Thus the primary component of the blood-aqueous barrier is the zonula occludens at 
the apical aspect of the NPE [6].  
The choroid has a blood flow that is comparable only to that of the kidney. Therefore systemic 
influences can be assumed to rapidly affect this portion of the eye. Hence, the large blood flow and 
its anatomy act as a sort of trap for many blood-borne problems, most notably metastatic fungal 
disorders. Indeed most fungal lesions begin as a choroiditis [7]. It has the capacity to function as a 
repository for immunoreactive cells, in the extreme taking on the anatomic structure of a lymph 
node (lymphoid hyperplasia). Therefore this organ can be the centre for profound immune 
responses. The high concentration of mast cells in the choroid may be one mechanism by which 
immunoreactive cells could spread to other parts of the eye. The mast cell’s release of 
immunoreactive factors could help T-cells egress and ingress from this compartment[8].    
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1.1.2 The Retina 
 
 The retina is the tissue layer that converts light into visual signals transmitted to the brain. 
This process is carried out by two major types of photoreceptors, rods and cones that are 
distinguished by their shape, type of photopigment, retinal distribution, and pattern of synaptic 
connections [9] (Fig.1.2). Photoreceptors consist of four major compartments: a photosensitive 
outer segment containing highly packed disc membranes and the proteins required to initiate a 
response to light, an inner segment (IS) where proteins and lipids are synthesised and energy 
produced, a nuclear region, and a synaptic terminal that sends information to the second order 
neurons in the retina [10]. The different architectures of photoreceptors’ outer segments (OS) 
represent a major distinctive feature of these two cell types. Rods with their longer OS composed of 
individualised discs unconnected to the ciliary plasma membrane contrast starkly with cones. The 
latter features shorter OS that arise initially as invaginations with subsequent formation of a series 
of discs (or invaginations), which are continuously connected to the membrane of the cilium that 
extends over the length of the OS. Lack of rim formation is the reason for this open formation of 
cone discs.[11]  A striking difference between rod and cone circuitry is the degree of convergence. 
Each rod bipolar cell is contacted by a number of rods, and many rod bipolar cells contact a given 
amacrine cell (Fig.1.2). In contrast, the cone system is much less convergent. Thus, each retinal 
ganglion cell that dominates central vision receives input from only one cone bipolar cell, which in 
turn, is contacted by only a single cone. More convergence makes the rod system better detector of 
light, because small signals from many rods are pooled to generate a large response in the bipolar 
cell. However, such convergence also reduces the spatial resolution of the rod system. The one-to-
one relationship of cones to bipolar and ganglion cells is just what is required to maximize visual 
acuity [9]. Proper functioning of photoreceptor cells requires a delicate balance of proteins, lipids, 
and metabolites, which, if disturbed, can lead to retinal degeneration. To prevent the toxic effects of 
accumulated photo-oxidative products, photoreceptor cells undergo a daily renewal process 
wherein ~10% of their volume is shed and subsequently phagocyted by adjacent RPE. To maintain a 
relatively constant length, the photoreceptor OS basally regenerates roughly the same volume of 
cellular material each day [12].    
The ganglion cell layer is constituted of at least three major classes of neurons. The smallest midget 
ganglion cells comprise approximately 80% of these neurons, and the larger parasol ganglion cells 
approximately 10%. The axons of the ganglion cells constitute the nerve fibre layer (NFL). Exiting the 
eye at the optic disc, these axons form the optic nerve (the second cranial nerve) and synapse in the 
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midbrain. The whitish appearance of the optic nerve head is due to the myelin sheath that covers 
these axons as they leave the eye[13].  Within the central area, ganglion cell densities reach 32,000-
38,000 cells/mm2 in a horizontally oriented elliptical ring 0.4-2.0 mm from the foveal centre. In 
peripheral retina, densities in nasal retina exceed those at corresponding eccentricities in temporal 
retina by more than 300%; superior exceeds inferior by 60%[14]. 
The RPE is a monolayer of cells that perform many functions vital for retinal preservation [15-17]. 
The apical membrane of the RPE lies adjacent to the OS of photoreceptor cells, whereas basolateral 
membrane contacts the Bruch’s membrane [18].    The retina is 
exposed to high levels of light throughout the day, which, if unabated could lead to damaging photo-
oxidative reactions and ultimately to retinal degeneration. The RPE has evolved several strategies to 
prevent these noxious effects. Light filtration by the RPE pigments functions as a preventive 
mechanism against photo-oxidation, high levels of antioxidants expedite either enzymatic or non-
enzymatic removal of resulting chemically reactive species, and RPE cells also can repair 
considerable damage to DNA, proteins , and lipids. In addition to its role as a protective barrier, the 
RPE transports nutrients and ions between the retina and the choriocapillaris. The RPE conveys new 
retinoids from the bloodstream and is absolutely required for the regeneration of 11-cis-retinal in a 
process referred to as “visual cycle” [19, 20]. Lipofuscin is an autofluorescent cellular waste product 
that cannot be degraded or removed from cells. Lipofuscin in the retina, formed from the 
condensation of two molecules of all-transretinal and one molecule of phosphatidylethanolamine, is 
believed to accumulate because of incomplete digestion of OS in the RPE [21, 22]. Once in the RPE, 
lipofuscin is converted to the photo-inducible free-radical generator A2E, a pyridinium bisretinoid 
toxic to RPE cells. Because RPE cells are post mitotic, they cannot dilute A2E by simple cellular 
division, so progressive build-up of A2E occurs within the cell. Indeed, one damaging effect of A2E is 
inhibition of phagolysosomal degradation of OS by the RPE [23, 24]. Additionally, oxidized low-
density lipoproteins (oxLDL) inhibit the breakdown of OS in the RPE by delaying the maturation of 
RPE phagosomes [25, 26]. OS renewal is a tightly regulated process, with the RPE challenged daily by 
a new batch of phagocytised OS. Breakdown in the ability of this cell layer to efficiently degrade 
these products would eventually lead to a build-up of undigested lipids and proteins within the RPE, 
resulting in further production of compounds like A2E. Such excessive accumulation of photo-
oxidized products in the RPE is believed to be an underlying cause of degenerative retinal diseases 
such as age-related macular degeneration. However, an alternative hypothesis is that all-trans-
retinal is a toxin, whereas A2E represents a product of de-toxification [27].  It has been estimated 
that each RPE cell phagocytes hundreds of thousands of OS discs over a human lifetime. Retinal 
health requires important interactions between photoreceptors cells, responsible for collecting and 
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processing visual stimuli, and the retinal pigment epithelium [12].    
 It is established that the human visual system presents a higher sensitivity to light beams 
entering the eye near the centre of the pupil than to those entering near the edge of the pupil. This 
effect is known as the Stiles-Crawford effect of the first kind (SCE I) [28]. The outermost aspect of a 
photoreceptor, the outer segment, contains a photo pigment that absorbs light, converting it into 
electrical activity. Outer segments form a distinct retinal layer. Photoreceptor inner segments, which 
contain many of the organelles of these cells, excluding their nuclei, also constitute a distinct retinal 
layer. Rods and cones synapse on retinal bipolar cells, which feed into retinal ganglion cells. This 
photoreceptor → bipolar cell→ ganglion cell arrangement reflects the feed forward or centripetal 
nature of retinal organization[13]. There are also lateral interconnections that provide for the 
horizontal transmission of retinal information. In addition to the feed forward and lateral 
interconnections, there is feedback transmission of information[13].         A 
vascular network covers the retina, except in what is referred to as the foveal avascular zone, a 
region that is larger than the foveola, but smaller than the fovea. This adaptation prevents the 
scattering of light by retinal vessels, maximizing visual resolution provided by the fovea. Metabolic 
nourishment for (and nonfoveal) cones is provided by the choroid[13].  
 
Figure 1.2 Photoreceptors arrangement in the retina[9]  
Rod and cone photoreceptors are displayed in a cross-sectional depiction of the retina also showing 
connections of these photoreceptors to retinal pigment epithelium distally and relaying cells 
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(bipolar, horizontal, amacrine, ganglion) proximally. Electron microscopic images are shown of a ROS 
(A) and a COS (B). 
The rod structure has a longer outer segment with discs packed without connections to the ciliary 
membrane, in stark contrast to the COS discs that are continuously connected by the ciliary 
membrane. 
Temporal to the optic disc is the fovea, a specialized retinal region of highly developed visual acuity. 
A number of anatomical features distinguish the fovea. To maximize vision, neural elements of the 
inner retina are pushed aside to allow light to fall directly on the photopigment-containing outer 
segments of cones. This creates a depression or pit with gently sloping borders that is approximately 
5 degrees in diameter, approximately the same size as the optic disc. (Figure1.3) The bottom of the 
pit, the foveola, subtends a visual angle of approximately 1.2 degrees. Cones are the only 
photoreceptors found in the foveola, where they have a density greater than in any other region of 
the retina. 
 
Figure 1.3 OCT showing normal foveal pit. 
 The mechanism of photoreceptor alignment remains a question without definite answer. 
The common hypothesis is that this alignment is governed by a phototropic mechanism that actively 
orients the photoreceptors’ axes toward a point close to the pupil centre [29]. Eckmiller et al. [30] 
proposed a model for photoreceptor alignment whereby light absorption in the outer segment (OS) 
causes fast membrane and slower cytoplasmic changes that spread from the OS to the myoid, where 
thy activate feedback-controlled motor functions by cytoskeletal elements (microtubules and 
microfilaments) to produce a differential local bending that adjusts photoreceptor orientation. 
Marcos and Burns proposed the alternative hypothesis that the eye’s optics and photoreceptors 
could act as an optimal instrument. They measured the wavefront aberrations and cone 
directionality function in 24 eyes of 12 subjects and found that although for some eyes the 
maximum of cone directionality corresponded to the pupil area of best optical quality, this was not 
general rule. They concluded that in general the ocular optics and cone alignment do not develop 
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toward an optimal optical design [31].       
 Using a high-resolution adaptative optics scanning laser ophthalmoscope, Chui et 
al.[32]demonstrated that in terms of cones per square millimetre, there is a systematic decrease in 
cone packing density with increasing axial length. They found that cone photoreceptor packing 
density was significantly lower in myopic eyes than in emmetropic eyes. The density decreased from 
27,712 cells/mm2 to 7,070 cells/mm2 from a retinal excentricity of 0.30 to 3.40 mm along the 
superior meridian, although more than 20% of the variance could be accounted for by differences in 
axial length.  
 
Figure 1.4  Distribution of photoreceptors in the eye [9]. 
Overall, rods outnumber cones by a ratio of 20:1 in the retina. However, in the fovea, the cone 
density is the highest and is correlated with visual acuity. 
1.1.3 Ocular barriers. 
 
 The blood- ocular barrier system separates the interior portion of the eye from the blood 
entering the eye. (Fig.1.5). Of the two blood-ocular barriers, the blood-aqueous barrier (BAB) 
regulates exchanges between the circulating blood and the aqueous humour, and the blood-retina 
barrier (BRB) regulates exchanges between the circulating blood and the neural retina [33]. At the 
blood-ocular barriers, unique distribution of plasma membrane transporters is required  to 
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efficiently supply nutrients to the interior portion of the eye and remove endobiotics and 
xenobiotics from the same interior portion [34].     
The BAB is closely associated with the secretion of aqueous humour. The regulatory role of the BAB 
is mainly controlled by the ciliary epithelial bilayer consisting of the pigmented ciliary epithelial (PE) 
layer facing the ciliary stroma and the non-pigmented ciliary epithelial (NPE) layer facing the 
aqueous humour [33]. Neighbouring cells between the PE and NPE layers are coupled by 
intercellular gap junctions, thereby, forming a functional syncytium[35]. 
The BRB plays a primary role in providing a controlled environment of the neural retina, which 
underpins highly regulated neurotransmission. The retina has two areas of interaction with the 
blood circulation and thus the BRB consists of two parts, the inner and the outer BRB (Figure 4). The 
blood supply to the inner two-thirds of the retina comes from the retinal circulation. The choroidal 
circulation nourishes the outer third of the retina [36]. Unlike retinal capillaries, the vasculature of 
the choroid has a high blood flow and leaky walls [37]. 
Because of the continuous diffusional exchanges between blood, ocular tissues, and intraocular 
fluids, almost any condition that affects the eye or has a marked effect on the blood composition or 
flow can be expected to have some influence on the blood-ocular barrier system and on the 
composition of the intraocular fluids [33]. One of the main reasons for the existence of the entire 
blood-ocular barrier system is to preserve and protect retinal function. It keeps the retina 
dehydrated in order to maintain its transparency to light. The consequences to the eye of a 
breakdown of the blood-ocular barrier system are many, depending on the location of the 
breakdown and the structure involved. Relatively minimal alterations of the BRB may result in a 
abnormal passage of fluids into the retinal extracellular space and cause retinal oedema, hence lead 
to visual impairment [33]. 
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Figure 1.5 Schematic representation of blood-ocular barrier system and aqueous flow. [34] 
 The interior portion of the eye is separated from the circulating blood by two blood-ocular 
barriers systems, the BAB and BRB. The BAB consists of ciliary NPE cells and iridial capillary 
endothelial cells. The BRB consists of retinal capillary endothelial cells (inner BRB) and RPE cells 
(outer BRB). The aqueous humour is secreted through ciliary NPE cells into the posterior chamber, 
passes through the pupil into the anterior chamber and then spreads peripherally toward the angle 
of the anterior chamber. Aqueous humour is mostly drained from the anterior chamber angle either 
through the trabecular meshwork into the Schlemm’s canal and aqueous veins (conventional 
pathway) or through the ciliary muscle into the suprachoroidal space (unconventional pathway). A 
part of the aqueous humour is cleared by passing through the vitreous humour and the retina. [28]. 
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1.2  Pathophysiology of uveitis 
 
 Uveitis refers to the inflammation of the uvea. It comprises a very diverse group of entities 
resulting from a variety of causes. This inflammation may lead to significant visual loss [38]. 
Inflammatory diseases of the eye were known to the ancients, but only recently have the underlying 
mechanisms to this problem become better defined. During the middle portion of the last century, 
most cases of uveitis were thought to be caused by infectious agents, such as those responsible for 
syphilis and tuberculosis. Since then, it has become clear that endogenous mechanisms of immune-
modulation play an important role in these disorders, which along with the environmental and 
genetic factors make up an important triad [2].              
It is now established that ocular inflammation is mediated by activated CD4+ T cells.     These cells 
play a central role in the immunogenic mechanisms. When infiltrating the eye, they are harmful to 
vision-related cells and tissues and cause sight threatening conditions [39]. However, the eye has a 
unique regional immune system which protects intraocular tissues from these pathogenic activated 
CD4+ T cells and contributes to the homeostasis of the intraocular microenvironment [40]. The eye is 
an excellent example of immune privilege site. This organ enjoys immune privilege to protect it from 
destructive inflammation that may impair vision [41]. The ocular microenvironment is both 
immunosuppressive and anti-inflammatory. Cultured ocular pigmented epithelium (PE) cells from 
the iris, ciliary body, and retina can individually suppress T-cells activation via mechanisms that 
partially overlap [42]. The blood-retina barrier and a special feature named anterior chamber 
associated immune deviation (ACAID) constitute the immune privilege mechanism which protects 
the eye from destructive effects of an intraocular cell mediated immune process. These special 
defence mechanisms contribute to the preservation of vision[43]. Also, we know that the ocular 
microenvironment is rich with immunosuppressive molecules that influence the activity of immune 
cells. Many soluble immunomodulators are found in aqueous humour, and are a mixture of growth 
factors, cytokines, neuropeptides, and soluble receptors. The mechanisms of ocular immune 
privilege induce apoptosis, promote the production of anti-inflammatory cytokines, and mediate the 
activation of antigen-specific regulatory immunity. These mechanisms of immune privilege also 
attempt to impose themselves upon immunity within the uveitic eye [44].         
It is generally assumed that this property is severely compromised or eliminated when the 
inflammation is present within the eye [43]. Tissue damage in uveitis is caused by various chemical 
mediators derived from either plasma proteins or inflammatory phagocytic 
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cells, Polymorphonuclear cells (PMNs), and macrophages. These mediators include arachidonic acid 
metabolites, proteolytic enzymes, and possibly oxygen metabolites [45]. 
In addition to the uveitogenic antigens resident in its layers, the retina, being an “extension of the 
brain”, makes it particularly prone to certain neurotropic organisms. Examples include Toxoplasma 
gondii and many viruses of the herpes family, which \have the propensity for central nervous system 
tissue. It is also important to remember that under normal circumstances the retinal vasculature has 
tight junctions; thus it is being impermeable to many molecules. Any perturbation, such as an 
inflammatory one, that alters this permeability can result in a profound change in retinal 
functioning.  It is interesting to speculate that because the retina maintains a high degree of 
oxidative metabolism, the potential for the generation of oxygen radicals may lead to 
autotoxicity[8].  Reactive oxygen metabolites (oxygen free radicals) released by PMNs and 
macrophages are believed to play an important role during initial phase of inflammation [46],[47]. 
These free radicals are found to be potent cytotoxic agents that readily cause tissue damage by 
peroxidation of lipid cell membranes. Recent studies of experimental uveitis indicate that other 
potent oxidants are generated in uveitis by macrophages[48]. One of these is ONOO-, which is 
formed from *NO preferentially in the outer retina following iNOS expression. In these phagocytes, 
outer retinal proteins, especially arrestin are found to be iNOS inducers. Current studies of RPE show 
that these cells protect the retina from ONOO- mediated damage in uveitis by releasing a novel 
protein called retinal pigment epithelial protective protein (RPPP). This protein is found to suppress 
O(-)2 and *NO generation by the phagocytes, both in vitro and in vivo uveitis models [48]. The pro-
inflammatory cytokines interleukin (IL)-1beta, IL-2, IL-6, interferon-gamma and tumour necrosis 
factor-alpha have all been detected within the ocular fluids or tissues in the inflamed eye together 
with others, such as IL-4, IL-5, IL-10 and transforming growth factor-beta. The chemokines IL-8, 
monocyte chemoattractant protein-1, macrophage inflammatory protein (MIP)-1alpha, MIP-1beta 
and fractalkine are also thought to be involved in the associated inflammatory response [49]. 
Determining the levels of IL-2, -4, -5, -10, TNF-alpha, and IFN-gamma in aqueous humour from 
patients with panuveitis and anterior uveitis, Ooi et al.[50]found that IFN-gamma is elevated in 
active uveitis and IL-5 is decreased in posterior. Perez et al.[51]reported elevated IL-6 in the vitreous 
of patients with active intermediate and posterior uveitis. Cytokines in aqueous humour of infectious 
uveitis are locally produced, whereas in non-infectious uveitis, IFN-gamma is produced both in the 
eye and the peripheral blood [52]. IL-6 is responsible for causing ocular inflammation, and it is, at 
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least partially due to IL-6-dependent Th17 differentiation, a recently discovered IL-17 producing 
helper CD4+ T-cell subset [53, 54]. 
Th-17 constitutes a Th cell lineage distinct from Th1 and Th2 cells, and plays a crucial role in several 
autoimmune diseases by mediating tissue inflammation [55]. 
IL-17 stimulates IL-17R-expressing cells, and these cells in turn induce the secretion of IL-6, IL-8, 
PGE2, MCP-1 and G-CSF, causing chronic inflammation [56]. 
IL-23 has been reported to be responsible for TH17 expansion and crucial for development of 
autoimmune inflammatory diseases [57, 58]. 
 New studies comparing cells in ocular fluids taken from inflamed eyes with different types 
have shown a difference in the cytokine profile, so that in visually benign disease interleukin 10 
levels are higher than in those which are blinding [59]. Verma et al.[60] found that the concentration 
of chemokines: IL-8, interferon-inducible protein 10(IP-10), monocyte chemoattractant 
protein(MCP-1), regulated on activation, normal T-expressed and secreted (RANTES) and 
macrophage inflammatory protein-1 beta (MIP-1 beta) were significantly increased during the active 
stages of AU, and correlated with the clinical severity of the disease. These chemo-attractant 
cytokines probably play a critical role in leukocyte recruitment in acute AU.    
 Macrophage migration inhibitory factor (MIF) was originally discovered as a T lymphocyte 
derived factor to inhibit macrophage migration [61]. This pro-inflammatory pituitary and 
macrophage cytokine is capable of overcoming glucocorticoid mediated inhibition of cytokines, such 
as tumour necrosis factor α (TNF-α), interleukin (IL)-1ß, IL-6, IL-8, and interferon ɤ (IFN-ɤ) [62, 63]. 
Although the function of MIF in the eye has not been well studied, Apte et al.[64]demonstrated that 
MIF shared more than 90% homology with the factor in the aqueous humour which inhibited natural 
killer (NK) cell mediated lysis of corneal endothelial cells. In patients with uveitis, serum levels of MIF 
were significantly higher than those in healthy control [65]. Evidences from the work byTaguchi et 
al.[66]show that aqueous humour and vitreous fluid of patients with uveitis contained significant 
levels of MIF, and these levels correlated with activity of intraocular inflammation. The authors 
suggested that intraocular infiltrating cells are upregulated much more actively than PBMC in terms 
of the capacity to produce MIF.            
 The explanation for why some patients develop chronic uveitis whereas others have a 
recurrent self-limiting type of uveitis is unknown. The development of chronicity is not due to 
inadequate treatment, is unrelated to HLA-B27 and it is likely that host factors are important 
determinants. Patients with chronic anterior uveitis (CAU) vary in their clinical phenotype. Some 
develop complications such as cataract, glaucoma and cystoid macular oedema, but others do not 
[67]. Idiopathic acute anterior uveitis (AAU), in which there is often a severe inflammatory response 
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in the anterior chamber is the most common type that occurs in the general population. The 
disease’s severity and course vary between individuals, and some patients have ocular complications 
that can threaten sight [68].  Neutrophil gelatinase-B associated lipocalin (Lcn2/NGAL or NGAL) is a 
21-kD protein of the lipocalin superfamily. NGAL is siderophore-binding antimicrobial protein that is 
upregulated in epithelial tissues during inflammation and seems to play an important role in this 
process [69]. This protein plays a cytoprotective role by transporting iron into cells, developing 
antioxidant activity and reducing apoptosis. NGAL is a potent inducer of heme oxygenase-1 (HO-1) 
and superoxide dismutase (1,2; SOD) [70]. Salom et al. [68] found elevated levels of NGAL in 
aqueous humour of patients with idiopathic AAU. These findings imply that NGAL is associated with 
the regulation of inflammation in AAU. In addition, NGAL is strongly upregulated by interleukin (IL) 
1-beta [71], and TNF-α in the presence of IL-17 [72], and increased levels of IL-1 have been observed 
in AAU [73]. 
In Sympathetic ophthalmia (SO), the loss of vision in the absence of recognizable retinal damage and 
inflammatory cell infiltration within the retina and choriocapillaris has been an enigma. Parikh et al. 
[74]demonstrated that in SO, photoreceptor mitochondrial oxidative stress occurs in the absence of 
leukocytic infiltration of the retina and may lead to photoreceptor apoptosis and subsequent vision 
loss.  
1.2.1 Immune response mechanisms in uveitis. 
 
 Accumulating evidence shows that the immune response may be a predominant mechanism 
involved in the development of various uveitis entities [75]. Immune responses have been classically 
divided into innate and adaptive according to the speed and specificity of the reaction. Innate 
immune responses act as the first line of defence against infection in every part of our body, 
including the uvea. [75]. Apparently, innate immune responses play an important role in uveitis 
induced by infections, such as uveitis caused by toxoplasmosis, tuberculosis, syphilis and Lyme 
disease. Furthermore, evidence from a number of clinical and experimental studies has also 
implicated a potential role of innate immune responses to some bacteria and its products in the 
pathogenesis of several immune-mediated, non-infectious uveitis entities with systemic 
involvement, including ankylosing spondylitis, sarcoidosis, and Behçet’s disease [76-78].  
 Antigen-presenting cells (APCs) are the critical components of the innate immune response 
system. These cells can bind to and take up microbial agents and their products by a variety of 
receptors. APCs can subsequently degrade microbial products or autoantigens to form small 
  Introduction 
           
 
38 
polypeptide fragments and present these polypeptides to the surface of APCs in association with 
human leukocytes antigens (HLA) [75].  Several autoantigens have been identified as potential 
triggers for autoimmune uveitis [79-81]. 
1.2.1.1 Factors  involved in the innate immune response. 
Toll-like Receptors. 
 
TLRs, a family of transmembrane receptors, are among the most important genes involved in innate 
immunity. Ten TLRs have been described to date in humans which recognize microbial components 
at the cell surface or endosome [82]. Recognition of pathogen-associated molecular patterns 
(PAMPs) by these receptors on APCs is able to induce the expression of various pro-inflammatory 
cytokines, chemokines, co-stimulatory molecules, and MHC molecules. Therefore, these APCs can 
initiate a rapid host defence against the invading pathogen. Meanwhile, these APCs acquire the 
ability to activate naive CD4+ T cells and induce their differentiation into Th1, Th2, or Th17 cells. In 
this way, TLRs may also have an effect on adaptive immune responses. When the activated T cells 
are self-antigen specific, autoimmune responses may ensure [83-85]. 
NOD I and NOD2.  
 
The NOD proteins NOD1 and NOD2 are members of the NACHT ( domain present in NAIP, CIITA, 
HET-E, and TP1)-LRR(leucin-rich repeat) family and they are encoded by the caspase-recruitment 
domain (CARD) 4 gene and CARD 5 gene respectively [86]. Both NOD1 and NOD2 are composed of 
three domains: a C-terminal LRR domain involved in ligand recognition, a central NOD domain with 
ATPase-activity-mediated self-oligomerisation, and an N-terminal CARD domain [86]. Watanabe et 
al. [87, 88] found that NOD2 deficiency may lead to markedly higher IL-12 production and enhance 
Th1 responses [89]. However, NOD2 was also found to upregulate production of IL-8, TNF, IL-1ß, and 
IL-10 from APCs mediated by TLRs.  
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1.2.1.2 Factors  involved in the adaptive immune response. 
HLA Complex. 
 
Antigen recognition is the foundation of all adaptive immune responses. In humans, the capacity of 
adaptive immune response to an antigen is genetically determined by products of the HLA system. 
HLA molecules, which are located on chromosome 6 and divided into three classes (class I, II, and III), 
are highly polymorphic and function as molecules that are capable of presenting antigens. After 
APCs degrade antigen into peptides, they present these peptides on their surface via HLA molecules. 
CD4+T cells recognize the peptide HLA complexes by their T-cell receptors (TCRs), which lead to their 
activation. Thus, appropriate adaptive immune responses are initiated by CD4+Tcells. Co stimulatory 
signals, such as CD28, are necessary for T- cell activation [75]. The association between the HLA-B27 
serotype and anterior uveitis was one of the first identified associations between HLA genes and 
human disease [90]. HLA-B27 seems to be just one of multiple factors involved in HLA-B27 –
associated anterior uveitis, since only about 1% of HLA-B27-positive individuals develop anterior 
uveitis in their lifetime [91]. Specific HLA alleles do not directly cause uveitis and the real causes 
for the association between HLA genes and human diseases remains unknown. Up to now, HLA 
genes have been shown to be associated with a number of uveitis entities including birdshot 
choroidopathy (HLA-A29), Behçet’s disease (HLA-B51), Vogt-Koyanagi-Harada syndrome (HLA-
DR1/DR4/DRw53), tubulointerstitial nephritis syndrome(TINU)-(HLA- DRB1*0102), sympathetic 
ophthalmia (HLA-DRB1*04) [92-94]. 
 Co- stimulatory Molecules. 
 
The specific peptide-HLA-TCR interaction is not sufficient to fully activate the T- cell, and co 
stimulatory signals must be present on the same cell. The most potent co stimulatory signals are 
mediated by a CD28-B7 interaction. These two molecules are expressed on T- cells and dendritic 
cells respectively. The CD28-B7 interaction has been shown to prolong and augment the production 
of IL-2 and to prevent the induction of tolerance [75].  
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Investigating the association of CTLA-4 gene polymorphisms (-1661A/G; -318C/T; +49G/A, and CT60) 
with Behçet’s disease and VKH syndrome in Chinese patients, Du et al[95] reported that the 
frequency of the G allele at the +49 site and the frequency of haplotype-1661A:318C:+49G: CT60G 
were significantly higher in patients with VKH syndrome than that observed in healthy controls. 
1.2.1.3 Immune response factors contributing to the susceptibility to uveitis.  
Tumor Necrosis Factor (TNF). 
 
In addition to HLA genes, a variety of immune response genes have been shown to be located in HLA 
gene region. TNF is a multifunctional proinflammatory cytokine located in the HLA gene region. TNF-
α is believed to play a pivotal role in Th1-mediated diseases, such as Behçet’s disease [75]. Although 
earlier studies did not support that some polymorphisms in the TNF promoter region played a role in 
the susceptibility to Behçet’s disease [96-98], Ahmad et al. [99] reported that the TNF-1031C allele is 
independently associated with susceptibility to Behçet’s disease in Caucasian patients. These 
findings have been confirmed by studies in patients from Turkey, Tunisia and Korea [100-103]. 
MHC Class I Polypeptide-related sequence A (MICA).  
 
Mizuki et al.[104] reported that the (GCT/AGC)(6) allele of microsatellite polymorphism in MICA 
gene was present in all HLA-B51-positive patients and in an additional 13 HLA-B51- negative 
patients, suggesting the possibility of primary association of Behçet’s disease with MICA rather than 
HLA-B. This association of MICA polymorphisms with uveitis was implied in subsequent studies [105, 
106].  Wallace et al.[107] found that MIC 009 allele was more prevalent among patients compared 
with controls. Their data also indicated that both MIC-A*009 and the triplet repeats polymorphism 
of MICA were in strong linkage disequilibrium with HLA-B51; they are unlikely to be susceptibility 
gene for Behçet’s disease, but may be markers for additional risk factors. Subsequently, a study 
performed on three populations also indicated that the pathogenic gene of Behçet disease id HLA-
B51 itself and not other genes located in the vicinity of the HLA-B region [108]. 
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Interleukin (IL)-I  
 
IL-1, a potent pro-inflammatory cytokine, has a critical role in autoimmune diseases, such as 
Behçet’s disease. The polymorphism of IL-1 gene cluster has also been studied in certain uveitis 
entities [75]. Karasneh et al.[109] investigated the association of IL-1 gene cluster polymorphisms 
with Behçet’s disease and found that IL-1A-889C and IL-1B+5887T haplotype contributed to the 
susceptibility to Behçet’s disease. Other studies have recently also shown an association of an IL-1 
polymorphism with the chronicity and complications of anterior uveitis and the recurrence of 
toxoplasmosis retinochoroiditis [67, 110]. 
1.2.1.4  Chemokines. 
 
Chemokines are chemotactic cytokines playing a critical role in cell migration during immune 
surveillance and inflammation. More than 50 human chemokines have been described and are now 
separated into four families (CXCL, CCL, XCL, and CX3CL). Several studies have demonstrated that 
neutrophils and chemokines are involved in uveitis through directing the migration and infiltration of 
leukocytes to the uveal sites [75]. A gender-specific association of CCL2 and CCL5 polymorphisms 
with Behçet’s disease has been reported by Chen et al [111]. Wegscheider et al.[112] demonstrated 
that the frequency of CCL-2518G was significantly higher in patients with HLA-B27 AAU than in HLA-
B27 positive controls. Other studies have shown that MCP-1 polymorphisms were associated with 
idiopathic anterior uveitis and posterior uveitis [113, 114]. The clinical outcome of many 
autoimmune diseases including different forms of intraocular inflammation appears to be influenced 
by the balance between inflammatory and down-regulatory cytokines[115],[116]. 
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1.3 Classification of Uveitis. 
 
 In 2008, the International Uveitis Study Group (IUSG) designed a simplified, clinical classification 
system based on aetiological criteria. It has 3 main categories, as followed:  
 Infectious (e.g., bacterial, viral, fungal, parasitic). Infectious agents such as toxoplasma 
gondii, herpes virus, Syphilis, CMV, HIV, onchocerciasis are well recognized [117],[118].  
 Non-infectious (e.g., known systemic association, no known systemic association). In the 
majority of patients the cause of the intraocular inflammation is unknown, but in some cases 
is a manifestation of a systemic disease process, such as sarcoidosis[119, 120], Behcet’s 
disease (BD), juvenile idiopathic arthritis(JIA), multiple sclerosis(MS), ankylosing spondylitis 
(AS), Inflammatory bowel/Crohn’s disease, SLE, Wegener’s granulomatosis, VKH[121, 122], 
whilst others may be associated with various conditions such as the HLA-B27-related group 
of diseases[45]. 
 Masquerade: Neoplastic and non neoplastic. 
However, the most widely used classification of uveitis is the Standard Uveitis Nomenclature (SUN) 
devised by International Uveitis Study Group (IUSG) in 1987, based on the anatomical location of the 
inflammation [123]. According to this, uveitis should be categorised as anterior, intermediate, 
posterior or panuveitis. 
Descriptors of the onset and course of the uveitis were addressed at the 2005 SUN workshop, and it 
was agreed that the condition should be described as acute, chronic or recurrent. Acute if of sudden 
onset and duration less than 3 months, chronic if the duration exceeds 3 months, and recurrent if 
after interrupting treatment the disease flares up after 3 months.[124] 
1.3.1 Anterior uveitis. 
 
Anterior uveitis refers to inflammation involving the iris and ciliary body, and is the commonest form 
of uveitis. In most patients, the aetiology is unknown, but the association with HLA-B27, a genetic 
marker, is present in about 50% of patients [122]. Ankylosing spondylitis (AS), an idiopathic, 
common, chronic arthritis is strongly associated with acute anterior uveitis. AS usually affects young 
men in the second or third decade; women are also affected to a lesser extend [125]. About 97% of 
AS patients are HLA-B27 positive and about 25% of AS patients will develop uveitis [90]. Systemic 
diseases, such as sarcoidosis or Behçet’s disease may be present as an anterior uveitis, but more 
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usually as panuveitis [126]. Juvenile idiopathic arthritis (JIA) describes a heterogenous group of 
idiopathic arthritides occurring in children under the age of 16 years. This is the commonest disease 
association with anterior uveitis in childhood [127]. Though no correlation exists between disease 
activity in the joint and eye inflammation, an association between the mode of onset of JIA and risk 
of eye inflammation is well recognised. 
 Patients with pauciarticular involvement, in the absence of systemic features, carry the highest risk 
of eye involvement, especially in the presence of anti-nuclear antibodies [127, 128]. In the majority 
of patients, arthritis precedes the uveitis that has an insidious onset on routine slit-lamp 
examination [129]. 
1.3.2 Intermediate uveitis. 
 
 Intermediate uveitis (IU) refers to a subset of uveitis in which inflammation is primarily observed in 
the vitreous cavity. It is characterised by low-grade, chronic inflammation of the posterior part of the 
ciliary body, the vitreous base and peripheral retina. This accounts for 4-8% of the uveitis cases. 
Children and young adults are typically affected. The inflammation is bilateral in the majority of 
patients. Some patients may have underlying systemic diseases like multiple sclerosis and sarcoidosis 
[126]. The diagnostic term pars planitis should be used only for that subset of IU where there is snow 
bank or snowball formation  occurring in the absence of an associated infection or systemic disease 
[130]. The aetiology is unknown but there are several associated diseases: multiple sclerosis, 
idiopathic optic neuritis, autoimmune corneal endotheliopathy, sarcoidosis, thyroid diseases and 
inflammatory bowel diseases [131]. Intermediate uveitis of childhood might exhibit a self-limiting 
course after several years [132].   
   
1.3.3 Posterior uveitis 
 
Posterior uveitis (PU) refers to inflammation of the choroid and retina and may result from localized 
ocular inflammation (focal, multifocal or diffuse choroiditis, chorioretinitis, retinitis, and 
neuroretinitis), or from a systemic condition [133, 134]. The aetiology is unknown in many patients, 
but systemic inflammatory diseases, such as sarcoidosis, Behçet’s disease and Vogt-Koyanagi-Harada 
syndrome, and infectious causes like Mycobacterium tuberculosis, syphilis, herpes group of viruses, 
toxoplasmosis and ocular toxocara need to be considered in the differential diagnosis [120]. Non 
infectious posterior uveitis may result in permanent vision loss. The inflammation can be constant, 
or characterised by periodic exacerbations on an underlying baseline of inflammation. Recent 
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studies indicate that vision loss often results from cumulative damage over multiple recurrences of 
inflammation, rather than from a single initiating event [135].  
1.3.4 Panuveitis. 
Panuveitis involves inflammation of the anterior, intermediate, and posterior uveal structures, and 
the differential diagnosis is similar to that of posterior uveitis. Herpetic viral retinitides may also 
present as panuveitis or posterior uveitis in both immunosuppressed and immunocompetent 
individuals.[133] 
1.3.5 Masquerade Syndromes. 
 
The term masquerade syndrome is classically used in ophthalmology to describe those conditions 
that include as part of their manifestation the presence of intraocular cells, but that are not due to 
immune-mediated uveitis entities [136]. The two underlying disorders for which the term 
masquerade is most commonly used are intraocular infection and intraocular lymphoma. Both can 
appear to be a chronic panuveitis with little in the way of other signs.[137] Acute endophthalmitis 
occurs within a few days after surgery and is usually recognised, but delayed onset endophthalmitis 
may occur weeks or months after the surgery, and can be much more difficult to diagnose. Aqueous 
and vitreous sampling may not yield viable organisms which can be grown on laboratory media, and 
the inflammation may be partially suppressed by corticosteroids.[137] Patients with intraocular 
lymphoma may be perfectly well with no systemic or neurological symptoms and signs, and few 
other ocular signs except cells, predominantly in the vitreous, with some in the anterior chamber. 
Vitreous sampling may not yield enough cells for the diagnosis to be confidently established, and the 
vitritis may be steroid sensitive, at least initially[137]. 
1.3.5.1 Lymphoid malignancies.  
A. Primary CNS lymphoma in immunocompetent patients. 
 
In a review of 828 consecutive patients seen in a tertiary referral clinic, Rothova et al found a 
frequency of neoplastic masquerade syndromes of 2.3% (19 patients). Of these, 13 patients (68%) 
had intraocular lymphoma, confirming the impression of many that intraocular lymphoma is the 
most common neoplastic “masquerader” [138]. Approximately 98% of primary intraocular 
lymphoma are extranodal, non-Hodgkin’s B cell lymphomas, which, as the name implies, are 
localized to the intraocular structures: vitreous, retina, subretinal, and sub-retinal pigment epithelial 
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spaces [136].  Approximately 2% of PCNSL are T cell lymphomas, with the very rare occurrence of 
other primary CNS neoplasms, such as Ki-1 lymphoma, lymphomatoid granulomatosis, T cell-rich B 
cell lymphoma, signet-ring cell lymphoma, angiotrophic lymphoma, Hodgkin’s disease, and 
plasmocytoma [139]. PCNSL is generally considered a rare condition, but its incidence is increasing. 
Data from the National Cancer Institute reveal that 2.7 cases per 10 million people were reported 
from 1972 to 1974, as compared with 7.5 cases per 10 million people from 1982 to 1984 [140]. A 
continuing increase has been reported during the years subsequent to these data [141-143]. 
Despite this increase, the risk of an immunocompetent individual developing PCNSL is very low 
[144]. 
 When the lymphoma involves the vitreous and the retina, the diagnosis may be more 
apparent, but it may still be difficult to establish definitively in the absence of CNS findings.  
Clinically described as creamy yellow subretinal infiltrates, with overlying retinal pigment epithelial 
detachment [145], but they may take on many forms, such as discrete white lesions, suggestive of 
acute retinal necrosis, toxoplasmosis, and frosted branch angiitis [146], branch retinal artery 
obstruction with coexistent multifocal chorioretinal scars [147], and retinal vasculitis [148]. 
B. Primary CNS lymphoma in patients with acquired immunodeficiency syndrome (AIDS). 
 
Immunocompromised patients have an increased risk of malignancy, of which lymphoproliferative 
disease is an important type, non-Hodgkin’s lymphoma being the second most common malignancy 
associated with AIDS [149]. Compared with nonimmunosuppressed patients, those with AIDS have a 
much greater risk of developing clinical CNS disease, ranging from 2-6% [150-152]. 
C. CNS lymphoma secondary to systemic lymphoma. 
T cell lymphoma and HTLV-1 lymphoma 
 
Ocular involvement in primary CNS lymphoma is typically different from that resulting from 
secondary involvement of the eye by systemic lymphoma [136]. Although the majority of intraocular 
lymphomas are of a B cell nature, there is increasing recognition of the existence of intraocular T cell 
lymphomas [148, 153, 154]. It is interesting that in the majority of case reports involving T cell 
lymphomas, patients present with primarily an anterior involvement, mimicking an anterior uveitis 
[136]. In contrast to these cases, Reim et al. [155] reported the presence of T cell lymphomas with 
primarily posterior findings. HTLV-1 is a retrovirus that has been reported as a cause of adult T-
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cell leukemia/lymphoma [156]. A variety of ocular  manifestations have been reported with HTLV-1 
infection, including retinal vasculitis [157], cotton-wool spots, granulomatous iridocyclitis, and vitritis 
[158], and subretinal infiltrative lesions [159]. Yoshimura et al.[160] described the clinical features of 
uveitis associated with seropositivity for HTLV-1 in 93 patients. They found that the incredibly 
nonspecific symptom of floaters was the only complaint found more commonly in HTLV-1 patients 
compared to non-HTLV-1 patients with uveitis that reached statistical significance. In addition the 
findings of vitreous opacities, retinal vasculitis and intermediate uveitis were significantly higher in 
HTLV-1 positive patients than seronegative patients. The possibility of HTLV-1 virus associated uveitis 
and adult T cell leukaemia/lymphoma must thus be always kept in mind in the setting of intraocular 
inflammation, especially in patients who have been in endemic areas [136]. 
Systemic B cell lymphoma. 
 
Ocular disease can be the presenting sign of systemic lymphoma [161, 162]. Although conjunctival or 
orbital involvement with systemic B cell lymphomas is relatively common [163], intraocular 
involvement is rare [161, 163, 164]. In general, systemic lymphomas arising from visceral organ tend 
to involve the uvea. This is in contrast to CNS lymphomas which typically involve the vitreous, retina, 
subretinal and sub-RPE areas [136]. Ocular involvement with systemic non-Hodgkin’s lymphoma 
usually carries a poor prognosis, with an average longevity of 31 months after diagnosis [165]. 
(Fig.1.6) 
 
Figure 1.6 Fundus photograph of a patient with choroidal infiltrates due to ocular lymphoma. 
The association of uveitis in patients with both systemic and intracranial lymphoma is now well 
known and, should rank high in the differential diagnosis of chronic vitreous inflammation, especially 
in patients who respond poorly to anti-inflammatory and immunosuppressive therapy [136]. 
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Leukemia. 
 
Intraocular findings occur in 28-75% of patients with acute leukaemia, less in patients with chronic 
leukaemia [166]. Retinal findings are common, including intraretinal haemorrhages, cotton wool 
spots, white-centered haemorrhage (Roth spots), microaneurysms, and peripheral 
neovascularisation.  
Occasionally, leukemic cells can break through the internal limiting membrane into the vitreous 
cavity, simulating vitritis. When the choroid is involved by the leukemic process, exudative retinal 
detachment may result. Angiographically, this may assume the typical pattern of Vogt-Koyanagi-
Harada disease or posterior scleritis, with multiple, pinpoint serous detachments of the retina and 
RPE [166]. Other masquerade presentations can include anterior “hypopyon uveitis”, with 
spontaneous hyphema, heterochromia iridis, or pseudohypopyon which is typically gray-yellow in 
colour [167]. 
1.3.5.2  Non- lymphoid malignancies. 
A. Uveal Melanoma. 
 
Uveal melanomas may present with clinical features suggestive of intraocular or orbital 
inflammation. In a series of 450 enucleated eyes with malignant melanoma of the uvea, Fraser et al 
found that 4.9% of patients presented with ocular inflammation. Clinical presentation included 
episcleritis, anterior and/ or posterior uveitis, endophthalmitis [168].  
B. Retinoblastoma. 
 
Although the classic presenting signs of retinoblastoma are leukocoria or strabismus, an 
inflammatory presentation may also occur in 1-3% of cases, usually in the relatively rare variant of 
diffuse infiltrating retinoblastoma which presents around 6 years of age [169, 170]. Clinical signs may 
include conjunctival chemosis, pseudohypopyon, and vitritis. The hypopyon typically shifts with 
changes of head position [171]. An important morphological clue is that, in contrast to the typically 
yellowish hypopyon of inflammation, the pseudohypopyon of retinoblastoma is usually white [136]. 
C. Metastatic tumors. 
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Metastatic tumours are the most common intraocular malignancy in adults. These lesions may 
involve the uvea, the retina, or optic nerve and produce findings that may be rarely be confused with 
uveitis [172].  
Uveal Metastasis. 
 
Tumour metastatic to the uvea most commonly involves the posterior segment. They tend to be 
plateau-shaped, yellow in colour, and associated with subretinal fluid [173]. Posterior segment 
metastatic lesions are infrequently misinterpreted as uveitis conditions [136]. In a series of 40 
patients with masquerade syndrome, Rothova et al.[138] reported only one case of metastatic 
disease (lung carcinoma) to the posterior uvea.  
 In addition to the posterior uvea, metastasis can present in the anterior segment. In this case, 
lesions may present with cells in the aqueous humour, as well as other features that are occasionally 
present in uveitis, such as iris nodules, rubeosis iridis, and elevated intraocular pressure [174-176]. 
Primary tumour sites commonly reported with anterior uvea metastasis from the lung and breast 
[174, 176,177]. 
Retinal Metastasis. 
 
Metastatic tumour isolated to the retina is extremely rare [178]. Although metastatic tumours to the 
retina can present with vitreous cells, those in metastatic melanoma are described as large brown 
spherules, whereas metastatic carcinoma typically has a white to yellow colour and may result in 
perivascular sheathing, possibly simulating a retinal vasculitis or necrotising retinitis [136]. 
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The first International Workshop on standardization of uveitis nomenclature for reporting clinical 
data agreed that the onset of uveitis should be reported either as sudden or insidious. It was also 
recommended that the course of an attack of uveitis should be described as either limited or 
persistent, if it is 3 months or less or greater than 3 months in duration respectively[124]. The term 
acute should be used when describing the course of specific syndromes characterized by sudden 
onset and limited duration such as HLA-B27-associated “acute anterior uveitis”[179]. 
The workshop also recommended that when reporting on the course of the disease, repeated 
episodes separated by periods of inactivity of at least 3 months duration without treatment should 
be labeled as recurrent, the term chronic should be reserved for those cases with persistent uveitis 
characterized by prompt relapse in less than 3 months after discontinuation of therapy[124]    
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1.4  Ancillary tests. 
A. Imaging. 
 
In recent years enormous progress has been achieved in investigational procedures for uveitis. 
Imaging is one such example with the advent of new methods such as indocyanine green 
angiography, ultrasound biomicroscopy and optical coherence tomography [180] 
Ultrasonography. 
 
Ultrasonography is usually an invaluable tool in the examination of the uveitis patients, allowing 
evaluation of the posterior segment of eyes with opaque media, and in determining the presence of 
thickening of the choroid [136] (Fig.1.7) 
 
Figure 1.7 BScan ultrasound image 
Ultrasound Biomicroscopy. 
 
During the past two decades, ultrasound biomicroscopy (UBM) has become available for the 
appraisal of the pathophysiology of the anterior segment [181-184]. UBM is based on high-
frequency transducers incorporated into a B-mode clinical scanner. This technology allows quasi-
histological sections up to 5mm in depth to be obtained in vivo [185]. A recent study by Tran et al 
suggested that UBM is of great clinical value in the assessment of inflammatory lesions of the iris, 
ciliary body, pars plana and peripheral vitreous [182]. Using UBM, Yang et al reported a variety of 
abnormalities in the posterior chamber, anterior chamber angle, and the ciliary body and its 
surrounding tissues in eyes with AAU (Fig.1.8).  
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Their findings suggested that the involvement of the ciliary body is perhaps a universal sign of AAU, 
whereas in slit-lamp microscopy, the inflammation is seen to affect the iris only in some patients. 
The authors concluded that UBM is not only useful for evaluating changes in the anterior segment 
which cannot be seen by slit-lamp microscopy, but represents a valuable tool for the guidance of 
treatment of patients with AAU [185].   
 
         A                                                                     B                                                                C 
Figure  1.8 Changes in the anterior segment revealed by ultrasound biomicroscopy (UBM) in acute anterior uveitis. 
  
(A) At 13 days after uveitis attack, UBM shows numerous cells in the posterior chamber and anterior 
vitreous body, striking oedema in the iris/ciliary body and irregular exudates adjacent to it. (B) At 26 
days after uveitis onset, UBM shows an open angle, improved oedema of the iris/ciliary body and 
few exudates adjacent to it or in the anterior vitreous. (C) At 45 days after uveitis onset, UBM shows 
an open angle, and no cells or exudates in the anterior chamber, posterior chamber or anterior 
vitreous [186]. 
Laser Flare Photometry (LFP). 
 
Clinical determination of aqueous humour protein levels (“flare”) has been considered less 
important. This belief may have evolved from the greater difficulty in clinically identifying changes in 
protein levels. Whereas cells can be counted, the quantification of aqueous humour protein levels by 
slit-lamp biomicroscopy is more subjective, based on the perceived intensity of light reflected off 
protein molecules within the aqueous humour [186].    
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 Laser flare photometry provides a more precise way to identify changes in aqueous humour 
proteins. The Kowa FM-500 Flare Meter projects a diode laser beam into the anterior chamber and 
measures the amount of light scattered by protein molecules in the aqueous humour [187]. Using 
this method, Gonzales et al.[188] have demonstrated the associations between elevated laser flare 
photometry values and posterior synechiae, low intraocular pressure (< 10mmHg), history of 
cataract, and macular oedema in patients uveitis. 
Fundus color photography.  
 
Mostly used in posterior uveitis, allows the mapping of lesions. Comparisons can be made with 
subsequent photos to determine whether the lesion has regressed, stabilized, or increased. 
 
Figue 1.9 Normal colour fundus photograph. 
Fundus autofluorescence (FAF) 
 
Fundus autofluorescence (FAF) has been used for the evaluation of RPE in degenerative, 
inflammatory, and neoplastic conditions [189, 190].  The FAF signal is derived primarily from 
lipofuscin accumulation within the RPE and may be indicative of altered structure and function [191, 
192]. The white dot syndromes (WDSs) classically include acute posterior multifocal placoid pigment 
epithelium epitheliopathy (AMPPEE), serpiginous choroidopathy (SC), birdshot retinochoroidopathy 
(BSCR), multiple evanescent white dots syndrome (MEWDS), and multifocal choroiditis (MFC) , and 
are characterized by multiple lesions of the posterior pole due to inflammation of the choroid, 
retinal pigment epithelium, and retina [193, 194]. Yeh et al.[195] found that FAF imaging was 
valuable in the evaluation of WDSs. They observed that foveal hypoautofluorescence appeared to be 
a marker for moderate to severe visual impairment. Fundus autofluorescence seems to be a very 
sensitive imaging technique for detecting damage of the RPE in acute episodes of serpiginous 
choroiditis. A sequence of autofluorescence changes reflects the passage from activation to 
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resolution of new lesions [196]. McBrain et al.[197] have shown that it can be used as a rapid, non 
invasive technique in the diagnosis of CMO.  
 
Figure 1.10 Normal FAF 
Roesel et al. [198] found that increased FAF in uveitic CMO is associated with poor vision. Wang et 
al. [199] reported that hyper-autofluorescence in the foveola is a non-specific manifestation of 
photoreceptor-retinal pigment epithelium dysfunction. Investigating the characteristics of fundus 
autofluorescence in birdshot, Koizumi et al.[200] found that FAF demonstrated the RPE atrophy, 
which was hard to see by other means of investigations. They found that the areas of RPE atrophy 
did not necessarily correspond to the hypopigmented lesions, which suggested that both the choroid 
and the RPE can be affected independently.  
Fundus fluorescein angiography (FFA) and Indocyanine green angiography (ICGA). 
 
Angiography may be performed to confirm elements already revealed by clinical examination or 
other investigational methods such as optical coherence tomography (OCT). A second reason to 
perform an angiography is for better grading of the inflammation of the fundus. A third reason is to 
make a good baseline inventory of inflammatory involvement to subsequently use it for follow-up 
purposes. In follow-up situations, angiography is usually performed to monitor disease intensity and 
impact of therapy [180]. 
Fluorescein angiography has been performed for over 4 decades. Fluorescein sodium (FNa) is 
injected intravenously to analyze the blood circulation of the ocular fundus, mainly the retina. It is a 
small hydrosoluble molecule of 354 daltons of which 80% is bound to proteins and 20% is free, the 
latter free portion being responsible for the emission of fluorescing light [180, 201].   
         Two crucial principles 
characterise FNa. (1) Fluorescein has a micromolecular behaviour. This means that it easily gets out, 
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at the slightest breakdown of the hemato-retinal barrier, from the usually impermeable retinal 
vessels. (2) Fluorescein fluoresces at 520-530 nanometers within the wavelengths of visible light ,and 
is therefore blocked by the RPE, giving no useful information on choroidal circulation, except on the 
choriocapillaris during the first 40-60 seconds of angiography [180].     
 Increased fluorescence can be due to three main mechanisms: (1) leakage producing pooling 
(in a space) or staining (in tissues); (2) increased transmission of fluorescence due to fundus atrophy 
with removal of the RPE producing larger hyperfluorescent areas or due to smaller window-defects 
produced by areas of RPE defects; (3) presence of abnormal vessels (retinal vessels or choroidal 
neovascular membranes) [180].         
 Decreased fluorescence can be either due to transmission decrease (blockage), or filling 
defect (vascular delayed perfusion or non perfusion) [180].    FFA 
furnishes three types of information on the retinal circulation which include: (1) imaging of 
inflammatory damage to vessel walls in retinal vasculitis, (2) display occlusive vasculopathy of retinal 
arteries or arterioles, and (3) detection of retinal new vessels situated at the disc (NVD) or elsewhere 
(NVE) [180].  Macular ischemia is best detected using FFA and has to be looked for in case of severe 
fundus inflammation such as Behçet’s uveitis [202, 203]. CMO is visible by funduscopy if it is 
sufficiently pronounced. However, until recently, FFA was recommended to determine the extent of 
CMO. Two grading systems of CMO have been put forward by the groups of Miyake and Yanuzzi 
[204, 205]. Cassoux et al. [206] reviewed the fluorescein angiographic findings in 44 patients with 
ocular and CNS lymphomas and reported punctuate hyperfluorescence window defects in 54.5%, 
round hypofluorescent lesions in 34%, vasculitis in 13.6%, papilloedema in 3.7%, and cystoid macular 
oedema in 2.5%.  
 For about 15 years, a second angiographic procedure is being used, using indocyanine green, 
a dye that fluoresces in the infrared wavelengths (830nm). Besides the different wavelength at 
which ICG fluoresces, the crucial difference between FNa and ICG comes from their binding affinity 
to proteins. The ICG molecule is nearly completely protein bound and predominantly so to large 
sized proteins (lipoproteins) [207, 208]. This procedure, in contrast to FFA, often gives additional 
information undetected by clinical examination or FFA or OCT. Therefore, ICGA is indispensable in 
the proper assessment of inflammatory involvement in uveitis as it gives information, which is 
otherwise lost. Very often, ICGA has a diagnostic value, rarely the case for FFA. For all these reasons, 
in most cases where angiographic work-up is required and choroidal involvement cannot be 
excluded, dual FFA and ICGA should be performed [209-211]. Fluorescein leaks readily from slightly 
inflamed retinal vessels with minor damage to the blood-retinal barrier and readily impregnates 
tissues, whereas only major damage to retinal vessels allows ICG to leak [212]. When analysing ICGA 
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in posterior inflammatory disorders, crucial differences with FFA interpretation have to be borne in 
mind to correctly analyse the images obtained [213].  Altan-Yaycioglu et al. [214] reported that 
the combined use of FFA and ICGA helps gauge the severity of inflammation in the choroid and the 
retina during active inflammation. In quiescent stages, however, ICGA does not give any additional 
information. 
Optical coherence tomography (OCT). 
 
Optical coherence tomography is an imaging technique able to provide cross-sectional high- 
resolution images of the retina. OCT is useful for the evaluation and diagnosis of several macular 
diseases, such as macular oedema, macular holes, epiretinal membranes, central serous 
chorioretiopathy, and age-related macular degeneration. OCT provides information for the 
diagnosis and follow-up of macular oedema caused by inflammatory diseases, diabetic retinopathy, 
vascular occlusions and macular degenerations [215-217]. It is an important technique 
providing information about inflammatory macular oedema [218]. OCT has a high sensitivity in 
showing epiretinal membranes and the presence of potential vitreoretinal abnormalities in the 
macular area, suggesting the hypothesis of a tractional mechanism as a probable origin or cofactor 
of onset of macular oedema during uveitis [219-221].  Using OCT, Moreno-Arrones et al found that 
patients suffering an AAU showed an increase in macular volume and superior RFNL thickness 
versus control eyes in the acute episode [222].  
Chest and joint x-rays and neuroimaging. 
 
 Plain postero-anterior and lateral chest X-rays may assist in the diagnosis of both 
tuberculosis and sarcoidosis [119, 223]. Chest x-ray findings are present in one-third of patients with 
extrapulmonary tuberculosis, although pulmonary disease is inactive in most cases. There may be a 
healed primary lesion visible as peripheral calcified pulmonary nodules and/or calcified hilar lymph 
nodes [224].  
Radiological examination of the joints is often of value in diagnosing the seronegative 
spondyloarthropathies. In particular, sacro-iliitis may be visible as juxta-articular sclerosis, blurring 
of the joint margins and erosive changes on pelvic X-rays [225].  
When suspecting a primary CNS lymphoma, computed axial tomography scans of 
immunocompetent patients typically show multiple, diffuse, periventricular lesions with high-
density tumour before contrast injection. After contrast injection, dense periventricular 
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enhancement appears and may involve the corpus callosum. Magnetic resonance imaging (MRI) 
shows isointense lesions on T1, and iso- to hyperintense lesions on T2. Periventricular contrast 
enhancement is strong in 75% of cases [155]. 
 
B.   Laboratory tests.  
 The aetiology of uveitis remains uncertain or unknown in 30-70% of cases after noninvasive 
investigations [226]. The diagnosis is often based on history, detailed clinical examination, and 
selected investigations [227]. Unless a thorough history suggests a systemic problem or there are 
additional suspicious clinical signs, adults with an isolated unilateral acute anterior uveitis are not 
usually investigated for systemic associations. Such cases are likely to be confined to the eye. 
However, chronic anterior uveitis or recurrent acute disease, bilateral uveitis and all childhood 
inflammations demand investigation.  Commonly requested tests include: Full blood count, HLA-
B27, B51 typing, serum angiotensin I-converting enzyme (ACE) measurement, erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP), syphilis serology, rheumatoid factor (RF), and 
anti-nuclear antibodies (ANA). Tuberculin test is reserved for those individuals in high-risk groups 
[224].  
It is obviously important to be able to distinguish between infectious, non-infectious, and malignant 
causes of uveitis. Infections are reported to be the cause in approximately 20% of cases of uveitis 
[228, 229]. Infections and intraocular malignancies often masquerade as immune-mediated 
conditions and present with similar clinical features [137]. 
Advances in molecular biology, microbiology, and cytopathologic techniques have been 
applied to the diagnosis of many diseases [230, 231]. 
 Polymerase chain reaction (PCR) analysis of peripheral blood, serologic testing of peripheral blood 
or both is not informative about the cause of inflammation in the eye. The accurate and timely 
diagnosis of infectious uveitis, however, is essential in providing appropriate treatment; 
immunosuppressive therapy commonly used to treat non-infectious uveitis may prolong or worsen 
any infectious process [232].  
Vitreous aspiration needle tap seems to provide a safe method for acquiring ocular fluid in 
cases of uveitis in which the pathogenesis is unknown, permitting subsequent cytopathologic, 
microbiologic, and molecular analysis of the material, which in combination with the clinical features 
helps identify the aetiology of the disease process [233-235]. Lobo et al reported that ocular sample 
collected by vitreous aspiration permitted the relevant diagnostic test to be carried out and the 
diagnosis to be made in 92% of patients. It allowed immunosuppressive treatment to be given to 
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50% of the patients, having excluded intraocular malignancy [227]. In the United States, diagnostic 
vitrectomy is used in patients with atypical or severe presenting symptoms [236]. 
 The diagnosis of intraocular lymphoma from vitreous specimens depends on proper 
handling of the specimens, methods of aspiration, concentration, fixation, and staining [237, 238]. 
Prior treatment of patients with steroids reduces the number of viable lymphoma cells, because 
central nervous system lymphoma cells have an unique sensitivity to corticosteroids, which are 
known to be cytolytic [238]. 
It is now possible to apply novel PCR techniques to vitreous samples to determine immunoglobulin H 
rearrangement and t (14; 18) translocation of the bcl-2 gene and show monoclonality [239, 240]. 
Herpes viruses such as varicella-zoster and herpes simplex are common agents inciting ocular 
inflammation in immunocompromised and immunocompetent individuals, whereas CMV is the 
major cause of retinitis in patients with immunodeficiency virus/AIDS. PCR analysis of ocular fluid 
samples in the early phases assists diagnosis and initiation of appropriate treatment, because 
retinitis can progress very rapidly [241, 242]. 
 Analysis of aqueous samples obtained by anterior chamber tap (paracentesis) is an 
underused approach [243-247]. A volume of approximately100 to 200μl aqueous allows analysis for 
multiple pathogens at real-time PCR for the detection of the infectious pathogen itself and the 
determination of the Goldmann-Witmer coefficient (GWC) as a parameter of intraocular production 
of specific antibodies [243, 248]. It has been demonstrated that the combination of both assays, PCR 
and GWC, improves the efficacy of intraocular fluid analysis of infectious uveitis [243, 247-249].  
Rothova et al.[232] considered it a clinically meaningful approach to perform aqueous analysis in PU 
patients with active inflammation and negative results of the initial uveitis screening and in severe 
cases when early diagnosis and treatment are essential. When positive results confirm the suspected 
diagnosis, optimal treatment can be used and vitrectomy is not necessary. In the event of negative 
results, unsatisfactory clinical development, or both, the authors proceeded with diagnostic 
vitrectomy. Only in very severe cases when retinal evaluation is not possible (such as possibility of 
endophthalmitis) and in those with a strong suspicion of malignancy did the authors opt for primary 
vitreous biopsy. Despite the posterior location of inflammation, aqueous analysis yields a high 
frequency of positive results [232]. 
1.5 Visual acuity.  
 
 Visual acuity is the single most-widely used eye test. It informs about a major aspect of a 
patient’s visual function in an easily administered form In its routine application it is a test of 
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resolution in the central fovea[250]. Foveal acuity and peripheral acuity are two important subject 
factors related to visual search performance [251]. 
1.5.1 Foveal acuity. 
Foveal acuity is the ability to discriminate fine details and is a visual function important for many 
tasks. It measures the capability of the visual system[252]. 
1.5.2 Visual acuity measurement. 
 
Visual acuity can be measured and analysed using a variety of strategies [253]. The Early Treatment 
Diabetic Retinopathy Study (ETDRS) protocol was designed in the 1980s based on recommendations 
from the National Academy of Science’s Working Group[254] and is similar to a chart created by 
Bailey and Lovie [255] and allows for standard reproducible visual acuity measurements as described 
in details by Ferris et al. [256, 257]. The ETDRS charts have the advantage of using a regular 
geometric progression of letter size and spacing [256, 257]. A 3-line change in visual acuity (± 15 
letters) using ETDRS charts is equivalent to a doubling or halving of the visual angle regardless of the 
baseline visual acuity measurement [256, 258]. This chart has been shown to be accurate and 
reliable [259] at high and low levels of visual acuity [255, 256]. Even low visual acuity as poor as 
20/800 can be calculated by moving the patient closer to the chart from a distance of 4 metres to 1 
meter [256]. 
The Bailey–Lovie distance visual acuity chart was developed to overcome the inaccuracies of the 
Snellen chart and has been widely accepted as an accurate and efficient measure of visual acuity, 
particularly for assessing patients with low vision [255, 260]. The chart has approximately equally 
legible letters on each row and the separation of letters within rows and between rows is uniform so 
that contour interaction is controlled. The visual task at each level of the chart is therefore the same 
irrespective of acuity or test distance [255]. The Bailey-Lovie chart employs a logarithmic progression 
of sizes and the log MAR visual acuity notation, which has been shown to represent a good 
approximation to an equal discriminability scale [261], and has been recognized by many 
investigators as the most logical measure of visual acuity [260, 262, 263]. The major advantage of 
the log MAR visual acuity notation and the use of the Bailey-Lovie chart for research purposes is the 
ability to measure and score low visual acuities accurately, which can thus be included in statistical 
analysis [264]. The log MAR visual acuity scoring method allows arithmetic procedures, including 
regression analysis and parametric statistics, to be applied legitimately to visual acuity scores, 
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because by the use of appropriate variations in test distances, the visual acuity scale is not 
truncated, as is the conventional Snellen visual acuity [265, 266].  
Routine clinical practice usually relies on the Snellen charts to measure visual acuity. The Snellen 
chart has well documented limitations, including inconsistent progression in letter size from one line 
to the next, large gaps between visual acuity levels at the lower end of the chart (20/80-20/800), 
unequal legibility of letters used, and unequal and unrelated spacing between letters and rows [267-
269].  Furthermore, there is no “one” Snellen scale, either in consistent number of letters or 
consistent lines on the chart, and as a result, visual acuity measurements can vary based on 
variations from chart to chart [253]. The Snellen chart is designed to measure visual acuity in angular 
units in which the numerator is the testing distance (in feet or meters), and the denominator is the 
distance at which a letter subtends the standard visual angle of 5 minutes of arc. Thus, on the 20/40 
line, the letters subtend an angle of 5 minutes of arc when viewed at 20 feet [270]. The reciprocal of 
the Snellen fraction represents the minimum angle of resolution (MAR) [270].  The negative base 
10  logarithm of the reciprocal Snellen fraction is the logarithm of the minimum angle resolution (log 
MAR), which converts the geometric Snellen progression into a linear function well suited for 
statistical manipulations [270]. The usual practice in retrospective research when using Snellen visual 
acuity measurements is to convert Snellen visual fractions to log MAR units, perform statistical 
calculations, and then report the visual acuity measurements as log MAR units[270].  
The accuracy of visual acuity measurements using a Snellen chart is poor because at low visual 
acuity, there are few letters on each line and each line represents a large interval change in visual 
acuity [253]. Nevertheless, Snellen visual acuity is relied on in many retrospective studies that report 
statistical results, and most retrospective data collection for clinical studies should use Snellen 
fraction nearest the line that was fully read with the likelihood that this Snellen fraction would be 
the most reproducible [253].   
 1.6  Epidemiology of uveitis. 
 
Uveitis is a relatively common inflammatory eye condition with reported annual incidences between 
17 and 22.6 per 100,000 populations[271-273], and a prevalence  between 38 and 370 per 100,000 
populations [274]. It may occur at any age, but most commonly afflicts those aged between 20 and 
59 years [275].  The total population prevalence being reported as 38 per 100,000 in France[276] 
and 68-76.6 per 100,000 in Finland [277]. One study from the USA in the early sixties showed a 
prevalence of around 200 per 100,000 [278]. In the largest population-based uveitis study in the USA 
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to date, Gritz et al.[279] found an incidence of 52.4/100.00 person-years and a period prevalence of 
115.3/100.000 persons. The incidence and prevalence were lowest in the paediatric age groups, and 
highest in patients aged 65 or older. It was also shown in this study that women had a higher 
prevalence of ongoing uveitis than men, and this difference was highest in the older age group. The 
incidence found was approximately 3 times that of previous US estimates and increased with the 
increasing age of patients. 
Many of the past and current epidemiological studies in uveitis have limitations [274]. These include 
the effects of referral or selection bias; the heterogeneity of diagnostic criteria, workup, and the 
availability of investigations in different study centres; and the lack of uniform classification systems 
or definitions of various uveitis entities, making comparisons of epidemiological data from different 
populations or regions difficult [134].  
 McCannel et al. [280] illustrated the significance of a referral bias, reporting a much higher 
proportion of patients with anterior uveitis in community-based practices and, in contrast, observing 
a shift in the relative frequency of uveitis cases in the tertiary referral centre toward posterior uveitis 
and panuveitis. Most of the hospital-based studies are not representative of the general population 
as they only include patients seeking treatment [93].  
It is estimated that the population-based incidence and prevalence of uveitis in children is  5 to 10-
fold lower than in adults, children constituting only about 5% to 10% of patients with uveitis in most 
tertiary uveitis clinics [281], and up to 16% in some reports [282],[127].  
In the elderly, different cohorts report an incidence and prevalence of 6-21.8%.[283-285]. Limited 
epidemiological data suggest that the incidence of uveitis may be increasing, at least in the western 
world, perhaps reflecting the general rise in autoimmune diseases, although this needs confirmation 
by appropriately designed studies [279]. Suhler et al.[286] in 2008 looking at the incidence and 
prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest found a crude 
incidence of 25.6 cases/100.000 person-years, and a prevalence of 69 cases/100.000 persons. There 
are similarities and distinct differences in the patterns of uveitis in the various geographic regions. 
Such patterns of uveitis are influenced by combinations of geographical, environmental and genetic 
factors [274].     In different studies, anterior uveitis is reported to be the commonest form of 
uveitis. Wakefield et al.[287] in Australia report 76% of AU, Rodriguez et al.[228, 288-292]in the 
United States and all European series report 49-92% of anterior uveitis. In a series from the south-
eastern of the US, panuveitis was the most common form of uveitis with 38% of all cases of uveitis, 
AU and PU accounting for 25% and 24% respectively [293]. In Japan, Kotake et al.[294] reported PU 
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being the most common type with 69%, followed by AU (29%) and PU (2%). In London, Perkins et 
al.[295] in 1984 reported 63% of AU, 19% and 18% for panuveitis and posterior uveitis respectively. 
Comparing this pattern to the one of uveitis in Iowa, the authors concluded that genetic factors 
were more important than geographic location in determining the types of uveitis. 
Uveitis is the fifth most common cause of visual loss in the developed world and is estimated to be 
responsible for up to 20% of legal blindness worldwide [296]. 
1.7 Definitions of Visual Impairment and Blindness. 
 
In the US definition, bilateral blindness is defined as BCVA ≤ 6/60 in the better-seeing eye (log MAR 
≥1.00), and visual impairment is defined as BCVA < 6/12 but >6/60 in the better-seeing eye (log MAR 
>0.30 to < 1.00). In the WHO definition, bilateral blindness is defined as BCVA < 6/120 in the better-
seeing eye (log MAR >1.30) and/or visual field < 10°; visual impairment is defined as BCVA < 6/18 but 
≥ 6/120 in the better-seeing eye (log MAR > 0.48 to ≤1.30). 
The SUN group came to a consensus that key visual acuity thresholds that should form the basis for 
reporting results of uveitis studies include 6/15 or worse (visual impairment) and 6/60 or worse 
(severe visual loss or blindness)[124]. 
1.8 Causes of visual loss worldwide and the part of uveitis.  
 
For the past 35 years, the World Health Organisation Programme for the Prevention of Blindness and 
Deafness has maintained a global data Bank on visual impairment with the purpose of storing 
available data on blindness and low vision. In 2002, 208 population-based studies on visual 
impairment for 68 countries were reported [297].  
 In a WHO report, it was estimated that more than 161million people were visually impaired 
worldwide. Of these, 37 million were blind and 124 million had low vision, the main causes of visual 
loss being cataract, glaucoma, AMD and diabetic retinopathy [298]. While many individual ocular 
inflammatory diseases are quite rare, ocular inflammation is one of the more common causes for 
visual disability, including blindness, in the developed world [93],[299].  
 Although the impact of uveitis on vision is well known, there are very few data on its 
prevalence and the incidence among the visually impaired or blind population in the literature; and 
in surveys on the causes of blindness uveitis is usually not included and is probably underestimated 
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[300]. The sequelae of uveitis are considered to be the direct causes of visual loss while the primary 
cause of the disease (uveitis) is not mentioned [301]. 
  It has been estimated that 5%-20% of blindness in the United States is due to the 
complications of ocular inflammation. Nussenblatt et al.[302] reported that uveitis accounted for 
10% to 15% of all cases of total blindness. Iwase et al.[303] looking at the prevalence and causes of 
low vision and blindness in a Japanese adult population found that uveitis accounted for 7%.       
A population based assessment of uveitis in an urban population in Southern India reported that 1 in 
370 people will develop a visual impairment of less than 6/18 in at least one eye and 1 in 625 people 
a visual loss of 6/60 in at least one eye [271]. 
In a hospital survey on blindness in Sierra Leone where secondary cataract and glaucoma were 
correctly attributed to Uveitis, this disease was the second leading cause of blindness, indicating 
how large the proportion of patients with uveitis is among the blind [304]. Williams et al.[305] in 
Scotland reported a prevalence of sight-threatening uveitis of 14.8 per 100,000 within the 
population. Recently, a Hospital based study in Malawi reported 3.6% of bilateral blindness caused 
by uveitis [306].   
Reviewing the causes of visual loss in England and Wales as recorded on BD8 certificates during the 
year April 1999 to March 2000, uveitis was not counted; Bunce et al.[307] noted an increase in the 
three main causes of visual impairment e.g. diabetic retinopathy, AMD and glaucoma comparing to 
the 1990-1991 period and suggested that there is a need to improve the collection of good quality 
data and causes of visual loss. Childhood uveitis is associated with unique diagnostic and 
management issues, tendency for chronic disease, high complication rates, with severe visual 
impairment in up to one-third of all children with uveitis[127],[308]. The rate and spectrum of vision 
threatening complications of paediatric uveitis are significant [309].  Delayed diagnosis, extended 
burden of disease over lifetime, limited treatment options in children, difficult examinations, and the 
risk of amblyopia are all challenges specific to childhood uveitis [310, 311].   De Boer et al. [308] 
reported that even after the average follow up limited to 3 years, 19% of young patients with uveitis 
will develop at least one legally blind eye.  Kump et al. and Friling et al. [312, 313] reported 
respectively 23% and 17% of all children with uveitis having their best corrected visual acuity (BCVA) 
< 6/12.  Looking at the course of disease in childhood uveitis, Smith et al. [314] in the USA recently 
reported that the proportion of patients with vision ≤ 6/60 was 9.2% at baseline, 6.5% at 1 year, 
3.2% at 3 years, 15.1% at 5 years, and 7.7% at 10 years [309].   
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Edelsten et al., in retrospective, multicenter, observational study from three primary and two 
referral ophthalmic units in England found that 17% of paediatric uveitic patients had a visual loss of 
< 6/12 in at least one eye.   
Recent population-based studies have demonstrated that glaucoma, cataract  and macular 
degeneration are the major causes of visual impairment in industrialised societies and their 
prevalence increases markedly with age [315]. The main sight-threatening complications of uveitis 
are cataract formation, glaucoma and maculopathy; these complications also have an increasing 
prevalence in the normal elderly population [300]. In most forms of uveitis, visual morbidity usually 
does not occur from a single episode of uveitis; rather recurrent episodes of inflammation cause 
cumulative damage. However some patients with severe disease can develop refractory cystoid 
macular oedema at an early stage whereas patients with Behçet’s disease can develop devastating 
visual loss within days despite intensive immunosuppression [296]. Suttorp-Schulten et al. 
[3]reporting on the main causes of vision loss in the 20-60 years age group found diabetic 
retinopathy (20%), tapetoretinal degenerations (20%), congenital anomalies (20%), uveitis (10%), 
and trauma (5%). There is little information on the relation of increasing age of onset to the 
prevalence of complications in the adult uveitis population apart from a reported decrease in 
prevalence of intermediate uveitis and an increase in secondary hypertension [316]. Recent 
epidemiological studies looking at serious eye diseases and blindness do not even mention uveitis 
[226, 317-319]. There are few studies documenting the frequency of visual loss in the general uveitis 
population. In a hospital based study from Minnesota from 1962, Darrell et al found a rate of visual 
loss (defined as < 25% of vision) in patients with uveitis of 6% [278]. Rothova reported that 35% of 
uveitis patients suffered from significant visual loss or visual impairment and found a similar rate of 
severe visual loss (< 6/60) in a mixed primary and secondary referral centre over 30 years later [278, 
300]. The latter study found cystoid macular oedema, corneal opacities, and macular inflammatory 
lesions to be the major causes of visual loss resulting from intraocular inflammation. Durrani et 
al.[296] looking at the degree, duration and causes of visual loss in uveitis reported that 69.9% of 
patients had visual loss of ≤ 6/18 in at least one eye of which  45.4% had moderate visual loss (6/18-
6/36), and 54.5% had severe visual loss of ≤ 6/60. Some degree of permanent visual damage was 
found in 24.5% of patients. Of the whole population in this series, 11.4% of patients met the WHO 
blindness criteria.  
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The authors reported panuveitis, Indian or Pakistani origin, increasing patient age, bilateral 
inflammation and increasing duration of visual loss as strong predictor factors of visual loss [296].  
The prevalence of visual loss reported in the later study was higher than those reported in other 
studies [3, 300, 317]. Some degree of referral bias is likely to be present in these studies as they 
investigate patients under treatment in secondary and tertiary centres [120]. 
Visual prognosis is worse in cases that present with severe intraocular inflammation, due primarily 
to retinal and uveal tissue damage in the form of vascular leakage, cystoid  macular oedema, and 
other alterations,  such as secondary cataract, secondary glaucoma, vitreous opacities, retinal scars, 
optic neuropathy and pthisis bulbi [300],[296].  
In a recent study, Forooghian et al. [320] reported that intraocular inflammation in a variety of 
uveitic syndromes could result in foveal atrophy. The cause of this is multifactorial and may include 
dysfunction and atrophy of the retinal pigment epithelium and choroid, CMO, macular ischemia 
secondary to occlusive retinal vasculitis, choroidal neovascularisation, retinal detachment, and 
possibly antibody-mediated damage directed against photoreceptors.  
Uveitis will continue to be, and perhaps, become increasingly more important as a group of 
potentially sight-threatening inflammatory eye diseases that have a significant impact on both the 
visual and systemic health of the generally young adult population that is affected [321].  
1.8.1 Cystoid macular oedema. 
 
The healthy BRB is impermeable to plasma proteins, whereas the BAB is partly permeable to plasma 
proteins. Small amounts of IgG can be found in the aqueous of healthy eyes [322]. Macular oedema 
is a common cause of decreased visual acuity in many ophthalmic diseases. It results from disruption 
of the blood-retinal barrier and subsequent accumulation of fluid leading to increased retinal 
thickness [323]. Patients with uveitis have elevated levels of intraocular IgG, particularly those with 
CMO, retinal ischemia or both. These observations indicate that a damaged BRB leads to both an 
accumulation of fluid in the macula and increased IgG concentration[324].   
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Elevated levels of pro-inflammatory cytokines and vascular endothelial growth factor were found in 
all types of CMO [325]. Numerous molecules may induce the retinal vascular hyperpermeability that 
leads to macular oedema. Depending on the underlying entity, these may include prostaglandins and 
leukotrienes, protein kinase C, nitric oxide, and various cytokines such as vascular endothelial 
growth factor ( VEGF), tumour necrosis factor α ( TNF-α), insulin-like growth factor-1, and 
interleukins [326-328]. 
A factor that often contributes to vascular leakage is the endothelial damage resulting from 
leukocyte adherence to vessel walls (leukostasis), a phenomenon mediated by nitric oxide, adhesion 
molecules, and other inflammatory mediators [328],[329]. In the normal healthy retina, the 
transretinal water fluxes are mediated by glial and pigment epithelial cells. These water fluxes are 
inevitably coupled to fluxes of osmolytes; in the case of glial (Muller) cells, to K+ clearance currents. 
Ischemic/hypoxic alterations of the retinal microvasculature result in gliotic responses which involve 
down-regulation of K+ channels in the perivascular Muller cell end-feet. This means closure of the 
main pathway which normally generates the osmotic drive for the redistribution of water from the 
inner retina into the blood. The result is  intracellular K+ accumulation which, then, osmotically 
drives water from the blood into the glial cells (i.e., in the opposite direction) and causes glial cell 
swelling, oedema, and cyst formation [330],[331]. 
  Clinical CMO that is responsible for a low visual acuity must be differentiated from 
angiographic CMO that can albeit uncommonly be present even without any decrease in visual 
acuity. Fluid progressively accumulates into the outer plexiform layer of the retina and pools into 
cystic spaces. Fluid accumulation can now be better seen with optical coherence tomography (OCT). 
In chronic CMO fluid accumulation is associated with thinning of the retina and fibrosis. At this stage 
CMO may or may not respond to medical therapies, but vision does not improve. Failure of vision to 
improve is because of the thinning and scarring [332].     
 Fluorescein angiography identifies the anatomical location and pattern of vascular leakage 
and is a qualitative and functional study, whereas OCT allows morphologic assessment of macular 
oedema by producing two or three dimensional images of the retinal tissue [333]. FFA and OCT are 
commonly used in conjunction with each other; correlating information obtained by these two 
imaging technologies is important to help understand the patho physiology of macular oedema. 
Some authors have found that macular oedema detected by either FFA or time-domain OCT was 
occasionally not present on the other imaging modality [323, 334, 335].  
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Spectral domain OCT allows the study of structural alterations in the different retinal layers and 
subtle changes associated with disease process [336].  
Using OCT to describe the morphologic characteristics of uveitic macular oedema, Markomichelakis 
et al.[337] reported 3 patterns of macular oedema: diffuse macular oedema (DMO), cystoid macular 
oedema (CMO), serous retinal detachment (RD), and found that epiretinal membrane (ERM) 
coexisted in a significant percentage of patients. The irreversible loss of visual acuity in macular 
oedema is usually attributed to permanent loss of photoreceptor cells, although there is hardly any 
information on changes in photoreceptor function in macular oedema. Assessing photoreceptor 
function in various stages of macular oedema, Lardenoye et al.[338] found that eyes with 
inflammatory or diabetic macular oedema showed decreased directional sensitivity and visual 
pigment density in the macular area. Kiss et al.[339, 340] reported a marked reduction in central 
retinal sensitivity in eyes with active macular oedema and substantial impairment at resolution of 
macular oedema. They also found that reading acuity and reading speed are significantly impaired in 
eyes with macular oedema. In one study, cystoid macular oedema was noted in 33% of all uveitis 
patients, of whom 44% had visual acuity of 20/60 or less in at least 1 eye. Of all uveitis patients, 35% 
had visual acuity of 20/60 or less in at least 1 eye, which was caused by CMO in 42%. Poor visual 
acuity in patients with CMO was associated with the advanced age of the patients, chronic 
inflammation, and various specific uveitis entities.[341] 
Nussenblatt et al.[342] suggested that macular thickening, and not the presence of macular oedema, 
is significantly correlated with visual acuity. Traditionally, the presence of CMO has implied that 
retinal thickening exists concurrently. However, Jun et al.[343] reported cases of cystoid spaces 
within the retina accompanied by normal foveal thickness and contour on OCT. Brar et al.[323] 
hypothesised that visual acuity correlates with the number, size, and location of the cysts and not 
just the presence or absence of cysts.  The reliable prognostic factors distinguishing eyes with CMO 
with a potential for improvement from the eyes with definitively damaged visual acuity are not yet 
known.  Regardless of the various pathogenic mechanisms causing macular oedema, the resulting 
visual acuity depends on many factors in addition to macular thickening, including duration of 
oedema, macular ischemia, photoreceptor impairment and/or loss, retinal pigment epithelium 
dysfunction, flat optical coherence tomography indicating atrophic macula, media opacities as well 
as poor contrast sensitivity, impaired colour vision and advanced age [325, 344, 345]. Sivaprasad et 
al.[346] reported that OCT is an important tool in monitoring the treatment response of uveitic 
macular oedema.  
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They found that assessing the patterns of uveitic macular oedema by OCT gives more useful 
information on the prognosis than the central macular thickness. Inner retinal cystoid oedema is 
more resistant to treatment than any other patterns of oedema and cysts in the inner retinal layers 
may indicate the presence of ERM that is difficult to define clinically[346]. 
 Fundus autofluorescence (FAF) imaging with confocal scanning laser ophthalmoscopy is 
increasingly becoming accepted as it is a noninvasive and rapid procedure for diagnosing macular 
diseases [189]. FAF in normal eyes is determined by the lipofuscin distribution in the retinal pigment 
epithelium. FAF is also influenced by macular pigments in the outer nuclear and outer nuclear and 
outer plexiform layers and in the fibers of Henle and inner nuclear layer of the retina [347].  As 
the concentration of macular pigments is highest in the foveal area, normal FAF exhibits a central dip 
in this area [198]. FAF is increased in many uveitis patients. However, Roesel et al.[198] report only 
50% of pathologic FAF in eyes with angiographically proven CMO. McBain et al.[197] found an 81% 
sensitivity and 69% specificity of FAF imaging for diagnosing macular oedema when compared with 
standard fluorescein angiography. This limitation indicates that FAF may not replace FFA or OCT for 
the detection and follow up of macular oedema [198].  
1.8.2 Uveitic glaucoma. 
 
Secondary glaucoma represents a frequent complication especially in chronic forms of uveitis. 
Different immunological and mechanical alterations can be responsible for the elevation of 
intraocular pressure(IOP) [348]. Uveitic secondary glaucoma is difficult and challenging to manage 
and may jeopardize a favourable visual therapeutic outcome in uveitis patients [349]. The delicate 
tissues of the anterior segment may become swollen, scarred, and distorted, or rendered 
malfunctional by the inflammatory response [350], leading to increase of intraocular pressure, 
glaucomatous damage to the optic nerve, and subsequent loss of visual field [351]. During the past 5 
decades, more light has been shed on cellular and biochemical modifications leading to uveitic 
glaucoma [352]. In a healthy eye, proteins concentration in aqueous humour varies between 10 to 
20mg/100ml. This concentration reaches 2300mg/ml in uveitic eyes[353]. In inflamed eyes, the 
breakdown of the blood-ocular barrier occurs with subsequent influx of proteins as well as 
inflammatory and immune-competent cells[354].       
Though the conventional aqueous outflow route is well characterised[355], the unconventional or 
uveoscleral outflow route is less well understood [356],[357],[358].  
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The latter, studied by Bill et al.[359] showed aqueous humour flow through interstitial spaces of the 
ciliary muscle into the suprachoroidal spaces, moving into the sclera. While removal of proteins from 
the eye is critical for optical clarity, the clearance route of these proteins has been unclear under the 
assumption that the eye is devoid of lymphatics[360]. Fairly recently, using endothelial cell markers, 
podoplanin, a transmembrane mucin- type glycoprotein, specifically detected with D2-40 antibody 
[361] and lymphatic endothelial hyaluronan receptor-1(lymphatic vessels endothelium-1) (LYVE-
1)[362], Yucel et al.[360] determined the presence of lymphatic channels in the human ciliary body.
 Lymphatics are highly permeable to large macromolecules, pathogens and migrant cells as 
they lack continuous basement membrane and pericytes [363],[364],[365].             
Several mechanisms are involved in the pathogenesis of inflammatory glaucoma, including 
obstruction of the trabecular meshwork by inflammatory cells and proteins, trabeculitis, formation 
of anterior and/or posterior synechiae, pupillary block, neovascularisation, and anterior rotation of 
the lens-iris diaphragm. In addition, the use of steroids to control intraocular inflammation may 
cause secondary elevation of IOP [366],[354].         
Inflammatory cells have a cytotoxic effect on tissues and induce the formation of arachidonic acid, 
cytokines, proteolytic enzymes, and free radical molecules. Inflammation and tissue necrosis could 
trigger the IOP rise by a direct action on trabecular endothelial cells, by the formation of peripheral 
anterior synechiae or by a combination of both mechanisms [352]. 
 Looking at the relationship between aqueous humour protein level and outflow facility in 
patients with uveitis, Ladas et al.[367] found that the aqueous flow is significantly reduced in uveitic 
eyes with elevated protein concentration in the anterior chamber when compared with eyes with 
active uveitis but with low aqueous protein level. This suggests that the role of inflammatory cells in 
the trabeculum meshwork blockage mechanism is minor, and is mostly played by proteins [367]. 
There is not always a relationship between the amount of inflammation, as measured by cells and 
flare, and inflammation induced rise of intraocular pressure. One therefore cannot predict in which 
patients intraocular pressure will drop when steroid therapy is increased [368]. 
 Myocilin also called trabecular meshwork-inducible glucocorticoid response protein (TIGR) is 
another protein excreted by the trabeculum, the sclera, the ciliary body and the retina [369, 370].  
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Wentz-Hunter et al.[371, 372] had demonstrated that the hyper expression of TIGR/Myocilin on 
cultured human trabecular endothelial cells induce alterations of their adhesive properties. These 
alterations within the trabecular meshwork increase the outflow resistance [373]. Many 
different types of uveitis have been associated with glaucoma, but certain disorders may have a 
relatively higher risk. For example, glaucoma is believed to be the major long term threat to vision in 
patients with Fuchs’ heterochromic iridocyclitis [374]. Glaucoma is also a major component of the 
Posner-Schlossman syndrome (glaucomatocyclitic crisis) [375].  
 In children, Edelsten et al.[376] suggested that the presence of complications early in the 
course of the disease may cause irreversible anterior segment changes that lead to cataract and 
glaucoma.  Several lines of evidences report glaucoma and elevated IOP to be the most common 
complication in children with chronic anterior uveitis [310],[377].  
1.8.3 Epiretinal membranes. 
 
Macular alterations are frequently seen in intraocular inflammatory diseases and include, apart from 
macular oedema: neovascularisation, both subretinal and retinal; pre-retinal membranes and 
macular holes [378]. A macular epiretinal membrane (ERM) is a disorder of the vitreomacular 
interface characterized by fibrocellular proliferation on the anterior surface of the internal limiting 
membrane (ILM) of the macula [379]. Epiretinal membranes are a common and treatable cause of 
vision loss, occurring in about 7% of the population [380]. Prieto-del-Cura et al.[381] reported 4.1%, 
a cumulative prevalence of epiretinal membranes, choroidal neovascular membranes and macular 
necrosis in complications of uveitis. Khaja et al.[382] found that ERMs occur in approximately 1 in 
21000 children and are most frequently associated with a traumatic, idiopathic, or uveitic cause. 
Gass[383] proposed grading the severity of ERMs on the following clinical scale: translucent 
membranes unassociated with retinal distortion, grade 0; membranes causing irregular wrinkling of 
the inner retina, grade 1; and opaque membranes causing obscuration of the underlying vessels and 
marked retinal distortion, grade 2.   
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 The natural history of epiretinal membranes is variable, with recent studies suggesting that 
the condition in some patients may be non progressive over time with a mild effect on vision [384, 
385].  
The initial progress of idiopathic ERM formation does not usually cause any clinically important 
reduction in vision; however, when advanced, visual acuity can significantly be reduced. Macular 
morphologic and functional abnormalities caused by tractional force generated by ERM such as 
damage to the neurons in the inner retinal layers (similar to macular oedema) and the outer retina 
[386, 387], reduction in perifoveal circulation [388], and macular morphologic changes [389-391] 
have been suggested to be related to a decrease in visual acuity. Gomes et al.[392] hypothesized that 
with time, accumulation of cellular debris in the foveal region results from either photoreceptors 
damage or RPE proliferation. Several studies have shown that foveal thickening is negatively 
correlated with visual acuity [389, 390, 393]. Because alignment of the discs is necessary for normal 
functioning of the photoreceptors, the presence of a normal IS/OS junction on OCT images indicates 
normally functioning photoreceptors [394]. In non operated ERM cases, it has been reported that 
defects in the IS/OS junction are related to poor visual acuity[395]. Photoreceptor disruption 
detected by OCT is found to be a predictor of poor visual outcome in eyes with ERM [391, 394]. Suh 
et al.[391] found that this disruption may be irreversible. Thus, early membrane peeling may 
beneficially prevent further progression of photoreceptor damage in ERM patients with 
photoreceptor disruption. The authors also emphasised that membrane removals should be 
performed carefully to avoid further photoreceptor disruption. Although surgical intervention may 
not be required, different studies have found that a significant proportion of patients have 
worsening metamorphopsia and declining visual acuity requiring surgery [396, 397]. Also 
spontaneous recovery has been reported with PVD. Despite a 70% to 80% success rate of an 
improved visual acuity of more than 2 Snellen lines [396, 398, 399], limited improvement of visual 
acuity of less than 2 Snellen lines may occur after successful ERM removal in the absence of 
significance complications [400]. Chronic untreated ERMs can induce permanent changes in the 
outer layers of the retina secondary to longstanding tractional forces [392]. Known prognostic 
factors such as preoperative visual acuity and duration of symptoms cannot fully explain limited 
visual improvement after successful surgery [396, 398].   
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1.8.4 Cataract. 
 
 Cataract formation is a common finding in uveitis patients either as a direct consequence of 
the disease process or as sequel of long-term corticosteroid use [401, 402]. Some forms of uveitis, 
such as Fuchs’ heterochromic cyclitis or uveitis associated with juvenile idiopathic arthritis(JIA), 
commonly feature cataract as part of the disease process, whereas others result from topical, 
periocular, or systemic corticosteroids used to treat uveitis[403].          
A specific diagnosis may guide clinical approach as well as surgical technique, thus, a comprehensive 
ocular and systemic history along with appropriate laboratory analysis is essential, including 
investigation for possible infectious and autoimmune causes [404],[405] The importance of such 
efforts is evidenced by BenEzra et al.[406] who found increased post-operative inflammation in 
patients with juvenile idiopathic arthritis (JIA)-associated uveitis and least complicated postoperative 
course in those with idiopathic disease. Moreover, increased rates of cataract development are 
encountered with JIA-associated uveitis, though the reported incidence of cataract development in 
children with uveitis varies widely [407].        
 The uveitic cataract poses for the surgeon special challenges given the commonly 
encountered consequences of chronic inflammation, which can include a miotic “stuck down” pupil, 
iris atrophy, posterior synechiae, pupillary membrane, band keratopathy, and bleeding from 
abnormal fragile iris vessels [408]. The goal of most cataract surgery is to improve vision. In young 
children, there is an additional aim to prevent amblyopia [408].  
 Visual results of cataract surgery depend on different uveitic entities and on posterior 
segment abnormalities. Fuchs’ heterochromic cyclitis has historically been thought to have a good 
prognosis after cataract surgery even with incomplete control of anterior chamber cell [409],[410]. 
Patients with observed preoperative macular lesions are at risk for poor visual outcome[411].     
Belair et al.[412] reported an incidence of CMO of 12% at 1 month post cataract surgery in uveitic 
eyes without a statistically significant difference when compared with non inflamed eyes. They 
found an incidence of CMO of 8% at 3 months, whereas in non uveitic eyes, there was no CMO at 3 
months post-op. They reported a 7-fold reduction in postoperative CMO with perioperative oral 
corticosteroids, and an increased risk of postoperative CMO in uveitic eyes with active inflammation 
within 3 months before surgery.  
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Cataract surgery in eyes with uveitis leads to an improvement of vision in the majority of cases. 
Severe postoperative uveitis is the most common postoperative complication and is associated with 
a significant risk of macular oedema in those with anterior disease. In the posterior group, poor 
visual outcome after surgery is most commonly the result of preoperative vision-limiting conditions 
[413, 414]. 
1.8.5 Retinal vasculitis and ischemia. 
 
Optimal retinal neuronal cell function requires an appropriate, tightly regulated 
environment, provided by cellular barriers, which separate functional compartments, maintain their 
homeostasis, and control metabolic substrate transport. Correctly regulated hemodynamics and 
delivery of oxygen and metabolic substrates, as well as intact blood-retinal barriers are necessary 
requirements for the maintenance of retinal structure and function [415]. 
Retinal vasculitis is a rare, but potentially blinding intraocular inflammatory condition with diverse 
aetiology [416],[417].  It belongs to a spectrum of inflammatory disorders involving the posterior 
segment of the eye, collectively assigned a variety of titles including posterior uveitis, uveoretinitis 
or posterior segment intraocular inflammation (PSII). The term PSII encompasses inflammatory 
disease of the choroid, retina, retinal vessels, vitreous and/or ciliary body  and pertains to broad 
range of aetiological and pathological process [416].  Retinal vasculitis represents small-vessel 
inflammation involving the arterioles, the capillaries, and the postcapillary venules, either singly or in 
various combinations. The signs of retinal vasculitis that involves the arterial side of the vasculature 
include attenuation, sheathing and, in some cases, cotton-wool spots representing microinfarcts. 
Sometimes large parts of the superficial retina may become opaque owing to the inflammation of 
the terminal retinal arterioles. Inflammation involving the venous side of the circulation, on the 
other hand, usually produces retinal haemorrhage, oedema, telangiectasia, and microaneurysms, 
although attenuation and sheathing may also be present [418].  The diagnosis of retinal vasculitis is 
clinical, based on an abnormal appearance of retinal vasculature due to inflammation. In many 
cases, abnormalities of retinal vessels may be caused by perivascular changes rather than true 
disease in the vessel wall itself [419]. 
 A strict definition of retinal vasculitis excludes forms of vasculopathy due to non-
inflammatory process such as atherosclerosis, congenital anomalies, or increased blood viscosity. 
Inflammation may involve retinal arteries, veins, or capillaries, although venous involvement is more 
commonly recognised [419].  
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In 2005, the standardization of uveitis nomenclature (SUN) working group came to a consensus that 
the term retinal vasculitis is a descriptive term for those situations in which there is evidence of 
ocular inflammation and retinal vascular changes. The presence of occlusive retinal vasculpathy, in 
the absence of visible inflammation such as in antiphospholipid antibody syndrome, should not be 
considered retinal vasculitis[124]. 
 Although the group provisionally agreed to consider perivascular sheathing and vascular 
leakage or occlusion on fluorescein angiogram as evidence of retinal vascular disease for the 
classification of retinal vasculitis, there was consensus that the definition of retinal vasculitis 
required more work. For example, it was unsolved as to how to distinguish between retinal vasculitis 
and the peripheral vascular sheathing sometimes seen in intermediate uveitis[124]. Retinal vasculitis 
detected by the ophthalmologist can be presenting sign of a systemic disease and has therefore to 
be approached in a multidisciplinary fashion [420]. The list of associated diseases is extensive and 
includes systemic diseases such as Behçet’s disease (BD), multiple sclerosis (MS), sarcoidosis, as well 
as a number of ocular diseases as shown in table 2.2.1 [421].  With a wide variety of disease 
associations, a search for an underlying aetiology should be undertaken based on a meticulous 
history, review of systems, and physical examination. The laboratory evaluation of patients with 
retinal vasculitis is an essential component of the work-up to facilitate detection of any underlying 
disease or to establish a limited differential diagnosis [421]. 
 The pathogenesis of retinal vasculitis is presumed to be an autoimmune phenomenon. 
Numerous studies have demonstrated the presence of CD4+ T cells within and surrounding the 
retinal vessels in patients with retinal vasculitis[422],[423],[424]. However, humoral immunity and 
immune complex formation may also participate in the immunopathogenesis of retinal vasculitis 
[425]. 
 Retinal vasculitis is characterised pathologically by migration of leucocytes across the blood-
retinal barrier leading to oedema and photoreceptor cell dysfunction [426]. Wallace et al have 
evidenced that serum levels of the chemokine macrophage inflammatory protein-1 beta (MIP-1 
beta) were significantly raised in patients with retinal vasculitis, whether active or not, 
demonstrating that chemokines are involved in the pathogenesis of retinal vasculitis [427].  In vivo 
and in vitro studies suggest that antinuclear cytoplasmic antibodies (ANCA) have a role in the 
pathogenesis of vasculitis [428-430]. When activated primed neutrophils degranulate, they generate 
free oxygen radicals [431, 432] which are directly toxic to vascular endothelial cells [432, 433]. ANCA 
are serum autoantibodies directed against neutrophils.  
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ANCA show two principal patterns of staining in immunofluorescence testing: a diffuse cytoplasmic 
pattern and a perinuclear pattern, designated cANCA and pANCA respectively [429]. The 
development of an enzyme immunoassay has revealed that cANCA is directed mainly against 
proteinase3 (PR3), while pANCA is directed mainly against myeloperoxidase (MPO), leading to new 
terminology for cANCA and pANCA: PR3-ANCA and MPO-ANCA, respectively [434-436]. The serum 
positivity of ANCA was found to be associated with several types of diseases that affect small blood 
vessels, including capillaries, venules, and arterioles, and sometimes involve middle-sized arteries 
[437, 438]. The role of cANCA testing is well recognized to aid in the diagnosis of Wegener 
granulomatosis in general setting as well as in an ophthalmological presentation [439-441]. In 
contrast, pANCA testing is useful for the differential diagnosis of glomerulonephritis and systemic 
vasculitis; however, its role in the ophthalmological setting remains to be established [429].   
 ANCA are useful diagnostic serological markers for the most common forms of necrotising 
vasculitis. Gallagher et al.[442] advocated the testing of all patients with retinal vasculitis for serum 
ANCA. Matsuo et al.[429] report that posterior segment manifestations such as retinal vein 
occlusion, anterior ischemic optic neuropathy (AION) and AMPPE were seen in patients with pANCA-
associated vasculitis.  
Retinal blood flow is autoregulated by the interaction of myogenic and metabolic mechanisms 
through the release of vasoactive substances by the vascular endothelium and retinal tissue 
surrounding the arteriolar wall. The close interaction between nitric oxide (NO), lactate, arachidonic 
acid metabolites released by the neuronal and glial cells during neuronal activity and energy-
generating reactions of the retina strive to optimize blood flow according to metabolic needs of the 
tissues. During the evolution of ischemic microangiopathies, impairment of structure and function of 
the retinal neural tissue and endothelium affect the interaction of these metabolic pathways, 
leading to a disturbed blood flow regulation. The resulting ischemia, tissue hypoxia and alterations in 
the blood barrier trigger the formation of macular oedema and neovascularisation [415]. 
 Vasculitis may result in leakage or occlusion of the lumen, and these sequelae account for 
the more advanced signs and symptoms of the disease. Leakage leads to retinal swelling, exudation 
and oedema, whereas retinal venous occlusion results in intraretinal haemorrhage, cotton wool 
spots (corresponding to hold up of axoplasmic flow in areas of ischemic nerve fibre layer) and retinal 
and optic nerve oedema. Venous occlusion may result in capillary nonperfusion and ischemia, with 
subsequent retinal neovascularisation and vitreous haemorrhage leading to further visual loss and, 
in the most severe cases tractional retinal detachment and anterior segment neovascularisation 
leading to secondary glaucoma [416]. Chronic complications are often associated with a poor visual 
prognosis and include branch vein occlusion, central vessel occlusion, macular ischemia, persistent 
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neovascularisation, vitreous haemorrhage, and tractional retinal detachment [421]. Palmer et 
al.[443] reported that patients with ischemic retinal vasculitis had a worse visual outcome when 
compared to those with non ischemic vasculitis. Bentley et al. [202] suggested that a poor visual 
outcome in some patients with posterior uveitis may be predicted by the presence of macular 
ischemia on fluorescein angiography. Macular ischemia secondary to retinal vasculitis can also lead 
to foveal atrophy as demonstrated by Forooghian et al.[320]
  Patients and methods   
           
 
76 
1.9 Diagnostic criteria for different types of uveitis and complications. 
1.9.1 Anterior uveitis. 
 
Anterior uveitis describes inflammation confined to the anterior segment that involves the 
iris or ciliary body. AU may be associated with multiple systemic diseases. While all these diseases 
share the ability to cause inflammation in the anterior uveal tract, the entities often can be 
distinguished by their presentation and course[444]. The sine qua non to diagnose anterior uveitis is 
the presence of leukocytes in the anterior chamber of the eye as detected by slit lamp examination. 
Normal aqueous humour should be virtually acellular. The detection of white cells in the aqueous 
humour is pathognomonic for anterior uveitis [445]. Anterior uveitis can present with acute, chronic 
or recurrent attacks. Anterior uveitis is the commonest type of intraocular inflammation and 
commonly presents as a unilateral sore red eye with pain or photophobia, circumlimbal redness and 
anterior chamber cells and flare. (Fig.1.11). Patients with anterior uveitis usually complain of pain, 
redness, blurred vision, photophobia, and watering.  Blurring of vision, which is perhaps the 
commonest symptom, is caused by turbidity of the aqueous. Photophobia is commonly due to ciliary 
muscle spasm but anterior chamber cellular infiltration, corneal epithelial oedema and pupillary 
muscle involvement can also contribute. Varying degrees of pain seen in anterior uveitis can be 
attributed to ciliary muscle spasm. It is usually a dull aching type of pain or a throbbing sensation. 
Severe pain can be associated with raised intraocular pressure[186]. 
 
                     Figure 1.11 Left eye with anterior uveitis. 
Investigations are rarely undertaken at the first episode of an acute non-granulomatous anterior 
uveitis or in Fuchs' heterochromic iridocyclitis. 
In other cases, the following investigations were requested as appropriate.  
a. Complete Blood Count:-Baseline, Leucocytosis in infectious aetiology 
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b. Erythrocyte sedimentation rate (ESR): Nonspecific indication of a systemic disease. 
c. Mantoux test: when suspecting prior exposure to tubercle bacilli. 
d. Venereal disease research laboratory test (VDRL) to rule out syphilis. 
e. Treponema pallidum hemagglutination test (TPHA): Highly specific for syphilis. 
f. Human leukocyte antigen (HLA) B27: Done in some patients with recurrent attacks of 
anterior uveitis. Not all patients were screened for this. 
g. Antinuclear Antibodies in vasculitis and collagen vascular diseases. 
h. Serum Angiotensin Converting Enzyme in active sarcoidosis. However it can be normal in 
patients with sarcoidosis and it can be physiologically elevated in chronic smokers and in 
children. Interpretation of serum ACE test has to be done in conjunction with clinical 
findings. S ACE is also raised in TB. 
i. Chest X-ray for Tuberculosis,  hilar lymphadenopathy in Sarcoidosis; 
j. Sacroiliac joint X-ray: Ankylosing Spondylitis (done less now as superceded by MRI which is 
done by the rheumatologist).    
k. High resolution CT scan chest: Sarcoidosis (done by the physician as necessary) 
l. Others as indicated by clinical history and examination. 
The above listed tests have to be done on a tailored basis and not all the tests are usually required in 
all patients with anterior uveitis.  
 
Anterior uveitis was classified as acute when the inflammation episode lasted for less than 3 months 
and chronic for cases where the inflammation was present for more than 3 months. Recurrent 
anterior uveitis describes repeated episodes of inflammation separated by periods of inactivity 
without treatment. 
Fuchs’ heterochromic iridocyclitis (FHC). 
 
 FHC is characterized by idiopathic non-granulomatous anterior uveitis. It is of insidious onset 
and chronic in nature. It's commonly seen in young females, mostly unilateral, and patients 
commonly present with blurring of vision in a white eye. Classical presentation of uveitis in Fuchs’ 
heterochromic iridocyclitis is occasional to 1+ anterior chamber cells, aqueous flare of 1+ to 2+, 
diffuse white stellate keratic precipitates on the endothelium which are non-pigmented non-
confluent in nature (Fig.1.12). Absence of posterior synechiae is a pathognomic sign of Fuchs’ 
heterochromic iridocyclitis. Most patients will present with findings at a routine optometry visit with 
signs of complications, e.g. posterior subcapsular lens opacification (PSCLO), or vitritis. Raised IOP is 
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present in about 30% over the course of the disease which may be many years. Patients with FHC do 
not require topical steroids to control the inflammation as they do not work. Heterochromia iridium 
is another feature of the disease due to iris stromal atrophy [446-448] but may also occur in other 
types of chronic anterior uveitis as well. There is no systemic association. Patients may have vitritis 
and require vitrectomy. 
 
Figure 1.12 Fuchs’ heterochromia uveitis showing a white eye with fine KPs. 
1.9.2  Intermediate uveitis . 
Intermediate uveitis is intraocular inflammation involving the anterior vitreous, peripheral 
retina and pars plana. It usually affects patients from 5 to 30 years old, without gender or racial 
preferences. It may be unassociated with any systemic disease, but can be associated with multiple 
sclerosis, sarcoidosis, inflammatory bowel disease and others. Symptoms are blurry vision, floaters 
and distortion of central vision. The syndrome is bilateral in 80% of the patients and chronic with 
periods of exacerbation and remission. Clinical presentation includes: mild to moderate anterior 
chamber inflammation, small keratic precipitates in the inferior portion of the cornea, vitritis, 
vasculitis in the peripheral retina, intravitreal "snowballs," retinal "snowbanking," optic neuritis and 
cystoid macular oedema [131] (Fig.1.13). In the Standardization of Uveitis Nomenclature (SUN) 
working groups international workshop for reporting clinical data the consensus reached was that 
the term IU should be used for that subset of uveitis where the vitreous is the major site of the 
inflammation and if there is an associated infection (for example, Lyme disease) or systemic disease 
(for example, sarcoidosis). The diagnostic term pars planitis should be used only for that subset of IU 
where there is snow bank formation.[449] 
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Figure 1.13 Intermediate uveitis with snowballs (left) and snowbank (right). 
1.9.3 Multifocal choroiditis (MFC) 
 
Multifocal choroiditis (MFC) is conventionally diagnosed when multiple yellowish white 50- 
to 1000-μm spots are seen at the level of the retinal pigment epithelium and inner choroidal layer, 
often accompanied by inﬂammatory cells in the vitreous and/or anterior chamber, optic disc 
swelling and macular oedema.(Fig.1.14) It can be associated with diseases such as sarcoidosis. 
Patients with MCP are usually older (median age 45) [450]. Many MCP patients develop 
inflammation related structural complications such as cataract, CMO, optic neuropathy and 
epiretinal membrane [450].   
 
Figure 1.14 Multifocal choroiditis in a patient with sarcoidosis. 
1.9.4 Punctate inner choroidopathy (PIC) 
 
Punctate inner choroidopathy (PIC) affects healthy young women with moderate myopia 
and manifest a high frequency of bilateral involvement [451]. Slit-lamp biomicroscopy is 
characterised by the absence of cells in the anterior chamber and vitreous cavity. Fundus 
examination  reveals multiple (12-25), small (about 100--300 mm in diameter), gray or yellow, 
opaque round lesions scattered throughout the posterior pole in a random or occasionally linear 
pattern [452] (Fig.1.15). The lesions are under the neurosensory retina at the level of the RPE and 
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inner choroid, and there may be a neurosensory retinal detachment overlying them [450]. In 77% of 
cases, patients with PIC will present with CNVM [450]. 
 
 
                                                               Figure 1.15 Fundus photographs of Punctate inner choroidopathy.                
1.9.5 Acute multifocal placoid pigment epitheliopathy (AMPPE) 
 
Acute multifocal placoid pigment epitheliopathy(AMPPE) is an inflammatory retinochoroidal 
disease characterised by sudden loss of vision and the appearance of  multiple yellow-white, flat 
inflammatory lesions at the level of the RPE and choriocapillaris in the acute phase [453](Fig.1.16). 
The lesions tend to fade after a few days, and after 2 weeks they are replaced by partly depigmented 
pigment epithelium clumps [454] (Fig.1.17). Depending on the localisation of the lesions, patients 
may develop central or paracentral visual loss. The overlying retina usually appears normal. It has 
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predilection for young healthy adults, with peak occurrence between the ages of 20 and 30 years 
[450]. AMPPE lesions are much larger than those seen in PIC and demonstrate hypofluorescence in 
the early phases of the angiogram with late hyperfluorescence [450]. Acute posterior multifocal 
placoid pigment epitheliopathy has been described in association with many common illnesses, 
including mumps, adenoviral infection, and Lyme disease; administration of vaccines for varicella, 
and hepatitis B; and in patients with Wegener’s granulomatosis [455-460]. Vascular inflammation is 
thought to be a component as evidenced by its association with neurosensory hearing loss [461] and 
central retinal vein occlusions[462]. Patients can present with headache, and some patients develop 
cerebral vasculitis and ischemia [463-466].  
 
Figure 1.16 Colour fundus photographs of AMMPE in acute phase. 
 
 
Figure 1.17 Colour fundus photograph of AMPPE in chronic phase with scarring. 
1.9.6 Serpiginous choroidopathy. 
 
Serpiginous choroidopathy is an inflammatory chorioretinopathy characterised by 
inflammatory yellow-grey choroidal lesions that eventually evolve into geographic areas of 
chorioretinal atrophy in both eyes [467-469]. These typically occur in the peripapillary region and 
then spread in a helicoid pattern along the major vascular arcades towards the macula and 
midperipheral retina (Fig.1.18). These lesions are much larger than those observed in PIC. 
Recurrences are common and manifest as yellow-grey extensions at the level of the 
RPE/choriocapillaris, contiguous or as satellites to existing areas of chorioretinal atrophy [470-473]. 
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In approximately one-third of cases inflammatory cells are seen in the vitreous [474]. Chorioretinal 
atrophy and pigmentary changes are prominent in previously affected areas. Visual disability may 
result directly from retinal lesions affecting the central macula, or secondary to the development of 
CNVM as a result of disruption of the Bruch’s membrane- RPE complex [475, 476]. 
 
             Figure 1.18 Serpiginous choroidopathy 
1.9.7 Birdshot retinochoroidopathy (BSRC). 
 
Birdshot retinochoroidopathy (BSRC) is an inflammatory condition characterised by the 
presence of multiple depigmented spots at the level of the RPE and choriocapillaris [477, 478]. The 
disease tends to occur between the ages of 35 and 70, with an average age of presentation of 50 
[450]. It is a slowly progressive disease with profound dysfunction of vision that may not be reflected 
in Snellen visual acuity [479]. Patients with BSRC most commonly present with varying degrees of 
gradual and painless visual loss [453, 480]. Floaters, photophobia, nyctalopia, and disturbances of 
color vision are frequently reported [481-483].  
The diagnosis of BSRC is clinical. Ryan and Maumenee[478] described the fundus lesions as 
‘‘multiple, small, white spots that frequently have the pattern seen with birdshot in the scatter from 
a shotgun.’’ These lesions are found in the midperipheral and peripheral retina.(Fig. 1.19) 
 
Figure 1.19 Fundus color photograph of Birdshot choroidopathy. 
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 In addition to its characteristic ocular features, the condition is unique from the 
immunogenetic standpoint by its association with the HLA-A29 allele which is one of the strongest 
link between an HLA class I antigen and a disease [484, 485].  
Diagnostic criteria include the presence of "birdshot lesions" and intraocular inflammation in both 
eyes. HLA-A29 is supportive of the diagnosis, but not required [486].  Macular oedema is the most 
frequent cause of decreased visual acuity. Macular atrophy, as reflected in OCT evidence of macular 
thinning and mfERG evidence of poor macular function, occurs in patients with long-standing 
birdshot retinochoroidopathy. Measurement of retinal layer thickness by frequency-domain OCT 
suggests that the atrophy occurs primarily in the outer retina [487].  
 Retinal capillary hyperpermeability and resultant cystoid macular oedema are common. The 
main objective of fluorescein angiography in patients with BSCR is the assessment of the retinal 
vasculature, and the following can be observed: attenuated vessels in 83%, irregular veins in 72%, 
and arteriovenous filling time longer than 10s in 6% of patients [488]. Choroidal neovascular 
membrane can also be detected. The cause of visual loss can be determined by this mean.  
ERG assessment of rods and cones is abnormal in a great number of patients, with a variable degree 
of impairment. ERG parameters may show early retinal dysfunction. Typical results show an 
electronegative pattern with a b-wave smaller than the normal or attenuated a-wave resulting in a 
low b:a ratio [481, 489]. 
 Autofluorescence photography can demonstrate the RPE atrophy, which may not be seen by 
other means of investigation. The areas of RPE atrophy do not necessarily correspond to the 
hypopigmented lesions, which suggest that both the choroid and the RPE can be affected 
independently. Retinal pigment epithelium atrophy in the macula may be an important cause of 
poor central visual acuity in eyes with BSCR [200]. 
 
1.9.8  Sympathetic ophthalmia (SO).  
 Sympathetic ophthalmia presents as (SO) presents as a bilateral, granulomatous uveitis 
following trauma to one eye[490]. Penetrating injuries and surgical procedures are the most 
common causes of SO. Other, less common causes are plaque brachytherapy[491], fungal 
keratitis[492], and cyclodestructive procedures[493]. The eye sustaining the injury or surgery is 
referred to as the inciting eye and the fellow eye is called sympathising eye. The time between the 
ocular injury or surgery of the inciting eye to the development of SO is quite varied. The 
sympathising eye usually presents with inflammation within 3 months after the injury but the range 
has been noted to be from 2 weeks to 50 years[494]. About 80% of cases occur within a 3-month 
time frame and 90% occur within 1 year [495, 496].  
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 Patients can present with bilateral acute anterior uveitis with mutton-fat keratic precipitates 
[490, 497]. Lymphocytic infiltration of the iris can lead to thickening and synechiae while change in 
the intraocular pressure may be due to ciliary body shutdown or blockage of trabecular meshwork 
[490]. In the posterior segment, SO can manifest itself in the form of moderate to severe vitritis, 
inflammation of the ciliary body, choroiditis, peripapillary choroidal atrophy and optic nerve 
oedema[490, 497, 498]. Serous retinal detachment and macular oedema may also be present[499]. 
Yellow-white  lesions at the level of retinal pigment epithelium correspond to Dalen-Fuchs nodules 
[500, 501](Fig.1.20). In a recent pilot study Furusato et al.[500, 501]demonstrated that M1 
macrophages are the predominant inflammatory cells within granulomas and DFN of SO. They 
further observed high levels of IL-17 within granulomas and the presence of Th1 and M1 cells. 
 
Figure 1.20 Dalen-Fuchs nodules in SO. 
 Before diagnosing a patient with sympathetic ophthalmia, it is necessary to rule out other 
causes of granulomatous uveitis. The diagnosis is made clinically, Dalen-Fuchs nodules are not a 
prerequisite for diagnosis, and histological proof is not required[502].   
If the patient has sustained previous trauma, one must rule out uveal effusion syndrome, lens 
induced uveitis, and post-traumatic iridocyclitis. Autoimmune illnesses including Vogt-Koyanagi-
Harada syndrome (VKH), sarcoidosis, multifocal choroiditis can be very similar to SO. Dalen-Fuchs 
nodules, choroiditis and papillitis can be found in SO and sarcoidosis. Infiltration by T lymphocytes 
can occur in VKH, SO and sarcoidosis and antibodies to retinal antigens can be identified in both SO 
and VKH[495].    
Intraocular lymphoma and bilateral phacoanaphylaxis can also have a similar presentation to SO. 
Landolfi et al.[503]reported a case where sympathetic ophthalmia presented like multiple 
evanescent white dot syndrome. Atypical presentations have also been reported and include 
progressive subretinal fibrosis with multifocal granulomatous chorioretinitis with the patient having 
antiretinal antibodies [504]. Fluorescein angiography is used commonly to confirm and assess the 
extent of SO. Characteristic findings include multiple fluorescing spots in the pigment epithelium 
during the venous phase of the study corresponding to areas of flourescein leak[505]. In the 
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presence of retinal vasculitis or Dalen-Fuchs nodules, the flourescein leaks will correspond to these 
regions. Staining of optic nerve can also be observed [506].  
1.9.9 Ocular toxoplasmosis (OT). 
  
The hallmark of ocular toxoplasmosis is the characteristic clinical picture of disease reactivation 
(secondary infection), which often makes it unnecessary to refer patients for laboratory testing 
[507]. The typical ocular lesion consists of focal necrotising chorioretinitis accompanied by vitreous 
inflammatory reaction, frequently associated with an adjacent old pigmented scar indicative of 
previous infection [508]. The classic“headlight in the fog” appearance is attributable to the presence 
of active retinal lesions with severe inflammatory reaction[509].(Fig.1.21)  Chorioretinitis in 
individuals with acute acquired toxoplasmosis can arise sporadically or in the context of an outbreak 
of acute disease[510]. Satellite lesions develop in 80% of patients compared with 20% with isolated 
lesions [511]. It is noteworthy that 72% of patients attending for the first time already have a 
combination of an active lesion with a healed retinal scar, indicating that these patients had a 
previously unnoticed retinal lesion [511]. Less typical manifestations comprise large, eventually 
multiple and/or bilateral lesions, endophthalmitis like presentations, punctate outer retinitis, 
neuroretinitis, and scleritis [117, 511-514]. Complications like granulomatous iritis, high intraocular 
pressure, retinal vasculitis and vascular occlusions, rhegmatogenous and serous retinal detachments, 
and diverse forms of secondary pigmentary retinopathies might disguise the original toxoplasmic 
lesion and make the correct diagnosis difficult [511, 512, 514]. OT is typically characterised by 8- to 
16-week active periods of intraocular inflammation in which new retinal lesions are formed and by 
long, disease-free intervals, which may extend for several years. Complications can include fibrous 
bands, secondary serous or rhegmatogenous retinal detachments, optic neuritis and neuropathy, 
cataracts, increased intraocular pressure during active infection, and choroidal neovascular 
membranes. 
 
Figure 1.21 Ocular toxoplasmosis showing an old scar with a satellite active reactivation lesion. 
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  Recurrences in untreated congenital toxoplasmosis can occur in the teenage years[515]. The 
causes of visual loss include location of toxoplasmic lesion in the macular area and retinal 
detachment [511]. Clinical diagnosis of OT, frequently used in practice, is only presumed and reliable 
when typical [516]. Although serology is crucial in acute infections where antitoxoplasma IgM is 
raised, it is not helpful in most of OT patients, who typically have low IgG antibody levels [508]. Even 
though toxoplasmosis is well recognised as the most common form of posterior uveitis worldwide 
and the etiologic agent has been known for over 100 years, there are still significant discrepancies 
regarding how to best diagnose and treat the condition [507]. 
1.9.10 Retinal vasculitis. 
 
Retinal vasculitis is a sight-threatening inﬂammatory eye condition that involves the retinal 
vessels. It may occur as an isolated idiopathic condition, as a complication of infective or neoplastic 
disorders, or in association with systemic inﬂammatory disease [417]. The term vasculitis is not used 
in its original histopathological sense of vessel wall inﬂammation but in the sense of visible clinical 
vessel wall changes seen by ophthalmoscopy and/or fundus ﬂuorescein angiography [517]. The most 
common symptoms reported by patients with retinal vasculitis are blurred vision, scotomata, and 
floaters. Less common symptoms include alteration of color vision, metamorphopsia, and rarely pain 
[518]. Some patients may have minimal or no symptoms if the vasculitis is confined to the retinal 
periphery. Systemic symptoms and signs may be present and suggest an underlying aetiology. 
Important systemic manifestations include oral and genital ulcers, skin lesions ulceration, arthritis, 
rash, neurologic disease, and evidence of embolic disease [519].    
 Detection of retinal vasculitis is made clinically, and is conﬁrmed with the help of fundus 
ﬂuorescein angiography. Active vascular disease is characterised by thickening and cellular infiltrates 
surrounding the basement membrane and retinal vascular wall resulting in white sheathing or 
cuffing of the affected vessels, which may be segmental (skip lesions) or conﬂuent [517].(Fig.1.22) In 
some patients, the peripheral retinal vessels may be preferentially affected. The vasculitis may 
involve the retinal arteries, veins, and/or capillaries although the retinal veins are most commonly 
affected. Minimal anterior chamber cells as well as vitritis, inferior vitreous snowballs, and posterior 
vitreous detachment are also common. Additional findings include retinal haemorrhages, cystoid 
macular oedema, optic disc oedema, or optic atrophy [421]. 
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Figure 1.22 Colour fundus photograph showing retinal vascular sheathing. 
 Characteristic features seen on fluorescein angiography include inflammatory and ischemic 
manifestations such as vascular staining and leakage with typical “skip lesions”, capillary 
nonperfusion, retinal neovascularisation, and sclerosis of vessels. Diffuse capillary leakage is also a 
common finding in many patients [421]. (Fig. 1.23) 
 
Figure 1.23 Diffuse capillary leakage on fluorescein angiography. 
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Table 1.1 Summary of diseases associated with retinal vasculitis[417] . 
Ocular disease Infectious diseases Systemic diseases 
Idiopathic Toxoplasmosis Behҫet disease 
Eales disease Tuberculosis Sarcoidosis 
Birdshot retinochoroidopathy Syphilis Multiple sclerosis 
Intermediate uveitis Lyme disease Crohn’s disease 
Frosted branch angeitis Cytomegalovirus Systemic lupus erythematosus 
Idiopathic retinal vasculitis 
and neuro-retinitis(IRVAN) 
Herpes simplex 
Varicella zoster 
Wegener granulomatosis 
Ankylosing spondylitis 
Vogt-Koyanagi-Harada Syndrome Whipple disease Polyartheritis nodosa 
Sympathetic ophthalmia  Burger disease 
Acute multifocal haemorrhagic retinal 
vasculitis 
Human T-cell lymphotropic virus 
Brucellosis 
Relapsing polychondritis 
Antiphospholipid syndrome 
Multifocal choroidopathy Hepatitis Chug-Strauss syndrome 
Panuveitis Cat scratch disease Sjögren’s disease 
 AIDS Polymyositis 
  Rheumatoid arthritis 
  Dermatomyositis 
  Takayasu disease 
  Primary central nervous system lymphoma 
  Acute leukaemia 
  Cancer-associated retinopathy 
 
 Less commonly, inflammation of the retinal vasculature may occur as an isolated disorder. 
These cases of retinal vasculitis without an associated systemic or ocular disease are termed 
idiopathic retinal vasculitis (IRV). Patients with IRV are typically young adults with no signs or 
symptoms suggestive of an underlying systemic or ocular disease e.g. Eale’s disease. [520]. Once the 
diagnosis of retinal vasculitis is made, investigations can be initiated, the diagnostic work-up being 
tailored according to the patient’s medical history, review of systems, and physical examination. 
 Acute inner retinal ischemia develops secondary to occlusion of the larger retinal vessels. 
The retinal appearance in the affected area depends on whether the occlusion is total or relative, or 
whether it affects an arteriole or a venule. After total occlusion of the arteriolar supply, the inner 
retina is emptied of blood and develops a characteristic whitish ischemic oedema in the inner 
layers[521]. Relative occlusion of the retinal arteriolar supply may lead to the development of 
haemorrhages and microaneurysms in the affected area, sometimes accompanied by a yellowish 
retinal oedema[522]. 
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Chronic inner retinal ischemia is primarily observed as capillary occlusion in the retinal midperiphery 
and periphery. It is diagnosed on the basis of its angiographic appearance: areas of capillary non-
perfusion consist of localised, well defined dark areas caused by closure of the retinal capillaries. In 
these areas, the choroidal contours are blurred, probably as a result of the accumulation of a serous 
material between the pigment epithelium and the retinal photoreceptors[523](Fig.1.24; 1.25) 
 
Figure 1.24 Peripheral capillary nonperfusion 
 
Figure 1.25 Capillary phase of fluorescein angiogram showing focal dropout of the perifoveal papillary arcade indicative of     macular 
ischemia. 
  
 Three patterns of retinal ischemia may be identified by FFA. Peripheral capillary closure is a 
feature of tuberculosis, sarcoidosis, Eale’s disease, and, in rare instances, multiple sclerosis, Behçet 
syndrome, and slow-flow retinopathy. Ischemic branch retinal vein occlusions are characteristic of 
Behçet syndrome and have also been reported in sarcoidosis[524]. Focal capillary dropout at the 
fovea (macular ischemia) is often missed because of either media opacity or a failure to identify the 
fovea at the appropriate phase of the angiogram run[524]. This is an important sign because its 
presence often explains a poor visual outcome despite adequate suppression of disease [525]. 
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1.9.11 Neovascularisation. 
 
 Both retinal neovascularisation at the disc (NVD) (Fig.1.26), elsewhere (NVE) (Fig.1.27) and 
choroidal new vessels leak fluorescein profusely in the late phase of fluorescein angiography. The 
neovascular response may occur secondary to widespread capillary closure or as a direct 
consequence of intraocular inflammation[524]. It is important to identify the presence or absence of 
retinal ischemia in this situation because the management is different. In the former case, laser 
photocoagulation may be indicated (although there is a risk of exacerbating macula oedema), 
whereas in the latter, adequate immunosuppression will usually induce regression of the 
neovascular response[526]. 
 
Figure 1.26 Neovascularisation of the optic disc. 
 
Figure 1.27  Peripheral capillary closure and early NVE. 
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1.9.12 Retinal vein occlusions (RVOs) 
 
 Depending on the location of the obstruction, RVOs can be divided into central retinal vein 
occlusion (CRVO) (Fig.1.28) and branch retinal vein occlusion (BRVO) (Fig.1.29). In BRVO, the 
obstruction is located in one of the branches of the central vein, affecting only part of the posterior 
pole and the portion of the peripheral retina drained by the occluded branch. In CRVO, it is located 
in the central vein, at the level of the optic nerve, so most of the retina is affected[527]. Both BRVO 
and CRVO can be subdivided in two types: ischemic (if more than 10 disc areas of capillary 
nonperfusion are noted on fluorescein angiography) and nonischemic (if fewer than 10 disc areas of 
retinal capillary nonperfusion are identified) [528]. Although most patients with CRVO are over the 
age of 50, it can occur in younger patients, commonly termed papillophlebitis. Younger patients 
frequently have an associated inflammatory cause[529] or coagulopathy [530, 531]. CRVO has also 
been reported in association with glaucoma[532, 533], ocular syphilis[534], acute posterior 
multifocal placoid pigment epitheliopathy [535]” tuberculosis and uveitis[536].  
A CRVO is characterised by what is often called a “blood and thunder” appearance with extensive, 
widespread intraretinal haemorrhages radiating from the optic nerve head, and dilated and tortuous 
retinal veins [537]. Other conditions associated with BRVO include BD, sarcoidosis, antiphospholipids 
syndromes, SLE and toxoplasmosis [538-541]. Risk factors for CRVO include high blood pressure, high 
cholesterol. It may occur as part of disease process or secondary to complications such as 
hypertension or secondary glaucoma. 
 
Figure 1.28 Central retinal vein occlusion(CRVO) 
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Figure 1.29 Branch retinal vein occlusion (BRVO). 
1.9.13 Retinal artery occlusion (RAO). 
 
 Branch retinal artery occlusions (BRAOs) typically occur at vessel bifurcations, with temporal 
vessels being involved 98% of the time[542]. Branch retinal arteries are mainly distributed in the 
nerve fibber layer of the retina, and branches of the capillary form the inner capillary and outer 
capillary plexus. The inner capillary plexus is mainly distributed in the ganglion cell layer while the 
outer capillary plexus is mainly distributed in the inner nuclear cell layer. Therefore, obstruction of 
the central retinal artery or branch retinal artery causes ischemic damage in various retinal layers 
mentioned above [543]. When retinal artery occlusions occur in association with CRVO, the arterial 
component is, in most cases, probably secondary to the CRVO, CRVO causing compression of artery 
in sheath portion with central retina artery [529]. 
Central retinal artery occlusion (CRAO) (Fig.1.30) and BRAO (Fig.1.31) have been reported in 
association with antiphospholipid syndromes, SLE and collagen diseases [544-546]. 
 
 
Figure 1.30 Central retinal artery occlusion (CRAO) showing the typical “cherry-red” spot. 
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Figure 1.31 Branch retinal artery occlusion (BRAO). 
1.9.14 Vogt-Koyanagi-Harada syndrome (VKH). 
 
VKH (Vogt-Koyanagi-Harada) syndrome is an autoimmune disease. Also known as 
uveomeningitic syndrome, is an idiopathic inﬂammatory disease characterised by bilateral, chronic, 
diffuse granulomatous panuveitis frequently associated with neurological, auditory, and 
integumentary manifestations [547]. It is an autoimmune disease against melanin. The prevalence of 
the disease varies among different populations of the world, and it commonly affects pigmented 
races and people of certain genetic predispositions [548]. The most common complaints of VKH 
patients include visual loss in one or both eyes, eye pain, and hearing disturbance. They typically 
show a prodromal aseptic meningitis-like syndrome, such as headache, vertigo, nuchal rigidity, 
vomiting, and low-grade fever. Although considered a systemic condition, VKH can present with 
disease ﬁndings limited to intraocular inﬂammation. In patients with acute VKH, 54% had only ocular 
manifestations, whereas in chronic disease, 40.9% had ﬁndings limited to the eyes[549]. Early ocular 
ﬁndings may include diffuse multiple choroidal granulomas more typical, optic disc swelling, and 
exudative retinal detachment. (Fig.1.32)                  Late ocular 
ﬁndings include depigmentation of the fundus (sunset glow fundus) and occasionally subretinal 
neovascularisation.  According to the clinical features, the course of VKH was classically classiﬁed as 
four distinct phases: prodromal, acute uveitic, chronic, and chronic recurrent stages [550]. The 
diagnosis is essentially clinical, no blood investigations are helpful. It is interesting to note that VKH 
disease can present in patients with clinical features limited to the eye in the acute phase in the 
form of bilateral uveitis associated with exudative retinal detachment, whereas in the chronic phase 
VKH patients may present with sunset glow fundus without extraocular ﬁndings. Recognition of this 
isolated ocular variant of acute and chronic VKH is important for prompt diagnosis. In patients with 
bilateral uveitis, the importance of exudative retinal detachment and sunset glow fundus changes as 
the main diagnostic ﬁndings in acute and chronic VKH, respectively[551]. In patients with uveitis 
without clinically apparent exudative retinal detachment, ultrasonography and ﬂuorescein 
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angiography can detect choroidal and retinal ﬁndings [552-555]. To exclude infection when there are 
meningo-encephalitic signs/symptoms, a lumbar puncture may be required and classically shows a 
lymphocytosis. 
 
Figure 1.32 VKH syndrome with pink optic disc and white choroidal granulomas. 
1.9.15 Behçet’s disease (BD). 
 
Behçet’s disease (BD) is a multisystem disorder that was described in 1937 by the Turkish 
dermatologist, Hulusi Behçet (1889-1948) as consisting of the triad of ocular inflammation and oral 
and genital ulcers. Other systemic manifestations include erythema nodosum, cutaneous 
thrombophlebitis, arthropathy, gastrointestinal disturbances, and, less commonly, central nervous 
system involvement and major vessel thrombosis [556]. 
The diagnosis of BD is entirely clinical as there is no specific diagnostic test. According to the 
International Study group for Behcet’s disease, it requires recurrent oral ulcerations as an essential 
symptom plus any two or more symptoms of genital ulcerations, eye lesions, skin lesions and a 
positive pathergy test [557]. The underlying pathology of Behçet’s disease (BD) is an obliterative and 
necrotizing vasculitis and typically presents itself in the eye as an anterior or posterior uveitis or, 
more commonly, as a panuveitis[558].(Fig.1.33)  
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Figure 1.33 Panuveitis in Behçet’s disease. 
The incidence of posterior segment involvement is reported to be 50–93% [558-560]. An anterior 
uveitis or iridocyclitis is seen frequently, with an associated hypopyon in about a third of cases in 
some series and in 10% of Europeans [561].  
Retinal disease is characterised by severe, often bilateral ischemic retinal vasculitis with retinitis 
which may involve the macula and optic nerve. These recurrent vaso-occlusive episodes ultimately 
result in extensive retinal damage with consequent profound visual loss [556]. Fluorescein 
angiography may show diffuse retinal vascular leakage, late staining of vasculature, leakage from the 
disc, macular oedema, areas of capillary dropout, and neovascularisation [517] 
1.9.16 Sarcoidosis. 
 
 Sarcoidosis is a chronic inflammatory disorder with an unknown aetiology characterised by 
noncaseating granulomas[562]. It is universally accepted that the gold standard for the diagnosis of 
sarcoidosis is histological proof on biopsy tissue showing noncaseating granulomas, and exclusion of 
other diseases that produce granulomatous lesions, such as tuberculosis [563]. Skin, peripheral 
lymph nodes, and lungs are the common biopsy sites for sarcoidosis [564].  
 Many reports in the literature described granulomatous uveitis as the hallmark of 
sarcoidosis. The criteria used to establish the diagnosis was in line with the 1st International 
Workshop on Ocular Sarcoidosis (IWOS) held in 2006 in Tokyo, Japan. According to their report, the 
following clinical signs were most suggestive for ocular sarcoidosis [565]:  
1. Mutton-fat/granulomatous keratic precipitates (KPs) and/or iris nodules (Koeppe/Busacca) 
(Fig.1.34) 
These two signs are the expression of granulomatous changes in the anterior segment of the eye. 
KPs can be large (mutton-fat KPs) or can take the form of smaller granulomatous KPs. The nodules at 
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the pupillary margin (Koeppe nodules) and those in the iris stroma (Busacca nodules) are classic 
manifestations of chronic anterior granulomatous uveitis. 
  
                     A                                                           B                                                           C 
Figure 1.34 Mutton-fat KPs (A), Koeppe nodules (B) and Bussaca nodules(C). 
2. Trabecular meshwork (TM) nodules (Berlin Nodules) and/or Tent-shaped peripheral anterior 
synechiae (PAS). Small nodules are commonly seen on the surface of the TM. The small size of the 
nodules and their colour (white or whitish grey) on the TM (white) make them difficult to find. 
Careful gonioscopic examination with high magnification may help to detect the TM nodules. Tent-
shaped PAS is considered to be the consequence of the resolution and scarring of TM nodules 
representing the same pathology at a different stage of inflammation. TM nodules can disappear 
soon after treatment with topical or systemic corticosteroids, while tent-shaped PAS stay there and 
can be found at any time once they have occurred. 
3. Snowballs/string of pearls vitreous opacities. 
These types of vitreous opacities represent granulomatous changes in the vitreous. These vitreous 
opacities are usually located at the inferior segment of ocular fundus, and can be single or multiple 
and forming a “string of pearls” configuration.(Fig.1.35) They are commonly seen in sarcoidosis, but 
also can be seen in pars planitis and intermediate uveitis associated with multiple sclerosis. 
 
Figure 1.35 Vitreous opacities/ String of pearls. 
4. Multiple chorioretinal peripheral lesions (active and/or atrophic) 
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Multiple chorioretinal lesions in sarcoidosis are small, round, white or whitish-yellow, and present in 
clusters, located at random in the periphery up to 360°, but are most commonly seen 
inferiorly.(Fig.1.36) The lesions are more whitish when active and become more yellowish-greyish 
with more sharp margins when cicatricial. 
 
Figure 1.36 Chorioretinal lesions in sarcoidosis 
5. Nodular and/or segmental periphlebitis (candlewax drippings). (Fig.1.37) 
Nodular or segmental sheathing of retinal veins is a typical manifestation of retinal vasculitis in 
sarcoidosis. It can cause obstruction of the retinal veins, resulting in retinal vein occlusion which may 
be associated with areas of nonperfusion, causing retinal neovascularisation. In addition to these, 
the presence of macroaneurysms in an inflamed eye may be a rare ocular sign of sarcoidosis. 
 
Figure 1.37 Candlewax dripping feature in sarcoidosis. 
6. Optic disc nodules/granulomas and/or solitary choroidal nodule. 
Although these two signs are rare, they are very typical signs of granulomatous uveitis such as 
sarcoidosis and tuberculosis. Optic disc nodules can be large or small. (Fig.1.38) The solitary 
choroidal nodule is usually round and whitish-grey (Fig.1.39). 
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Figure 1.38 Large optic nerve head granuloma in sarcoidosis. 
 
Figure 1.39 Solitary choroidal granuloma in sarcoidosis. 
 
7. Bilaterality. 
More than 80% of patients with ocular sarcoidosis have bilateral uveitis [566]. Bilaterality can be 
established either by clinical examination or by adjuvant methods capable of showing subclinical 
disease. Bilaterality can also be documented when, in addition to activity in one eye, there are 
sequels of previous inflammation in the other eye, such as PAS found on gonioscopic examination. 
To support the diagnosis of ocular sarcoidosis, the following investigations/laboratory tests are 
recommended by the IWOS: 
-Chest X-ray: Showing bilateral hilar lymphadenopathy (BHL). 
- Chest CT scan in patients with a negative chest X-ray 
-Negative Tuberculin test in a BCG-vaccinated patient or in a patient with previously positive 
tuberculin skin test. This state of immune unresponsiveness is known as anergy. It is induced when 
the T-cell's antigen receptor is stimulated, effectively freezing T-cell responses. 
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-Elevated serum Angiotensin Converting Enzyme (ACE) and/or elevated serum lysozyme. 
-Abnormal liver enzyme tests: three times the upper limit of normal values for alkaline phosphatase 
or elevation twice over the upper limit of two of the following liver enzymes: aspartate 
aminotransferase (ASAT), alanine aminotransferase (ALAT), or alkaline phosphatase. 
-Interferon Gamma Release Assays (IGRAs) testing for the exclusion of TB might be useful in the 
diagnosis of ocular sarcoidosis. 
Classic ocular features of OS will be: 
- Anterior uveitis with mutton-fat KPs and/or iris nodules(Koeppe/Busacca) 
- Intermediate uveitis/ posterior uveitis: snowballs/ strings of pearls vitreous opacities, multiple 
choriretinal lesions, BRVO with vitritis, optic nerve nodules. 
Patients who had the diagnosis of ocular sarcoidosis confirmed were jointly followed up by a 
chest physician and the uveitis team. 
1.9.17  Neurosarcoidosis. 
 
The incidence of nervous system involvement in sarcoidosis is about 5% [567]. 
Neurosarcoidosis characteristically presents with the onset of cranial nerve palsies or endocrine and 
electrolyte disturbances in a patient with known systemic sarcoid [568]. Cranial nerve involvement is 
the most common neurological manifestation [569], acute lower motor neurone facial palsy the 
most frequently seen. Many patients also have anterior uveitis. Patients with neurological symptoms 
and associated intraocular inflammation should have a routine work-up for sarcoidosis and the 
differential diagnosis may include multiple sclerosis. Investigations should include MRI scan of the 
brain and orbits and lumbar puncture in selected cases. Tissue biopsy should be attempted when 
clinically accessible lesions are available i.e., conjunctiva or lacrimal gland [569]. 
 
 
1.9.18 Multiple sclerosis (MS). 
 
Multiple sclerosis is primarily an inﬂammatory disorder of the brain and spinal cord in which 
focal lymphocytic inﬁltration leads to damage of myelin and axons. Initially, inﬂammation is transient 
and remyelination occurs but is not durable. Hence, the early course of disease is characterised by 
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episodes of neurological dysfunction that usually recover [570]. It is the most common chronic 
immune-mediated central nervous system disorder among young adults [571]. In most patients, 
clinical manifestations indicate the involvement of motor, sensory, visual, and autonomic systems 
but many other symptoms and signs can occur (Table 1.2). Few of the clinical features are disease-
speciﬁc, but particularly characteristic are Lhermitte’s symptom (an electrical sensation running 
down the spine or limbs on neck ﬂexion) and the Uhthoﬀ phenomenon (transient worsening of 
symptoms and signs when core body temperature increases, such as after exercise or a hot bath) 
[570]. 
Table 1.2 Symptoms and signs of multiple sclerosis.[570] 
 Site                     Symptoms                                               Signs      
 Cerebrum                   Cognitive impairment                       Deficit in attention, reasoning, and                                                                                          
                                                                             executive function (early); dementia (late). 
                   Hemisensory and motor                   Upper motor neuron signs. 
                   Affective                                            Mainly depression 
                   Epilepsy(rare) 
                   Focal cortical deficits(rare) 
                    
 Eye 
Optic nerve 
                                                                                Intermediate uveitis, retinal vasculitis, retinal vein closure  
                  Unilateral painful loss of vision            Scotomata, reduced visual acuity, colour vision, and  RAPD  
                                                                              
     Cerebellum and  
Cerebellar 
pathways                             
                  Tremor                                               Postural and action tremor, dysathria 
                  Clumsiness and poor balance             Limb incoordination and gait ataxia 
 Brainstem                                                    Diplopia, oscillopsia                               Nystagmus, internuclear and other complex ophthalmoplegias. 
                  Vertigo 
                  Impaired swallowing                            Dysarthria 
                  Impaired speech and emotional           Pseudobulbar palsy 
                  lability. 
                  Paroxysmal symptoms 
 Spinal cord                                     Weakness                                             Upper motor neuron signs 
                 Stiffness and painful spasms                Spasticity 
                 Bladder dysfunction 
                 Erectile impotence 
                 Constipation 
 Others                    Fatigue 
                 Temperature sensitivity and exercise intolerance 
 
 In many situations, clinical evidence is suﬃcient for establishment of the diagnosis and 
laboratory studies are superﬂuous; but, when the diagnosis is ambiguous, investigations can help. 
MRI shows focal or conﬂuent abnormalities in white matter in more than 95% of patients. Their 
presence alone, however, does not make the diagnosis of multiple sclerosis; characteristic 
radiological lesions can appear in people without clinical signs of disease and many individuals older 
  Patients and methods   
           
 
101 
than 50 years have non-speciﬁc white matter cerebral lesions [570]. The presence of oligoclonal 
bands after protein electrophoresis of the cerebrospinal ﬂuid, which is seen in about 90% of 
patients, suggests intrathecal immunoglobulin synthesis [570]. The reported frequency of uveitis in 
MS patients varies widely, from 0.4% to 26.9% [572, 573]. The prevalence of MS in the total 
population of patients with uveitis is 1% to 2% [574]. The most common type is intermediate uveitis 
[575-577] which may be mild or severe with vaso-occlusive disease [578, 579]. The diagnosis of MS is 
always made by a neurologist. 
1.9.19 Juvenile idiopathic arthritis (JIA). 
 
JIA is a collection of heterogeneous chronic childhood arthritides with onset before 16 years 
of age and persisting 6 weeks or longer with likely distinct pathophysiologic mechanisms that lead to 
a common pattern of tissue destruction [580]. There are four subtypes of JIA: persistent 
oligoarticular (four or less joints involved throughout course of disease), extended oligoarticular 
(four or less joints involved during first 6 months and five or more joints involved thereafter), 
rheumatoid factor-positive polyarticular and rheumatoid factor-negative polyarticular. The female : 
male ratio in oligoarticular JIA is 3 : 1[580]. Susceptibility to JIA is inherited; siblings of patients with 
JIA have a 15–30-fold higher risk of developing JIA compared with the general population [581].     
JIA subtypes associated with antinuclear antibodies and those classified among the undifferentiated 
spondyloarthropathies carry the highest risk of ocular involvement [582-585]. The risk of ocular 
involvement is highest in pauciarticular JIA, which predominantly affects girls before 5 years of age. 
The risk of uveitis persists for years after arthritis onset, extending into adulthood [586]. Ocular signs 
include white eyes with intraocular inflammation.(Fig.1.40) In patients with uveitis, AU is present in 
83% of cases, IU in 9%, pan/posterior uveitis in 8%[587]. The functional symptoms are subtle, 
resulting in delayed diagnosis, and contributing to the severity of the ocular involvement [588]. Most 
common ocular complications include posterior synechiae reported in 68%, cataract in 59.6%, band 
keratopathy and glaucoma in 48% and 25% respectively[589]  The diagnosis of JIA was usually made 
by a paediatrician. 
 
Figure 1.40 JIA uveitis. Note a white eye with posterior synechiae and band keratopathy. 
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1.9.20 Ankylosing spondylitis (AS). 
 
Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects the 
sacroiliac joints and is characterised by restricted spinal mobility. Disease may be accompanied by 
peripheral joint symptoms and enthesitis or extraarticular involvement such as uveitis. When 
preceding symptoms occur in individuals ≤ 16 years of age and followed by radiographic sacroiliitis in 
later stages, the disease is termed juvenile onset AS (JOAS) [590].  JOAS differs from its counterpart, 
adult onset AS (AOAS), with clinical features and pattern at onset of high prevalence of peripheral 
expression and low prevalence of axial involvement [591, 592]. Almost 90% of patients with 
ankylosing spondylitis are HLA-B27 antigen positive [593]. Diagnosing early spondyloarthritis (SpA) in 
young patients presenting with symptoms of inflammatory back pain (IBP) and normal findings on 
plain radiographs of the sacroiliac joints (SIJ) remains a challenge in routine practice. This is reflected 
by a substantial diagnostic delay of 5 to 7 years in many cases [594].     
Radiography displays postinflammatory structural changes in the subchondral bone of the SIJ that 
are often visible only after symptom duration of several years [595, 596].  Magnetic resonance 
imaging (MRI) shows early inflammatory changes in bone marrow and soft tissues and is regarded as 
the most sensitive imaging modality for detecting early SpA. It may therefore display early 
inflammatory abnormalities in the SIJ and the spine before the appearance of structural lesions on 
radiography. MRI may allow a confirmation of a diagnosis of early SpA suspected on clinical grounds 
as early as 4 months after symptom onset [597]. The most frequent extraarticular manifestation in 
SpA is eye involvement, which is found in 30%-50% of patients.     
  Prevalence of uveitis increases with duration of disease[598]. Uveitis associated with AS is 
characterised by acute nongranulamatous anterior uveitis with recurrent episodes in most patients. 
Diagnosis is made according to typical clinical features and radiological evidence of bilateral 
sacroiliitis [599]. AAU associated with AS is often recurrent and unilateral, but may flip to the 
alternative eye with subsequent epsodes[600]. The ocular disease may be associated with macular 
oedema and may also become chronic [601]. 
 
1.9.21  Systemic lupus erythematosus (SLE).  
Systemic lupus erythematosus (SLE) is a chronic, relapsing and remitting, autoimmune 
disorder. The clinical presentations are diverse and depend on the organ systems involved [602]. A 
pathologic immune response involving the production of autoantibodies and immune complex-
mediated  tissue damage is thought to play a central role in the disease process[603]. Women with 
SLE outnumber men by 9 : 1 and the peak age of onset ranges from the late teens to the fourth 
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decade of life [604]. Individuals of African or Asian descent appear to be at greatest risk for 
developing the condition [604]. The diagnosis of SLE is based upon the presence of four or more of 
the 11 criteria from the American College of Rheumatology. These criteria are malar rash, discoid 
rash, photosensitivity, oral ulcers, arthritis, serositis (pleuritis or pericarditis), renal disorder 
(proteinuria or cellular casts), neurologic disorder (seizures or psychosis), hematologic disorder 
(haemolytic anaemia or leucopoenia or lymphopenia or thrombocytopenia), immunologic disorder 
(positive tests for antiphospholipid antibodies or anti-DNA antibodies or anti-Sm antibodies or false 
positive serologic test for syphilis), and presence of antinuclear antibodies [605, 606].   
 Retinal vascular changes are a significant ophthalmic finding, as they appear to correlate to 
the degree of systemic disease activity [607]. The retinal microangiopathy associated with SLE is 
thought to result from immune complex-mediated vascular injury and microvascular thrombosis. 
Antiphospholipid antibodies (anticardiolipin antibodies or lupus anticoagulant) may play a critical 
role in some patients [602]. Antiphospholipid antibodies are present in 77% of patients with lupus 
related retinal or optic nerve disease, compared with only 29% of SLE patients without such ocular 
involvement [608]. Retinal findings most commonly associated with lupus are cotton wool spots and 
intraretinal haemorrhages[609].(Fig.1.41) Other retinal manifestations may include microaneurysms, 
vascular tortuosity, arteriolar narrowing, retinal oedema, or exudates [610-612]. Fluorescein 
angiography may be helpful in patient evaluation [610-612].(Fig.1.42)    
 Severe vaso-occlusive retinopathy(Fig.1.43) is a rare but well described entity that is 
associated with widespread retinal capillary nonperfusion, multiple branch retinal artery occlusions, 
ocular neovascularisation, vitreous haemorrhage, and significant resultant visual loss [613, 614]. 
Patients may also develop opportunistic infections of the retina (HZV, HSV, CMV, Toxo) as a 
consequence of their immunosuppressive treatment. 
 
 
 
                   Figure 1.41. Retinal microangiopathy in SLE. 
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                    Figure 1.42 Severe retinal vaso occlusion in SLE. 
 
               
                         Figure 1.43 Capillary nonperfusion with neovascularisation in SLE. 
1.9.22 Diabetes. 
 
There is an underlining association between AU and type I and type 2 diabetes [615-617]. 
Diabetic patients presenting with uveitis, whatever the aetiology, may have severe inflammation, 
reduced vision, and poor glycaemic control [618]. All patients included in this study had a baseline 
blood sugar test and subsequent glycaemic checks, especially for those started on systemic steroids. 
Patients with visual loss due to diabetic retinopathy were excluded from this study. 
1.10 Definition of complications seen in this study. 
1.10.1 Cystoid macular oedema (CMO). 
 
 Cystoid macular oedema is deﬁned as perifoveal macular oedema evident on  biomicroscopy and 
conﬁrmed by ﬂuorescein angiography and/or optical coherence tomography. 
On fluorescein angiography, CMO is recognised as a classic “ﬂower petal” leakage pattern. 
CMO appears as cavitations of the outer plexiform and inner nuclear layers in the OCT scan.(Fig.1.44) 
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Figure 1.44 CMO on fluorescein (Left), on OCT (Right) 
1.10.2 Epiretinal membrane (ERM). 
 
 Epiretinal membrane, also referred to as retinal folds, wrinkling of the internal retinal 
surface, preretinal gliosis, preretinal macular ﬁbrosis, cellophane maculopathy, and macular pucker, 
is a condition characterized by proliferation of abnormal tissues on the surface of the macula or 
central retina of the eye [379, 619, 620].(Fig.1.45) ERMs are associated with a variety of ocular 
diseases, such as vascular occlusion, diabetic retinopathy, cataract, retinal detachment surgery, and 
posterior vitreous detachment, and also occur after photocoagulation, inﬂammation, or prior 
trauma [621-624]. The majority of patients who develop epiretinal membranes are over age 50 years 
[379, 625, 626]. Occasionally, epiretinal membranes can develop in children and young adults [627].   
In early stages, epiretinal membranes may be asymptomatic or may create a mild reduction in visual 
acuity, which seldom progresses below 6/60 [625, 628-630].  Metamorphopsia, central blurring, and 
distortion of the Amsler grid pattern develop once the foveal centre is involved. Absolute scotomas 
are rare. In some cases, membrane contraction may exert tangential traction on the macular retina 
causing severe vision loss [619]. Clinically, epiretinal membranes start as a mild glinting, water-silk, 
shifting light reﬂex on ophthalmoscopic examination [379, 630]  known as cellophane macular reﬂex 
(CMR).  
 
Figure 1.45 Epiretinal membrane. 
 
At this time, superﬁcial retinal vessels cast visible shadows on the pigment epithelium with the 
oblique slit-lamp illumination. As the membrane thickens and contracts, superﬁcial retinal folds or 
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traction lines appear and a glinting reﬂex becomes opaque and gray, and is seen as clumps or bands 
extending over the retinal surface known as preretinal macular ﬁbrosis (PMF). As the retinal traction 
lines develop, the small vessels become increasingly tortuous and macular oedema may develop. 
This change is often apparent on ﬂuorescein angiography [380, 631-635]. OCTs, especially Spectral 
Domain are more sensitive than clinical examination in detecting ERM and vitreo macular traction 
syndrome (VMT)[219]. Epiretinal membrane-induced retinal damage associated with visual acuity 
reduction is located within the outer retina external to the inner plexiform layer [636]. In most 
uveitis patients, it is secondary to CMO. It may spontaneously separate, or may require surgical 
removal if causing visual loss 
1.10.3 Chronic macular damage. 
 
 These occur as a result of cumulative damage over multiple recurrences of inflammation. 
They include macular changes due to long lasting CMO, ERMs, RPE mottling from retinal 
detachments, lamellar macular holes etc. 
A lamellar macular hole is by definition a partial thickness macular hole where the inner layers of the 
fovea are involved with traction and detached from the underlying cellular layers of the fovea. 
Lamellar macular holes typically appear as a round or irregular-shaped, well-circumscribed reddish 
lesion on biomicropscopy, but clinical detection of lamellar holes at an early stage can be difficult 
[637]. On OCT, lamellar macular holes are easily diagnosed, and their characteristic features of an 
irregular foveal contour, break in the inner fovea, intraretinal split and an absence of a full-thickness 
foveal defect with intact foveal photoreceptors are well recognised [638]. 
Macular pseudo holes (MPH) were originally described as being caused by epiretinal membrane 
contraction, which surrounds but does not cover the foveal area [639].(Fig.1.46) Biomicroscopically, 
they often cannot be differentiated from lamellar and full-thickness macular holes. In TD-OCT, they 
are described as having a steep fovea contour and a normal or slightly elevated central and 
paracentral retinal thickness [640]. 
 
Figure 1.46 Fundus colour photograph of macular pseudo hole (left), OCT (Right) 
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Pigmentary changes are seen on funduscopy and can be documented with FAF. Since retina 
autofluorescence is mainly derived from lipofuscin fluorophores [8,9], this method is a valid tool for 
retinal evaluation, providing additional information on RPE viability and function [191, 192]. In 
contrast to normal background fluorescence, hyper- and hypofluorescence seem to be focal 
hallmarks of changes in health and metabolism of RPE and photoreceptor cells. Hypofluorescence is 
mainly attributed to either atrophy of RPE cells or light absorption by melanin pigmentation, 
haemorrhage, or intraretinal exudates [641].  
1.10.4 Choroidal neovascular membrane (CNVM). 
 
 Choroidal neovascular membrane (CNVM) formation is a well-documented sight-threatening 
complication of posterior segment intraocular inflammation (PSII). Patients present with reduced 
visual acuity and distortion. Fundus examination reveals an elevated macula with grey appearance 
and haemorrhages.(Fig.1.47) Based on their histology, Gass classified CNVMs into Type 1 and Type 2 
[642]. In Type 1, the sub epithelial CNVM grows between the basement membrane of the RPE and 
the inner collagenous zone of Bruch's membrane. The CNVMs associated with punctate inner 
choroidopathy (PIC), and with other PSII are assumed to be type 2 membranes; so called 
inflammatory membranes [643]. There is a correlation between leakage on FFA from an active 
CNVM and increased retinal thickness on OCT [644, 645]. OCT diagnostic accuracy, compared to FFA 
as gold standard, is improved with the use of additional colour photographs [646]. 
 
Figure 1.47 Colour fundus photograph of CNVM (Left), OCT (Right). 
1.10.5 Optic atrophy. 
 
 Optic atrophy is a clinical term used to describe an optic disc that is paler than normal. 
(Fig.1.48) Optic atrophy is not a diagnosis but an ophthalmoscopic sign. Evidence of visual loss 
(acuity, colour vision, central vision) and afferent pupillary defect are often present. Most optic 
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atrophy is diffuse and nonspecific, but historical and examination clues exist that help differentiate 
the many causes of optic atrophy [647, 648].  
 
Figure 1.48 Optic atrophy. 
 Optic neuritis is a common feature of inflammatory diseases of the central nervous-system 
such as multiple sclerosis and neuromyelitis optica. It may also reveal systemic inflammatory 
disorders including sarcoidosis, lupus, Sjogren's syndrome, Behcet's disease, or infections such as 
neurosyphilis or with Bartonella [649-651]. Optic disc swelling is a common finding associated with 
Vogt-Koyanagi-Harada disease[652]. In patients with an acute unilateral optic neuropathy, optic 
neuritis in the young patient and ischemic optic neuropathy in the older patient are common 
aetiologies of optic atrophy [647, 648]. Patients with unexplained optic atrophy should be evaluated 
with magnetic resonance imaging to exclude a compressive lesion. Most patients with optic atrophy 
were seen by a neurologist. 
1.10.6 Cataract. 
 
The diagnosis of cataract, mainly PSCLO (Fig.1.49) in type was made on slit lamp examination. The 
clinical diagnosis was made if the lens opacity had a significant impact on vision. Patients with a lens 
opacification that would prevent fundus view had a B-scan ultrasound to rule out a possible retinal 
detachment before being listed for cataract surgery. 
 
Figure 1.49 Posterior subcapsular cataract. 
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 Patients were started on aggressive steroid regimen prior to surgery if macular oedema or posterior 
segment inflammation had occurred. Surgery was performed only when the inflammation was well 
controlled for three months and if visual acuity was reduced to the level where it caused functional 
impairment. The vast majority of patients underwent phacoemulsification with intraocular lens (IOL) 
insertion, most commonly the foldable Acrylic soft lens. 
1.10.7 Glaucoma. 
 
 The diagnosis of glaucoma was made in situations where the intraocular pressure (IOP) was 
greater than 21 mmHg in association with optic disc cupping (Fig.1.50) and/or typical visual fields 
defects. 
 
Figure 1.50 Glaucoma cupped disc. 
1.10.8 Ocular hypertension. 
 
 The term ocular hypertension was reserved for cases where the intraocular pressure (IOP) 
was above 21mmHg on more than two examinations, but with normal visual fields and normal optic 
disc appearance. 
1.10.9 Steroid responder. 
 
 Steroid-induced ocular hypertension/glaucoma is a form of open-angle glaucoma usually 
associated with topical steroid use, but may develop following oral, intravenous, inhaled, or 
periocular steroid administration. In the majority of cases, the IOP lowers spontaneously to baseline 
levels after the steroid therapy is discontinued [653]. Steroid responders were defined as having an 
increase in intraocular pressure (IOP) of 6 mmHg and an absolute IOP 21 mmHg when on steroid  
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together with an anatomically open anterior chamber angle and minimal inflammation[654]. Thus 
steroid-induced OHT/glaucoma can be differentiated from uveitic OHT/glaucoma. 
1.10.10 Hypotony. 
 
 Hypotony is low intraocular pressure (5 mmHg or less). This can be acute, transient, chronic 
or permanent in an individual eye, leading to functional changes. It can be asymptomatic or  
symptomatic  and   structural  changes can be reversible or irreversible [655].  Acute hypotony is any 
immediate lowering of IOP, a process that is often readily reversible. If it can be reversed in 15 days 
to one month, the hypotony is retrospectively termed transient. Transient hypotony is associated 
with severe uveitis and ciliary body dysfunction, retinal detachment, cilioretinal detachment and 
usually is without irreversible functional loss.        
 Chronic (prolonged or persistent) hypotony does not reverse itself easily after two to four 
weeks. Because it is not known how long an individual eye will tolerate a given low pressure, there is 
the danger of irreversible structural and functional changes.  Permanent hypotony denotes 
irreversible structural and functional change that, on the continuum of severity, is close to phthisis 
[656]. The commonest causes are chronic retinal detachment, cyclitic membranes, and chronic 
intractable uveitis. Chronic hypotension shrinks and thickens the sclera. Epiretinal and intraretinal 
gliosis may cause loss of photoreceptors. Proliferation of the non pigmented epithelium of the 
anterior vitreous base then often leads to the formation of a cyclitic membrane in the end- stage 
[657] .  Breakdown of the blood-aqueous barrier and the impairment of intraocular fluid dynamics 
ultimately results in corneal oedema, cataract, and dystrophic calcification of the corneal 
epithelium(band kerathopathy), pigment epithelium, and inner choroid [656].   
1.10.11 Phthisis bulbi. 
 
 Phthisis bulbi defines the end stage appearance of the globe after any multitude of insults 
(i.e. injury or infection or inflammation). The intraocular structures are not easily identifiable, by 
physical exam or with imaging, and there is often calcification within the eye. The globe is small, 
shrunken (Fig.1.51) and anatomically disfigured, with generalised disorganization of the intraocular 
contents.  
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There is a reduced axial length on A-scan ultrasound as compared to the other eye. 
 
Figure 1.51 Phthisical left eye. 
1.10.12 Band keratopathy (BK). 
 
 Calcium deposition in the Bowman's membrane and the stroma of the cornea that 
appearing as an opaque gray streak(Fig.1.52) and occurs in hypocalcaemia and various chronic 
inflammatory conditions of the eye e.g. JIA, chronic posterior uveitis. 
 
Figure 1.52 Band keratopathy. 
1.10.13 Retinal detachment (RD). 
 
 Clinical signs of retinal detachment include sudden visual loss typically occurring like a 
curtain or peripheral visual field defect. Retinal detachment was diagnosed on clinical examination 
using biomicroscopy and indirect ophthalmoscopy. (Fig.1.53)  When the retina is detached, but the 
macula is not, the patients have more subtle physical ﬁndings than when the macula is off because 
the visual centre is still functional[658].  
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Figure 1.53 Retinal detachment. 
 In uveitis, RD can be rhegmatogenous, serous or tractional. Retinal detachment can be 
accurately characterised using ultrasonography, and the size of the detachment can be correctly 
identified within a small sector of the eye (3 clock hours) in 94.2% of cases [659]. Retinal detachment 
is a known complication in uveitis and has been reported in up to 8.3% of cases of pars planitis[660]. 
Brockhurst et al. showed that retinal detachment secondary to peripheral uveitis can be either 
rhegmatogenous or exudative[661]. Retinoschisis has also been reported as a complication of 
intermediate uveitis [661-663], especially following snowbank regression.   
 Rhegmatogenous retinal detachment (RRD) is a potentially blinding ocular pathology. The 
pathogenesis of RRD is a complex process resulting from inherited and/or age-related changes in 
vitreous structure and vitreoretinal adhesion, which predisposes to retinal break formation initiating 
separation of the neural retina from the underlying retinal pigment epithelium (RPE)[664].  
 Tractional retinal detachment occurs when glial fibrosis over the pars plana and peripheral 
retina contracts, causing both tangential and radial traction. This leads to peripheral retinal 
elevation, which in itself relieves further traction, explaining the lack of progression in the vast 
majority of cases. The traction is not exerted by peripheral vitreous, which is usually already 
detached, but from gliosis over the ora serrata[665]. The terms uveal effusion, choroidal effusion, 
ciliochoroidal effusion, ciliochoroidal detachment, and choroidal detachment have been used 
interchangeably in the literature. These labels all describe an abnormal collection of fluid that 
expands the suprachoroidal space, producing internal elevation of the choroid [623]. There are many 
causes of uveal effusion, often occurring in association with hypotony or inﬂammation. Examples 
include trauma, scleritis, pars planitis, and following surgery for cataract, glaucoma, and retinal 
detachment [666]. There is often co-existing, shifting subretinal fluid that may involve the macula. 
Chronic disease may lead to secondary retinal pigment epithelial (leopard spot) changes and 
permanently reduced visual acuity [666]. 
 Central serous chorioretinopathy (CSR) is a disease of the retina characterized by serous 
detachment of the neurosensory retina secondary to one or more focal lesions of the retinal 
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pigment epithelium (RPE)[667]. CSR occurs most frequently in mid-life and more often in men than 
in women [668]. Major symptoms are blurred vision, usually in one eye only and perceived typically 
by the patient as a dark spot in the centre of the visual field with associated micropsia and 
metamorphopsia. CSR has been described in patients with endogenously high levels of 
corticosteroids as well as in patients with hypercortisolism due to the treatment of ocular or 
systemic diseases [669]. Ophthalmoscopic signs of CSR range from mono- or paucifocal RPE lesions 
with prominent elevation of the neurosensory retina by clear fluid - typical of cases of recent onset - 
to shallow detachments overlying large patches of irregularly depigmented RPE. The spectrum of 
lesions includes RPE detachments. Eyes with acute central serous chorioretinopathy (CSC) have focal 
leakage at the level of the retinal pigment epithelium (RPE) seen on fluorescein angiography (FA). 
The subsequent changes at the RPE allow the fluid to enter the subretinal space and constitute the 
sub-retinal fluid(SRF) which can be well documented with OCT[670]. Chronic CSR may be difficult to 
differentiate from occult choroidal neovascularisation secondary to CSR [667]. Serous retinal 
detachment is a common feature in VKH, toxoplasmosis, and in certain metastatic neoplasms. 
Bilateral SRD and multifocal hyperfluorescence beneath the detachment in the early phase of 
fluorescein angiography would support VKH as the most likely diagnosis [166, 671]. 
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Aims and objectives. 
 
 The last main study on causes of visual loss in patients with uveitis was published in 1996 by 
Rothova et al.[300]. They found that 35% of patients were visually impaired, with bilateral legal 
blindness in 4% of patients, 4.5% had one blind eye with visual impairment of the other, and 1.5% 
had bilateral visual impairment. Unilateral blindness developed in 14% of patients, whereas 11% 
exhibited unilateral visual impairment. The most important cause of both blindness and visual 
impairment was cystoid macular oedema (29% and 41% respectively). Complications of uveitis were 
encountered in more than half of the patients and 23% underwent one or more surgical procedures. 
When the patients were subdivided according to anatomical site, those with panuveitis had the 
worst visual prognosis. The systemic diseases associated with poor visual prognosis were juvenile 
chronic arthritis and sarcoidosis. Ocular toxoplasmosis was the most frequent cause of unilateral 
visual loss.  
In the last decade, the treatments for uveitis have changed considerably and many patients are 
much more successfully treated for macular oedema, particularly with intraocular steroids and 
additionally with immunosuppressive agents. 
The outcome of cataract surgery in uveitis patients is very much improved, and more powerful 
topical treatments are available for adequate IOP control. 
Ischemia is not common but does occur in certain types of uveitis and is currently not influenced by 
any of the medications. Vitreoretinal procedures are common for epiretinal membrane removal with 
varying degrees of visual recovery. Retinal thinning from atrophy occurs in certain types of uveitis 
e.g. Birdshot choroidopathy and effect of immunosuppression on this in the long term is unknown. 
Despite advances made in the management of uveitis, patients still lose vision. 
In this study we aimed: 
 To evaluate the types of uveitis,  
 To determine the cause of irreversible visual loss in uveitic eyes. 
 To determine the impact of different surgeries on visual acuity. 
 To assess the impact of different therapeuctics on visual acuity in eyes with ischemia. 
While previous studies had less than 600 patients, our population is three times bigger. We looked 
at the visual outcome in patients with different types of uveitis, treatment and complications. In 
particular we looked at the visual outcome of patients who underwent surgical procedures. 
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The information gathered from this study will enable us to identify the current causes of visual loss 
and address them with targeted therapeutic strategies with the aim of preventing these where 
possible in the future. 
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Chapter 2.  Patients and methods. 
 
Ethics approval for the study was obtained from the R&D department at Moorfields Eye Hospital 
(LIGS 1021). 
This was a retrospective study of patients attending the uveitis clinics of one consultant (Prof. Sue 
Lightman) at Moorfields Eye Hospital from June 2008 to June 2010. Case notes of patients due to 
attend two adults clinics and one paediatrics clinics were pulled out one day before the clinics. I 
reviewed those notes twice a week and extracted data over a two-year period. 
I was aware of a selection and referral bias by using this strategy. 
All patients had their visual acuity (VA) measured separately in each eye by using an illuminated 
Snellen chart at a distance of 6m. The best corrected visual acuity (BCVA) ± a pin hole was recorded. 
If VA could not be measured with the Snellen chart, finger counting, hand movements and light 
perception were assessed at a distance of 1 m. 
A full history was taken by the clinician, including ocular history, past medical history, systems 
review, a sexual history where relevant and drugs history including allergies. 
All patients underwent a full ophthalmological examination including slit-lamp examination, 
funduscopy using indirect ophthalmoscopy after pupil dilation and intraocular pressure (IOP) was 
measured using Goldman applanation tonometry. Ancillary tests such as optical coherence 
tomography (OCT) using Heidelberg Spectralis, Topcon 3D OCT or Zeiss Stratus machines depending 
on the period the patient was seen, fundus fluorescein angiography (FFA) (performed by injecting 
5ml IV of sodium fluorescein 10%), B-Scan ultrasound, electrophysiological and laboratory tests were 
requested as appropriate to the history and the clinical examination. 
Humphrey visual fields were performed for each eye separately when the IOP was raised.  
In this study, uveitis was classified anatomically as per the SUN criteria. 
(i) Anterior uveitis: the inflammation is confined to the anterior segment.    
(ii) Intermediate uveitis: presence of anterior vitreous cells, snowballs or snowbank.    
(iii) Posterior uveitis: the inflammation affects the choroid and/or the retina 
(iv) Panuveitis: the inflammation is present in the anterior chamber, the vitreous, the retina and 
the choroid. 
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To be included in this study, patients had to have a minimum follow-up time of 6 months and have a 
non infective uveitis. Exceptionally, I included cases of Toxoplasmosis choroiditis. Although being an 
infective cause of uveitis, the immune mechanism is more damaging than the parasite itself. 
Patients with bacterial, viral and fungal uveitis, scleritis, retinitis, corneal graft rejection, severe 
allergic keratoconjonctivitis, GVHD,  and those who had another ocular co-morbidity not related to 
uveitis (such as diabetic retinopathy) and which could have an impact on visual acuity were excluded 
from this study.  
Different diagnosis were made by the examining clinicians in accordance with the criteria described 
the Illustrations of different clinical entities included in this study were graciously provided by Prof. 
Lighman from her collection.  
2.1 Data collection. 
 
Data extracted from the case notes and recorded on a designed proforma (Annex) were age, sex, 
date of first presentation, date of onset where possible, best corrected visual acuity (BCVA) at 
presentation and on subsequent visits, intraocular pressure, diagnosis, systemic associated disease, 
treatment, complications and cause of visual loss. Complications or vision loss present at the first 
visit were considered to have occurred on that date, unless there was documentation in the form of 
a referral letter or outside medical records that indicated an earlier date. Complications were 
included only if there was clear documentation of clinically significant events in the case notes. 
Data collected on the proforma were transferred to an excel spreadsheet on MEH HD drive with full 
database protection, and datasheets with patient’s identifiable data were kept locked in a filing 
cabinet in the offices of Prof Lightman. Patients were anonymized on the database by being given a 
study number to comply with the regulations on data protection. 
2.2 Main outcome measures. 
Key outcome measures such as irreversible vision loss < 6/12, i.e. 6/18- 6/36 and vision loss to 6/60 
or worse, and causes of visual loss were recorded.  
For technical reasons the 6/15 Snellen vision cut-off as recommended by Jabs et al[124] was not 
used because the charts used to evaluate visual acuity do not have the 6/15 line.  
The cause of visual impairment was recorded for each eye separately. 
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For patients who developed more than one complication, I chose the complication that caused the 
initial irreversible visual impairment.  
Bilateral visual impairment and blindness were defined by BCVA in the better-seeing eye. If a patient 
was blind in one eye and visually impaired in the other, he/she was considered to have bilateral 
visual impairment. Unilateral visual impairment and blindness were based on BCVA in the worse eye. 
I identified patients who had cataract surgery but did not improve visual acuity. In this group I 
recorded time of onset or first presentation with cataract formation, time of cataract surgery, visual 
acuity at presentation, type of uveitis, visual acuity post operative at 1 month, 3 month, 6 months, 1 
year, 2 years, 3, 4 and 5 years, and cause of visual loss.   
Although the key element of surveillance for patients who undergo glaucoma surgery is IOP 
measurements, in the scope of this study I mainly focussed on the impact of surgery on visual acuity. 
Hence, IOP measurements post glaucoma surgery is not included. 
Patient who developed ischemia were also identified as described earlier. I looked at the impact of 
different treatments including laser on their visual acuity with time.  
In cases of bilateral disease, I report the results seen in all affected eyes, and the results seen in the 
better eye (e.g. the eye with the better visual acuity) [672] 
To enable data comparison, I used the SUN recommendations for reporting data from clinical series 
[124]. Visual acuity results are reported as rates falling below 6/12(i.e 6/18-6/36), or 6/60 or 
worse[672].  
To allow statistical analysis, Snellen visual acuity was converted to Log MAR using the formula: log 
MAR = - log10 (visual acuity fraction). 
Referring to a study by Holladay[270], count fingers at a given distance can be converted to a Snellen 
equivalent by assuming that the fingers are approximately the size of the elements of a 200 feet 
letter. Therefore, a person who can count fingers at 20 feet would have approximately 20/200 
vision. A person able to count fingers at 2 feet would have 2/200 vision or the equivalent of 20/2000. 
Hand motion at a given distance is ten times worse than count fingers, i.e., a person who can detect 
hand motion at 20 feet has approximately 20/2000 Snellen visual acuity equivalent. A person who 
has hand motion at 2 feet would have an equivalent Snellen of 20/20,000. 
In this study, patients had count fingers or hand movements tested at 1m distance. Visual fields 
were not analysed. 
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Eyes that have halved the minimum angle resolution are reported to have improved visual acuity; 
eyes that have doubled the minimum angle resolution are reported to have worsened visual 
acuity[124].  
When looking at associated systemic conditions, we deliberately did not consider HLA-B27 antigen 
to avoid a bias as all patients presenting with any type of uveitis were not systematically screened 
for this. 
2.3  Statistical analysis. 
 
 The IBM SPSS statistics software version 19 was used for statistical analysis. Statistical 
analysis included descriptive statistics of the types of uveitis, age at onset and at final follow up visit, 
complications, and level of visual loss. Multiple comparisons were calculated using the one-way 
ANOVA. The Pearson correlation was used to assess correlation between variables when comparing 
two groups. The Pearson correlation was significant at the 0.01 level. Results are presented with 95% 
confidence interval (CIs). Nominal p values were calculated using t-test and the level of significance 
for changes of visual acuity or other parameters was significant at 0.05.  P value was highly 
significant when < 0.01. 
The incidence rate of visual loss is reported as the number of eyes with visual loss divided by the 
total follow-up of eyes exposed. It is expressed per unit time (e.g., 0.50/Eye-Year). 
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Chapter 3: Demographics of uveitis and visual loss. 
3.1 Introduction 
  
Uveitis may occur at any age, but most commonly afflicts people between 20 and 59 years of age 
[134, 228, 275, 278]. Numerous studies have been performed worldwide to determine the 
distribution, clinical patterns and aetiology of uveitis as this knowledge may assist in improving the 
management of the disease[134]. The aetiologies and disease types of endogenous uveitis differ 
depending on many factors including ethnicity, geographical region, and age. Statistics from Japan 
and European or American countries show distinct characteristic distribution patterns of uveitic 
diseases [280, 673-675].  
Uveitis is not a single disease but includes ocular involvement related to various systemic disorders 
as well as primary ocular conditions. The association of uveitis with systemic disease is well known 
[228]. In 20-30% of cases a systemic disease is associated with the intraocular inflammation [228, 
673]. 
The main complications leading to visual loss are CMO, cataract, glaucoma, retinal detachment, 
vitreous opacities, epiretinal membranes and other chronic macular damage. The extent of visual 
loss is influenced primarily by the location, severity, and duration of CMO [676]. Previous studies 
documented various prognosticators of poor visual outcome in uveitic macular oedema, including 
prolonged duration of the uveitis and of CMO itself, a large foveal avascular zone, the presence of an 
incomplete vitreous detachment, and an increased macular thickness on OCT [325, 341]. The 
advanced age of patients was reported to be an independent factor for early development and poor 
outcome of CMO in uveitis [341, 677]. 
In this chapter I describe the types of uveitis encountered, the proportion of eyes which developed 
visual loss and the causes of visual loss in different types of uveitis. Visual loss at presentation and 
their causes in different follow-up groups is another question I tried to find an answer to. I also 
looked at the impact of systemic diseases on visual acuity in different uveitis entities.  
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3.2 Results 
3.2.1 Demographics. 
 
A total number of 1594 patients (2543 eyes) fulfilled our inclusion criteria. Of these, 737 were males 
and 857 females.      
The mean age at first presentation or onset was 41.8 years (range 3-92). 
The mean follow up was 5.7 years (range 1/2 - 45 years). 
Table 3.1 Patients by age group at presentation. 
 
   
 
 
 
The majority of patients (74%) were in the age group 25-63 years, 8% were aged between 3 and 16 
years. Ten percent of patients were aged > 64 years at first presentation. 
Table 3.2 Mean age at onset/first presentation of different types of uveitis 
Types of uveitis Mean age (SD) 
AU 42.4 (± 17.3) 
IU 39.6 (± 16.8) 
Pu 41.5 (± 15.3) 
Panu                              42.7 (± 18.4) 
 
The difference in age at first presentation of patients with different uveitis types was statistically 
significant (p = 0.043), patients with IU were younger than those with AU or Pan and Pu. 
Age groups 3-16 17-24 25-34 35-44 45-53 54-63 64-95 Tot. 
 
N.patients 
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299 
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224 
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Table 3.3 Types of uveitis, laterality and comparison between sexes. 
Uv. types↓ Unilat (%) Bilat.(%) Male (%) Female(%) Tot.eyes(%) 
AU 332 (51.3) 718 (45.2) 323 (44) 366 (43) 1050 (41.3) 
IU 104 (16) 562 (35.4) 165 (22.5) 220 (25.9) 666  (26.2) 
Pu 139 (21.5) 150 (9.4) 150 (20.5) 139 (16.3) 439 (17.2) 
Panu             72 (11.2) 158 (10) 95 (13) 126 (14.8) 388 (15.3) 
Tot.(%) 647 (100) 1588 (100) 733 (100) 851 (100) 2543 (100) 
 
AU accounted for 41% of all types of uveitis, followed by IU diagnosed in 26% of eyes. A further third 
of eyes developed PU in 17% and Panu in 15%. 
Amongst uveitis that presented as unilateral cases, half were AU, followed by PU, accounting for 
22%. When looking at cases with bilateral involvement, AU accountd for 45%, followed by IU with 
35.4%. 
Both genders developed different types of uveitis in the same proportions. 
Figure 3.1 Types of anterior uveitis by chronicity. 
 
Sixty seven percent of all anterior uveitis were chronic, while AAU and recurrent   accounted for 
33%. 
 
 
 
 
 
AAU/recurrent AU 
33% 
CAU 
67% 
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Table 3.4 Patients by uveitis types and associated systemic diseases. 
 
At least one associated systemic disease was found in 455 patients, representing 29% of our 
population. 
A systemic condition was associated with anterior uveitis in 22%, with intermediate uveitis in 21%. In 
46% and 39%of patients who developed posterior uveitis and panuveitis respectively, a systemic 
disease was present.  
Sarcoidosis was the most common systemic disease associated with all types of uveitis, accounting 
for 10%. Of these, half developed anterior uveitis. 
 Behçet’s disease was found in 4% of patients. Of these, 42.3% developed PU and 30.5% panuveitis.   
Toxoplasmosis was the commonest systemic disease associated with posterior uveitis where it 
accounted for 23.5%. 
Uveitis was associated with MS in 1%, the majority (87%) of whom had intermediate uveitis. Ninety 
one percent of all patients with ankylosing spondylitis associated uveitis developed anterior uveitis. 
Lupus was found in 11 patients, half of these patients developed retinal vasculitis. 
Patients/uv.type→ 
 
Assoc.disease↓ 
AU:689  
----------- 
n. (%)              
IU:385 
----------- 
n. (%) 
 
   PU: 293 
  ---------------- 
    n.  (%) 
Panu: 227      
----------------- 
n. (%) 
 
 Tot.:1594 
----------- 
n.  (%) 
Sarcoidosis 81(11.8) 40(10.4)      9(3.0 ) 34 (14.9.)  164(10.3) 
Behçet’s disease. 7(1.0) 9(2.3)      25(8.5 ) 18 (8)   59(3.7) 
JIA 15(2.2) 4(1.0)      - 6 (2.6)  25(1.6) 
AS 39(5.6) 1(0.3)      1(0.3) 2 (0.9)  43(2.7) 
VKH - 1(0.3)      - 10 (4.4)  11(0.7) 
MS - 11(2.8)      - 2 (0.9)  13(0.8) 
Lupus 1(0.1) 5(1.3)      5(1.7) -  11(0.7) 
Toxo. - -      68(23.2)        -  68 (4.2) 
Miscellanous 11(1.6) 9(2.3)     26(9) 15 (6.6)  61(3.8) 
Total(%) 154(22.3) 80(20.7)     134 (45.7) 87 (38.3)  455(28.5) 
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Table 3.5 Miscellaneous systemic diseases. 
  Disease        N.patients 
Crohn’s disease   3 
Ulcerative colitis   8 
Polymyalgia rheumatic  7 
Interstitial nephritis   3 
              Reiter’s disease                 4 
Rheumatoid arthritis   10 
TB                                                                   18 
Waldenstrom macroglobulinemia  1 
Wegener’s granulomatosis   3 
Intraocular lymphoma                                2 
 
TB was diagnosed or presumed in 18 patients. Rheumatoid arthritis was associated with uveitis in 10 
patients, ulcerative colitis and polymyalgia rheumatica in 8 and 7 patients respectively. Three 
patients developed uveitis associated with interstitial nephritis. One patient had Waldenstrom 
macroglobulinemia associated with uveitis. Three patients had Wegener’s granulomatosis and 2 
other patients had the diagnosis of intraocular lymphoma. 
Table 3.6 Types of uveitis associated with diabetes. 
N.patients  *DM            % 
AU (689) 28               4.1 
IU (385) 19               5 
PU(293) 11               3.8  
Panu(227) 9                 4.0 
Total(1594) 67               4.2 
                                                                         *DM= Diabetes mellitus 
Overall, diabetes was associated with uveitis in 4.2%. It was found to be associated with different 
types of uveitis in the same proportions. 
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            Table 3.7  Eyes with BCVA  6/18-6/36 and BCVA ≤ 6/60  in different uveitis types at presentation. 
BCVA AU(n=1050) 
n.(%) 
IU(n=666) 
n.(%) 
PU(n=440) 
n. (%) 
Panu(n=387) 
n. (%) 
   6/18- 6/36 118 (11.2) 136 (20.4) 85 (19.3) 88 (22.9) 
≤ 6/60 80 (7.6) 52 (7.8) 89 (20.2) 83 (21.6) 
 
Eleven percent of eyes with AU presented with BCVA 6/18- 6/36, and 8% had BCVA 6/60 or worse 
similarly with eyes with IU. In the latter 20% presented with BCVA 6/18-6/36. Eyes with posterior 
uveitis and panuveitis presented with severe visual loss in 20 and 22% respectively. 
Table 3.8 Laterality of visual loss by uveitis types at presentation. 
Laterality 
 
Uveitis types 
Bilat.≤6/60 
 
n.patients  (%) 
Bilat.6/18-6/36 
 
n.patients  (%) 
Unilat. 6/18-6/36 
 
n.patients  (%) 
Unilat ≤6/60 
 
n.patients (%) 
 
6/18-6/36 and ≤6/60. 
 
n.patients  (%) 
AU (n=689) 15  (2.2) 12 (1.7) 63  (16.4) 40 (5.8) 10  (1.5) 
IU  (n=385) 18  (4.7) 10  (2.6) 69  (17.9) 16  (4.1) 9   (2.3) 
PU (293) 10 (3.4) 7 (2.4) 60 (20.5) 55 (18.8) 15 (5.1) 
Panu (227) 16 (7.1) 13 (5.7) 47 (20.7) 40 (17.6) 13 (5.7) 
Total (n=1594) 59  (3.7) 42  (2.6) 239 (15) 151 (9.5) 47 (2.9) 
 
From the whole population, 257(16.1%) developed severe visual loss or blindness in at least one eye. 
Of these, 4% presented with bilateral severe visual loss or blindness. The proportion of patients with 
panuveitis was higher than those with other uveitis types in the latter group. Ten percent of patients 
had unilateral severe vision loss, when a further 3% had severe visual loss in one eye and BCVA 6/18-
6/36 in the other. Fifteen percent of patients had unilateral vision loss to 6/18-6/36 and 3% had this 
level of visual loss bilaterally. 
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Table 3.9   Eyes with BCVA  6/18-6/36  by uveitis types in different follow-up groups (Time from presentation to data collection in years). 
Follow up→ 
n.eyes uveitis type↓ 
1/2 - 1 yr 
n.     v.loss(%) 
>1yr- 3 yrs 
n.     v.loss (%) 
>3yrs – 5 yrs 
n.    v.loss (%) 
>5 yrs- 10 yrs 
         n.     v.loss (%) 
˃ 10 years 
n.   v.loss (%) 
 
AU(n.=1050) 381     31 (8.1) 154    16 (10.4) 120   12 (10)         219    25 (11.4) 176    12(6.8)  
IU(n.=666) 214     19 (8.9)    100    15 (15) 93    15 (16.1)          139    14 (10.3) 120    31(25.8)  
Pu(n.=440) 143     14 (9.8)     66      9 (13.6) 52     7 (13.3)          94    14 (14.9)  85     12 (14.1)  
Panu(n.=387)   119      22 (18.5) 66      8 (12.1) 33    11 (33.3)          89    19 (21.3)  80      20 (25)  
 
The proportion of eyes with AU which developed BCVA 6/18-6/36 did not change much in different 
follow-up groups. Only 7% of eyes with AU followed up for more than 10 years were visually 
impaired. 
Twenty six percent of eyes with IU followed up for more than 10 years were visually impaired, 3 
times fold the proportion of eyes followed up for 1 year or less. 
Visual impairment in eyes with posterior uveitis did not increase with time, while the number of eyes 
with panuveitis with BCVA 6/18-6/36 reached a peak in the group of eyes followed up for 3-5 years 
before a sharp decline and plateauing.     
The incidence rate of visual loss to < 6/12 was 0.02/EY for AU, 0.04/EY and 0.08/EY for IU and Pan 
/Pu respectively. 
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Table 3.10 Eyes with BCVA ≤ 6/60 by uveitis types in different follow-up groups.(Time from presentation to data         
collection in years) 
Follow up→ 
 
Uveitis types↓ 
1/2 - 1 yr 
 
 n.      v.loss(%) 
    >1yr- 3 yrs 
   
n.     v.loss(%) 
>3yrs - 5 yrs 
  
n.     v.loss(%) 
>5yrs - 10 yrs 
 
n.      v.loss(%) 
     >10years                    
 
    n.    v.loss (%) 
 
AU(n=1050)  
 
381    12 (3.1) 
 
154   8 (5.2) 
 
120   10(0.8) 
 
219    14(6.4) 
 
   176     24(13.6) 
 
IU(n=666)  
 
214    11(5.1) 
 
100   5(5) 
 
93      8(8.6) 
 
139    16(11.5) 
   
   120    16(13.3) 
 
Pu (n=440) 
 
143     25(17.5) 
 
66  12 (18.2) 
 
52     14(26.9) 
 
94      34(36.2) 
                                                     
    85     20 (23.5) 
 
Panu(n=387) 
 
119    18 (15.1) 
 
66   9 (13.6) 
 
33      6 (18.2) 
 
89     17 (19.1) 
 
    80     24 (30) 
 
There is a constant increase in the proportion of eyes with severe visual loss with time.  
The incidence rate of visual loss of 6/60 or worse was 0.01/EY for AU, 0.02/EY for IU and 0.13/EY for 
Pan/Pu.  
Table 3.11 Causes of BCVA 6/18-6/36 in different follow- up groups.(Time from presentation to data collection in years) 
FU groups→ 
Complications↓        
   1/2 -1year 
 n.eyes=88(%) 
>1 - 3 years 
n.eyes= 49(%) 
>3 - 5 years  
n.eyes= 42(%) 
>5 -10 years 
n.eyes= 75(%) 
> 10 years 
n.eyes=75(%)   
Tot. (%) 
n.eyes=329 
 
CMO 
    
  54(61.3) 
 
13(26.5) 
 
15((36) 
 
  6(8) 
 
  6(8) 
 
94(28.6) 
 
Chr.mac.damage 
    
  11(12.5) 
 
21(43) 
 
13((31) 
 
 44(58.8) 
 
  46(61.4) 
 
135(41) 
 
Glaucoma 
    
  8(9) 
 
6(12.2) 
 
9(21.4) 
 
 19(25.3) 
 
  8(10.7) 
 
50(15) 
 
Hypotony 
    
  1(1) 
 
- 
 
1(2.3) 
 
 1(1.3) 
 
  - 
 
3(0.9) 
 
Macular ischemia 
    
  2(2.2) 
 
1(2.0) 
 
 - 
 
 1(1.3) 
 
  4(5.3) 
 
8(2.4) 
 
Op. Atrophy 
   
  - 
 
- 
 
- 
 
1(1.3) 
 
 4(5.3) 
 
5(2) 
 
Retinal 
detachment 
  
  - 
 
 
3(6.1) 
 
 1(2.3) 
 
- 
 
 4(5.3) 
 
8(2.4) 
 
Cataract 
    
  6(7) 
 
4(8.2) 
 
 3(7) 
 
3(4) 
 
 1(1.3) 
 
17(5) 
 
Miscellaneous 
 
  6(7) 
 
1(2.0) 
 
  - 
 
- 
 
2(2.7) 
 
9 (2.7) 
 
Total (%) 
 
 88(100) 
 
49(100) 
 
 42(100) 
 
75(100) 
 
75(100) 
 
329(100) 
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CMO was the cause of 2/3 of vision loss to 6/18-6/36 in eyes followed up to one year. The main 
cause of visual loss to 6/18-6/36 in eyes followed up for 10 years or more was chronic macular 
damage. At ten years follow-up, the incidence of glaucoma had tripled. 
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Table 3.12 Causes of BCVA ≤6/60 in different follow up groups.(Time from presentation to data collection in years) 
Follow up 
groups→ 
 
Complications↓ 
1/2 -1 year 
n. eyes=68(%) 
>1-3 years 
n. eyes=41(%) 
>3-5 years 
n.eyes=40(%) 
>5- 10 years 
n.eyes=82(%) 
>10 years 
n.eyes=94(%) 
Total (%) 
n.eyes=324 
 
 
CMO 
 
     19(28.8) 
 
4(10) 
 
6(15) 
 
3(3.7) 
 
1(1.1) 
 
33(10.5) 
 
Chr.mac 
damage 
 
     21(31.8) 
 
12(30) 
 
14(35) 
 
25(30.9) 
 
46(52.9) 
 
118(37.6) 
 
Glaucoma 
 
     8(12.1) 
 
10(25) 
 
8(20) 
 
19(23.5) 
 
14(16) 
 
59(18.8) 
 
Hypotony 
 
      - 
 
2(5) 
 
- 
 
3(3.7) 
 
4(4.6) 
 
9(2.9) 
Mac. Ischemia  
     3(4.5) 
 
6(15) 
 
2(5) 
 
2(2.5) 
 
6(6.9) 
 
19(6) 
 
Op. Atrophy 
 
     2(3) 
 
2(5) 
 
2(5) 
 
9(11.1) 
 
2(2.3) 
 
17(5.4) 
Retinal 
detachment 
 
     8(12.1) 
 
3(7.5) 
 
3(7.5) 
 
2(2.5) 
 
3(3.4) 
 
19(6) 
 
Phthisis 
 
     - 
 
- 
 
3(7.5) 
 
12(14.8) 
 
8(9.2) 
 
23(7.3) 
 
Cataract 
 
     3(4.5) 
 
1(2.5) 
 
1(2.5) 
 
3(3.7) 
 
3(3.4) 
 
11(3.5) 
 
Miscellaneous 
 
     2(3) 
 
   - 
 
1(2.5) 
 
3(4) 
 
   - 
 
6(1.9) 
 
Total 
 
     66(100) 
 
40(100) 
 
40(100) 
 
81(100) 
 
87(100) 
 
314(100) 
 
The main cause of severe visual loss was macular damage throughout.  Ninety one percent of 
phthisis developed from 5 years. Seventy four percent of RD developed within the first five years. 
 The one-way ANOVA shows a stastistically significant correlation between time and glaucoma (p= 
0.034, 0.18-9.1 95% CI), time and phthisis (p= 0.002, 1.9-15.6 95%CI) and time-chronic macular 
damage (p< 0.001, 2.8-10.3 95% CI). The incidence of hypotony, macular ischemia and optic atrophy 
was not affected by time.  
There was no correlation between age at onset of the intraocular inflammation and complications 
developed (p= 0.68). 
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Table 3.13 Complications in different uveitis types. 
  
Glaucoma developed in 32% of eyes with AU, and CMO in 38% of eyes with IU. Chronic macular 
damage was the major cause of visual loss in posterior uveitis and panuveitis, accounting for 59% 
and 46% respectively. Phthisis bulbi occurred mainly in panuveitis and anterior uveitis. Macular 
ischemia developed essentially only in posterior uveitis. Of the total number of eyes which 
developed retinal detachment, 52% had panuveitis. Hypotony developed in 4% of eyes with AU and 
3% of eyes with panuveitis. Miscellaneous complications developed in 15 eyes. These included 
corneal decompensation and opacities in 6 eyes, vitreous haemorrhage in 1 eye, macular 
dysfunction evidenced by electrophysiological tests, and cyclitic membranes.  
 
 
 
 
 
 
Uveitis types→ 
Complications↓ 
    AU 
n.eyes=164(%) 
    IU 
n.eyes=144(%) 
   Pu 
n.eyes=153(%) 
Panu 
n.eyes=192(%) 
Total  
n.eyes=653(%) 
CMO 26 (16) 55 (38.2) 12(7.8) 35(18.2) 128(19.6)) 
Chr. mac damage 40 (24.4) 53 (36.8)  90(58.8) 89(46.3) 272(41.6) 
Glaucoma 52 (31.7) 15 (10.4) 12 (7.8) 23(12) 102(15.6) 
Op.atrophy 4 (2.4) 2 (1.4) 6 (3.9) 6(3.1) 18 (2.7) 
Mac.ischemia - - 27 (17.6) 1(0.5) 28(4.3) 
Phthisis 10 (6.0) -  - 13(6.7) 23(3.5) 
Cataract 14 (8.5) 9 (6.3) - 5(2.6) 28(4.3) 
Retinal detachment 4 (2.4) 9 (6.3) 3 (1.9) 11(5.7) 27(4.1) 
Hypotony 6 (3.7) - - 6(3.1) 12(1.8) 
Miscellaneous 8 (5) 1 (0.7) 3(1.9) 3(1.5) 15(2.3) 
Total (%) 164 (100) 144(100) 153 (100) 192(100) 653(100) 
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Table 3.14 Eyes with BCVA 6/18-6/36 at presentation in patients with a systemic disease associated. 
 
Sarcoidosis was the main systemic disease found in patients who presented with vision loss  6/18-
6/36, accounting for 24%, followed by BD and diabetes with 17% each. Toxoplasmosis accountd for 
15% 
When looking at systemic diseases in different uveitis types which presented with vision loss, 
sarcoidosis was predominant in AU with 43%, and in 32% of eyes with panuveitis. In 17% of eyes 
with IU and visual loss of 6/18 to 6/36 at presentation, sarcoidosis was associated. 
 
 
 
 
 
Uveitis types→ 
 
Assoc. disease↓ 
      AU 
----------------- 
n.eyes=28(%) 
       IU 
----------------- 
n.eyes=12(%) 
 Pu 
----------------- 
n.eyes=39(%) 
    Panu 
------------------ 
n.eyes=34(%) 
 
       Tot. 
------------------- 
n.eyes=88(%) 
Sarcoidosis 12(42.9)  2(16.6) 2(5.1) 11(32.3) 27(23.9) 
Behçet’s disease - 2(16.6) 6 (15.4) 11(32.3) 19(16.8) 
JIA 6(21.4) - -  6(5.3) 
AS 3(10.7) - - - 3(2.6) 
VKH - - - 5(14.7) 5(4.4) 
MS                              1(3.6) 3(25) - - 4(3.5) 
SLE - - 2(5.1)  1(1.8) 
Toxo. - - 17(43.6)  17(15) 
Diabetes 3(10.7) 3(25) 8(20.5) 6(17.6) 20(17.7) 
Miscellaneous 3(10.7) 2(16.6) 4(10.2) 1(2.9) 6(5.3) 
Tot. (%) 28(100) 12(100) 39(100) 34(100) 113(100) 
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Table 3.15 Eyes with BCVA ≤ 6/60 at presentation in patients with a systemic disease associated. 
Uveitis types→ 
 
Systemic disease↓ 
       AU 
__________ 
n.eyes=17(%) 
      IU 
_________ 
n.eyes=12(%) 
 Pu 
_________   
n.eyes=39(%) 
 Panu 
-------------- 
n.eyes=26(%) 
Total 
________ 
n.eyes=94(%) 
Sarcoidosis 4 (23.5) 7(58.4) 1(2.6) 8(30.8) 20(21.2) 
Behçet’s disease - - 16(41) 8(30.8) 24(25.5) 
JIA 7(41.2) 1(8.3) - 5(19.2) 13(13.8) 
AS 1(5.9) - 1(2.6)  2(2.1) 
VKH - - - 2(7.7) 2(2.1) 
MS - 1(8.3) - - 1(1.0) 
SLE - - 3(7.7) - 3(3.2) 
Toxo. - - 13(33.3) - 13(13.8) 
Diabetes 4(23.5) 3(25) 1(2.6) 2(7.7) 10(10.6) 
Miscellaneous 1(5.9) - 4(10.2) 1(3.8) 6(6.4) 
Total 17(100) 12(100) 39(100) 26(100) 94(100) 
 
BD was the main systemic disease found in patients who presented with severe visual loss. It 
accounted for 25%, followed by sarcoidosis with 21%. Toxoplasmosis and JIA were present in 14% of 
eyes with visual loss of 6/60 or worse at presentation. Miscellaneous diseases including ulcerative 
colitis, polymyalgia rheumatic, Crohn’s disease, rheumatoid arthritis, Gout and TB were found in 6% 
of cases with severe visual loss. 
Thirteen percent (344) of affected eyes improved visual acuity over follow up period, while in 9% 
(228 eyes), visual acuity worsened. 
The incidence rates of visual loss to 6/18-6/36 and 6/60 or worse in patients with sarcoidosis were 
0.024/EY and 0.020/EY respectively. 
Incidence rates of visual loss to 6/18 - 6/36 and 6/60 or worse were respectively 0.03/EY and 0.05/EY 
in patients with BD. 
For patients with JIA related uveitis, incidence rates of vision loss were 0.01/EY for 6/18-6/36, and 
0.04/EY for vision of 6/60 or worse. 
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Table 3.16 Patients with chronic complications and systemic disease. 
Complications→ 
Systemic disease↓ 
  CMO 
n.patients=19 
Glaucoma 
n.patients=34 
Mac.ischemia 
n.patients=7 
Op. atrophy 
n.patients=11 
Hypotony 
n.patients=7 
AS - 2(6) - - 1(14.3) 
Behçet’s disease 3(16) 4(11.8) 3(43) 4(36.4) - 
Diabetes 4(21) 6(17.6) - 1(9) 1(14.3) 
JIA 2(10.5) 6(17.6) - - 2(28.6) 
MS - - - 2(18.2) - 
Sarcoidosis 5(26.3) 14(41) - 4(36.4) 3(42.8) 
SLE - 1(3) 3(43) - - 
Toxo 1(5.2) - - - - 
Miscellaneous 4(21) 1(3) 1(14). - - 
Total 19(100) 34(100) 7(100) 11(100) 7(100) 
 
Nineteen patients with chronic CMO had an underlying systemic disease. Of these, 26% had 
sarcoidosis, and 21% had diabetes. BD and JIA were present in 16% and 10.5% respectively. 
Thirty four patients had glaucoma associated with systemic disease. Sarcoidosis was the commonest 
disease, accounting for 41%. JIA and diabetes accounted equally for 18% and BD accounted for 12%. 
The two main systemic conditions associated with macular ischemia were BD and SLE. 
Eleven patients had a systemic disease associated with optic atrophy. BD and sarcoidosis accounted 
for 36.4% each, and MS was found in 18.2%. 
The commonest disease associated with hypotony was sarcoidosis, accounting for 43%, followed by 
JIA with 29%.  
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3.2.2  Sarcoidosis-related uveitis. 
 
 Out of the whole population of uveitis patients, 161(11%) had sarcoidosis associated. Of 
these, 103 females and 58 males (sex ratio 2:1). 
The mean age at first assessment was 45.06 years (STD ± 14.7), range 5-91. The difference of age at 
first presentation for males was 42.4 years (SD 14.8) and 46.5 years (SD 14.5) for females. The 
difference between genders was not statistically significant (p= 0.08). The mean follow up was 6.3 
years, range 0.6- 45 years. 
In 83.8% of patients, the inflammation was bilateral. 
The types of uveitis developed were as followed: 144 AU (48%), 82 IU (27.3%), 74 Pan/pu (24.6%).  
Table 3.17 Eyes with BCVA 6/18-6/36  and ≤ 6/60 at presentation in sarcoidosis associated uveitis. 
Types of uveitis  6/18- 6/36  n.eyes (%)                 ≤ 6/60  n.eyes  (%) 
AU 
n.eyes= 144 
 
  
16  (11.1)                                          8  (5.6) 
IU 
n.eyes=82 
 
  
13  (15.9)                                          4  (4.9) 
PU 
n.eyes=15 
 
  
-                                                       1  (6.6) 
Pan 
n.eyes= 60 
 
  
13 (21.7)                                            8 (13.3) 
 
Twenty two percent of eyes with panuveitis associated with sarcoidosis presented with vision loss to 
6/18-6/36, while 13% had severe visual loss at first visit. Sixteen percent of eyes with IU associated 
with sarcoidosis had 6/18-6/36 at presentation, 5% had visual loss to 6/60 or worse, the same 
proportion for eyes with AU. 
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 Table 3.18 Causes of BCVA 6/18-6/36 in sarcoidosis-related uveitis. 
 
Chronic macular damage was the major cause leading to visual loss to 6/18- 6/36 in eyes with 
sarcoidosis related uveitis, accounting for 35.1%, followed by glaucoma and CMO found in 32.4% 
and 16.2% respectively.  
When looking at different uveitis types separately, glaucoma accounted for 58.8% of all causes of 
BCVA 6/18 - 6/36 in eyes with anterior uveitis, while it caused visual loss in 16.7% of eyes with 
intermediate uveitis and 7% of panuveitis. No eyes with posterior uveitis associated with sarcoidosis 
developed vision loss of 6/18-6/36. 
 
 
 
 
 
 
 
 
 
 
 
 
Uveitis types→ 
Complications↓ 
AU       (%)  IU         (%) Panu    (%) Tot.     (%) 
CMO 2         (11.7) 1           (16.7) 3   (21.4)   6     (16.2) 
Chr.m. damage 4         (23.5) 2           (33.3) 7   (50 )  13    (35.1) 
Glaucoma. 10       (58.8) 1           (16.7) 1   (7.1)  12    (32.4) 
Hypotony -           - -             - 1  (7.1)    1    (2.7)  
Opt. atrophy. -           - 2           (33.3)     2    (5.4) 
Cataract 1          (6) - 2  (14.3)    3    (8.1) 
Total 17        (100) 6          (100) 14 (100)   37   (100) 
                                                                                                               Demographics of uveitis and visual loss       
 
 
136 
Table 3.19 Causes of severe visual loss in sarcoidosis related uveitis. 
Uveitis types→ 
Complications↓ 
AU       (%) IU     (%) Pu   (%) Panu  (%) Total   (%) 
CMO - 1  (16.7) 1 (25) 1 (12.5) 3  (12.5) 
Chr. mac .damage - 3   (50) 2 (50) 1 (12.5) 6  (25) 
Glaucoma 5  (83.3) - - 3 (37.5) 8  (33.3) 
Hypotony - 1  (16.7) - - 1  (4.1) 
Op.atrophy - - 1  (25) - 1  (4.1) 
Retinal detachment - - - 1 (12.5) 1  (4.1) 
Mac. Ischemia - 1  (16.7) - - 1  (4.1) 
Phthisis - -  1 (12.5) 1  (4.1) 
Cataract 1  (16.7)  - 1 (12.5) 2  (8.3) 
Total 6  (100) 6 (100) 4 (100) 8(100) 24  (100) 
 
Glaucoma was the main complication leading to severe vision loss in sarcoidosis related uveitis, 
accounting for 33.3%. In eyes that developed AU, it was the leading cause with 83%. Chronic macular 
damage caused severe visual loss in 50% of eyes with IU. 
Incidence rates for visual loss in sarcoidosis associated uveitis were 0.03/EY and 0.02/EY for visual 
impairment and severe visual loss or blindness respectively. 
3.2.3  Behçet’s disease. 
 
 Sixty three patients (4.3%) of the uveitis population had the diagnosis of Behçet’s disease. Of 
these, 37 were males and 26 females. 
The mean age at first presentation was 38.0 years (range17- 58). There was no difference between 
genders (p=0.60). 
The mean follow-up was 7.3 years (range1/2-38 years). 
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Table 3.20 Types of uveitis in Behçet’s disease. 
 
 
 
 
 
A total of 105 eyes were affected. Of these, 44% developed posterior uveitis and 34% panuveitis. 
Anterior and intermediate uveitis accounted respectively for 9.5% and 12.4% of eyes.  
Figure 3.2 Visual acuity at presentation in males and females patients with BD. 
 
The mean log MAR BCVA at presentation was 0.67(SD 0.87) for males, and 0.29 (SD 0.64) for 
females. The difference was statistically significant (p= 0.049). Overall, 45% of affected eyes 
presented with vision loss. Of these, 19% had BCVA 6/18-6/36 and 26% severe visual loss. 
 
 
 
 
Uveitis types         N. eyes      (%) 
AU 10             (9.5) 
IU 13             (12.4)  
Pu 46             (43.8) 
Panu 36             (34.3) 
Total 105           (100) 
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Figure 3.3 Visual loss at baseline and in different follow-up groups in BD. 
 
At presentation, 19% of affected eyes had BCVA 6/18-6/36, 27% of eyes had severe visual loss or 
blindness. At 1 year follow-up, the number of eyes with vision loss was dramatically reduced to 3% 
for BCVA 6/18- 6/36 and 6% for BCVA≤ 6/60. Then these proportions increased gradually to reach 
9.5% and 14.3% for visual impairment and severe vision loss respectively. At presentation, 4 patients 
(6.3%) were legally blind. This proportion increased to 7.9% (5 patients) over time. Fifteen eyes 
improved visual acuity, while 7 eyes had visual acuity worsened. 
Table 3.21 Causes of visual loss 6/18-6/36 in BD associated uveitis. 
 
 
 
 
 
 
Chronic macular damage was the main cause of BCVA 6/18-6/36 accounting for 52.6%, followed by 
macular ischemia (15.8%). CMO caused BCVA 6/18-6/36 in 2 eyes (10.5%). 
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Follow-up in years. 
BCVA  6/18-6/36 
BCVA ≤6/60  
Complications N.eyes        % 
Cataract 3                15.8 
CMO 2                10.5 
Glaucoma 1                 5.3  
Mac. Ischemia 3                15.8 
Chronic m. damage 10               52.6 
Total 19              100 
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Table 3.22 Causes of BCVA ≤ 6/60 in eyes with BD associated uveitis. 
Complications N.eyes             % 
Cataract 1                     4.2 
CMO 2                     8.3 
Glaucoma 5                     20.8 
Mac ischemia 4                     16.7 
Op. Atrophy 9                     37.5 
Chronic m damage 1                     4.2 
Phthisis 2                     8.3 
Total 24                    100 
 
One third (37.5%) of eyes with BCVA≤ 6/60 had optic atrophy. Glaucoma was the second cause of 
severe visual loss, accounting for 21%, followed by macular ischemia with 17%. Thirteen eyes 
(12.3%) had improved visual acuity, and 10 eyes (9.5%) had worsened visual acuity over follow-up 
time. 
3.2.4  JIA- related uveitis. 
 Twenty five patients (48 eyes) had JIA related uveitis.  Ten were males, 15 females (ratio 1.5 
in favour of females). 
 The mean age at diagnosis was 12.1 years (range 3-49 years). The mean follow-up was 14.5 years 
(range 0.6-41 years). 
Table 3.23 Types of uveitis developed in JIA. 
 
 
 
 
 
Two-third of eyes developed AU. Panuveitis accounted for 25%, and a further 15% of eyes developed 
IU. 
At presentation 10 eyes (20.8%) had BCVA 6/18-6/36, 15 eyes (31.3%) had BCVA ≤ 6/60. The 
incidence rate for visual loss to 6/18-6/36= 0.02/EY, incidence rate for BCVA≥ 6/60 = 0.04/EY.                             
Uveitis types N.                 % 
AU 29               60.4 
IU 7                14.6 
Pan 12               25 
Total 48              100 
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Glaucoma accounted for 43% of causes of severe visual loss, 3 eyes (21.4%) developed chronic CMO. 
Two eyes (14.3%) were phthisical, 2 (14.3%) retinal detachment and 1 eye (7%) had non operated 
cataract.   
Incidence rates for cataract development and for glaucoma were 0.05 /EY and 0.03/EY 
respectively.Twenty-six eyes underwent cataract surgery. Of these, 20 (77%) were aphakic and 23% 
pseudophakic. Of the aphakic eyes, 45% had severe visual loss or blindness, 1 eye had BCVA 6/18-
6/36. Of the pseudophakic eyes, 33.3% developed severe vision loss or blindness, 1 eye had BCVA 
6/18-6/36.  
Overall 8 eyes had improved visual acuity, 4 eyes had worsened visual acuity over follow-up.                                                                                                                                                                                                                                    
3.2.5 Uveitis in Multiple sclerosis. 
 
Thirteen patients (0.8% of the whole population) with MS were identified (24 eyes); 8 were females 
and 5 Males (ratio 1.6). 
Twenty eyes (83.3%) developed intermediate uveitis, 4 eyes (16.6%) panuveitis. 
In the whole group of patients who developed IU (385), 11 patients (2.9%) had MS. 
The mean age at first presentation was 46 years (range 26-78); the mean follow-up was 4.7 years 
(range 0.6-12 years). 
Nine patients (69.2%) had the diagnosis of MS before uveitis, 4 patients presented with uveitis first. 
The mean age at diagnosis of MS was 44.4 years (limits 27-78years). The mean time interval 
between the diagnosis of MS and uveitis was 8.1 years (limits 1-15 years). For patients who 
developed uveitis first, time to diagnose MS varied from 6 months to one year. 
Five eyes (20.8%) had BCVA 6/18-6/36 at first visit, one eye presented with severe visual loss. 
With time, 4 eyes improved visual acuity to normal. 
Causes of visual loss were as followed: 1 eye had chronic macular damage, 1 eye developed optic 
atrophy.     
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3.2.6 Vogt Koyanagi Harada disease (VKH). 
 
Nineteen patients (37 eyes) with VKH were identified. Five were males and 14 females. The mean 
age at first presentation was 28 years ± 14.7 for males, 36 years ± 14.4 for females. The difference 
was not statistically significant. 
Ninety-two percent of eyes had panuveitis, 2 eyes developed IU. 
At presentation, 11 eyes (30%) were visually impaired. Seven eyes (19%) had BCVA 6/18-6/36, 4 eyes 
(11%) had severe visual loss. 
With time, 4 eyes (33.4%) improved visual acuity. 
The causes of irreversible visual loss were as followed: 5 eyes had BCVA 6/18-6/36 due to CMO in 4 
eyes and chronic macular damage in 1 eye. Two eyes had BCVA ≤6/60 due to glaucoma. 
Multivariate tests showed that visual acuity at presentation is a predictive factor for visual outcome 
(p = 0.003) 
3.2.7  Diabetes and uveitis. 
 
Fifty-six patients had diabetes associated with uveitis. The mean ages at presentation were 51.8 
years ± 18.2 for males and 56 ± 10.2 for females. (p= 0.057) 
Table 3.24 Types of uveitis in patients with diabetes. 
Uveitis types AU (n=(1050) 
n.eyes  (%) 
IU (n=666) 
n.eyes (%) 
Pan (n=827) 
n. eyes (%) 
 33 (3.1) 22 (3.3) 36 (4.3) 
  
 Three percent of eyes with AU and IU developed in patients with diabetes. Four percent of eyes 
with panuveitis had diabetes associated.   
The incidence rate for vision loss to 6/18-6/36 was 0.034/EY. 
 
 
 
 
                                                                                                               Demographics of uveitis and visual loss       
 
 
142 
Table 3.25 Causes of visual loss in eyes with diabetes assoctiated uveitis. 
Complications BCVA 6/18-6/36 
n. eyes (%) 
BCVA ≤6/60  
n.eyes (%) 
CMO 5 (35.7) - 
Glaucoma 2 (14.4) 4 (30.8) 
Hypotony 1 (7.1) - 
Macular ischemia 1 (7.1) - 
Chronic mac damage 5 (35.7) 7 (53.8) 
Phthisis - 2 (15.5) 
Total 14 (100) 13 (100) 
 
The main causes of BCVA 6/18-6/36 were CMO and chronic macular damage. In the group of eyes 
which developed severe visual loss or blindness, chronic macular damage was the leading cause with 
53.8% followed by glaucoma accounting for 30.8% 
3.2.8  Birdshot choroidopathy. 
 Twenty four patients (48 eyes) representing 1.5% of the whole population had the diagnosis 
of BSCR. Six patients were males, and 18 females (ratio 3:1). 
The mean age at first presentation was 57.2 years (limits 41-74 years).  
The mean follow up time was 5.9 years (limits 0.6-18 years). 
At presentation, 8 eyes (33.3%) had BCVA 6/18-6/36. Five eyes (20.8%) had vision loss of 6/60 or 
worse. 
Visual loss between 6/18-6/36 was due to chronic CMO in 4 eyes (50%), chronic macular damage in 
2 eyes (25%), and cataract in a further 25%. 
Three eyes developed severe visual loss. In 2 eyes, vision loss was caused by CMO and by chronic 
macular damage in 1 eye. 
Over the follow up period, 6 eyes had gained 3 Snellen lines or more, 3 eyes had lost 3 Snellen lines 
or more. 
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Figure 3.4 Visual loss with time in eyes with BSCR. 
 
At presentation, 10.4% of affected eyes had BCVA 6/18-6/36. At one year follow-up and up to 3 
years, there was no eye with BCVA 6/18-6/36. After 3 years, there was a sharp rise in the number of 
eyes with BCVA 6/18-6/36, reaching 14.3% at 5 years and 50% at 10 years or more. During the first 
year of follow up, the number of eyes with severe visual loss increased from 8.3% at presentation to 
14.3% before starting a gradual improvement to reach 12.5% at 3 years. From 5 years follow-up, no 
eye had severe visual loss. 
Incidence rates on follow-up for visual loss were 0.05/EY and 0.03/EY for BCVA 6/18-6/36 and BCVA 
6/60 or worse respectively. 
3.2.9 Multifocal choroidopathy (MFC). 
 
Fifty two patients with MFC were identified (104 eyes), of whom 20 were males and 32 females. The 
mean age at first presentation was 46.8 years (range 11-79). The mean age for males was 43 years 
(SD± 17.2), and 49 years (SD± 15.8) for females. The difference was not statistically significant (p= 
0.71). 
The mean follow up time was 6.1 years (range 0.6- 20). 
At presentation, 15 eyes (14.4%) had BCVA 6/18-6/36, 16 eyes (15.4%) had BCVA 6/60 or worse. 
Bilateral vision loss to 6/18-6/36 was present in 3.8% of patients and the same proportion presented 
with BCVA 6/60 or worse. 
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Figure 3.5 Visual loss over time in eyes with MFC. 
 
Visual acuity of eyes which presented with BCVA 6/18-6/36 was erratic over time. During the first 
year, there was a dramatic improvement with a drop in the number of eyes visually impaired to only 
3.2% at 1 year follw-up. After 1year, VA worsened. The number of eyes with vision loss reached 18% 
at 3 years follow-up before another drop to 6.3% at 5 years. The proportion of eyes with BCVA 6/18-
6/36 at 10 years follow up or more was almost equal to the proportion at presentation. As for eyes 
with severe visual loss or blindness at presentation, there was an increase in number over time, with 
a peak at five years follow-up. Overall, there were more eyes with severe visual loss or blindness in 
the group of eyes followed-up for 10 years or more. 
The incidence rates of visual loss to 6/18-6/36 and 6/60 or worse were 0.03/EY and 0.06/EY 
respectively. 
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Table 3.26 Causes of visual loss in eyes with MFC. 
Vision loss →                                6/18-6/36 
Complications↓                            n.eyes= 9 (%) 
                         ≤ 6/60  
                      n.eyes= 20 (%) 
Chronic mac. damage/scars         6     (67)                  15       (75)   
CNVM                                           2     (22)                          4       (20) 
CMO                                              1     (11)                          1       (5) 
Total  (%)                                       9    (100)                            20    (100) 
 
With time, 9 eyes with MFC developed visual loss to 6/18-6/36. Chronic macular damage accounted 
for 67%. CNVM and CMO accounted for 22% and 11% respectively. 
Twenty eyes developed severe visual loss due to chronic macular damage in 75%, CNVM and CMO in 
20% and 5% respectively. 
Thirteen eyes (12.5%) with MFC improved visual acuity with time, 16 eyes (15.4%) had visual acuity 
worsened. 
Incidence rates on follow-up for BCVA 6/18-6/36 and ≤ 6/60 were 0.03/EY and 0.06/EY respectively.  
3.2.10 Punctate inner choroidopathy (PIC). 
 
Seventeen patients (28 eyes) with PIC were identified. Fifteen (88%) were females, 2 were males. 
The mean age at first presentation was 33.8 years (range16-58). 
The mean follow up was 4.7 years (range 0.6-11) 
Eight eyes (29%) with PIC presented with BCVA 6/18-6/36, 4 eyes (14.3%) with BCVA ≤6/60. 
Three eyes developed visual loss to 6/18-6/36. This was due to CNVM in 2 eyes and chronic macular 
damage in 1 eye. Five eyes developed severe visual loss due to CNVM. 
Seven eyes (25%) had improved visual acuity, 10.7% had worsened visual acuity at the end of the 
follow-up period. 
Incidence rates for vision loss were 0.02/EY for BCVA 6/18-6/36 and 0.07/EY for BCVA ≤ 6/60. 
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3.2.11 Acute multifocal placoid pigment epitheliopathy (AMPPE). 
 
Eleven patients (22 eyes) had the diagnosis of AMPPE. Ten were males and one female. The mean 
age at first presentation was 27.1 years (range 16-42). 
The mean follow up was 4.3 years (limits 0.6-12). 
At presentation, 5 eyes (22.7%) had BCVA 6/18-6/36, 3 eyes (13.6%) had BCVA 6/60 or worse.  
One eye developed visual loss to 6/18-6/36 due to chronic macular damage and 1 eye due to SRF. 
Three eyes developed severe visual loss due to chronic macular damage in 1 eye, to CNVM in 1 eye, 
and SRF in 1 eye. 
Visual acuity improved in 7 eyes (32%) and worsened in 3 eyes (14%). Multivariate analysis show a 
strong correlation between visual acuity at presentation and final visual acuity (p = 0.04). Age at 
diagnosis and follow-up do not influence visual outcome. 
Incidence rates for vision loss were 0.04/EY and 0.06/EY for BCVA 6/18-6/36 and ≤ 6/60 respectively. 
3.2.12  Fuchs’  heterochromia uveitis (FHU). 
 
In this series, 47 patients (50 eyes) had Fuchs’ heterochromia iridocylitis. Of these, 20 were females 
and 27 males. The mean age at first presentation was 39.6 years (range 15-76). 
The mean follow-up was 7 years (range 0.5-27). 
Three patients (6.4%) had the condition bilaterally. 
Five eyes (10%) presented with IOP> 21mmHg. 
At presentation, 11 eyes (22%) had BCVA 6/18-6/36. Two eyes (4%) had BCVA 6/60 or worse. 
With time, only 3 eyes developed visual loss between 6/18 and 6/36. No eyes had developed severe 
visual loss.  
Twelve eyes (24%) underwent cataract surgery, and 4 eyes (7.7%) developed glaucoma. Of the eyes 
which developed glaucoma, 3 underwent glaucoma surgery. 
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In one eye vision loss was due to glaucoma, and chronic macular damage caused visual impairment 
in 2 eyes. 
3.2.13 Sympathetic ophthalmia. 
 
Twenty patients (20 eyes) developed SO. Thirteen of these were males, 7 females.The mean age of 
patient at first presentation was 41 years (range 4- 85). 
Four eyes (20%) presented with AU, while in 16 eyes (80%), SO manifested as panuveitis. 
At presentation, 5 eyes (25%) had BCVA 6/18-6/36, 3 eyes (15%) had BCVA 6/60 or worse. 
At the end of the follow-up period, 47.4% of eyes maintained visual acuity of 6/12 or better. Four 
eyes developed vision loss to 6/18-6/36 while 5 eyes developed severe vision loss or blindness. Two 
eyes had improved visual acuity, 5 eyes had worsed visual acuity, while in 13 eyes visual acuity 
remained unchanged over time. 
Incidence rates for visual loss were 0.01/EY and 0.02/EY for BCVA 6/18-6/36 and ≤ 6/60  
respectively. Causes of visual loss to 6/18-6/36 were as followed: CMO 2 eyes, hypotony 1 eye and 
RD 1 eye. Severe visual loss was due to hypotony in 1 eye, RD in 1 eye and chronic macular damage 
in 3 eyes. 
3.2.14 Uveitis in patients aged ≤ 16 years. 
 
Ninety five patients aged ≤ 16 were identified (157 eyes). Of these, 51 were males and 44 females. 
The mean age at presentation was 10.1 years (range 3-16).The mean follow up was 1.9 (range 0.6-
11). 
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Figure 3.6 Types of uveitis in 95 patients aged ≤ 16 years. 
 
Anterior uveitis was the most common entity in the paediatric group (63 eyes) representing 40.6% of 
all uveitic eyes in children. Fifty eyes (32%) developed IU 26 eyes developed panuveitis and 16 eyes 
posterior uveitis, representing respectively 16.8% and 10.3%. 
Figure 3.7 Systemic diseases associated with uveitis in children. 
 
We found 24 patients (25.2%) who had a systemic condition associated with uveitis. Of these, 33.3% 
had JIA. Toxoplasmosis and VKH accounted for 20.8% each. Sarcoidosis accounted for 16.6%, 2 
patients had the diagnosis of tubulointerstitial nephritis.   
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Table 3.27  Associated systemic disease by uveitis types in patients aged ≤16. 
 
Of the 37 patients with AU, 19% had a systemic associated disease. JIA was topping the list with 14%.  
In twenty two percent of patients with intermediate uveitis, a systemic disease was found, and 
sarcoidosis accounted for 11%, followed by JIA with 7.4%. Thirty three percent of patients with 
panuveitis had a systemic disease associated, VKH being the most common. Toxoplasmosis was the 
main condition found in posterior uveitis. Of the two patients with tubulointerstitial nephritis, one 
developed AU and another intermediate uveitis.  
Table 3.28  Eyes with BCVA  6/18-6/36  in children at presentation by uveitis types. 
Uveitis types n.eyes with visual loss       % 
 
AU(n=63) 
            
          2                               3.2 
 
IU(n=50) 
           
          9                               18 
 
Pan(n=26) 
           
          6                               23 
 
PU(n=16) 
              
             2                              12.5 
Total(n=155)                            17                               11 
 
Twenty three percent of eyes with panuveitis presented with visual loss of 6/18-6/36 and 18% of 
eyes with intermediate uveitis had vision of 6/18-6/36 at first visit.  
Of the 27 children who developed IU, 16 were males and 11 females. Nine children (33.3%) 
presented aged </= 7, 18 children (66.7%) were aged >7 when diagnosed with IU. 
There was no difference in BCVA at presentation between these two age subgroups (p=0.44). 
 
Uveitis types.→ 
 
Systemic disease↓ 
       AU   
n.patients=37   (%) 
       IU  
n.patients=27 (%) 
       Pan 
 n.patients =18(%)  
PU 
n.patients=13 (%) 
Total 
n. patients= 95(%) 
 
JIA 
 
5     (13.5) 
 
2      (7.4) 
 
1   (5.6) 
 
- 
 
8 (8.4) 
 
VKH 
 
1     (2.7) 
 
- 
 
3   (16.6) 
 
- 
 
4 (4.2) 
 
Sarcoidosis 
  
3      (11.1) 
 
2   (11.1) 
 
- 
 
5 (5.3) 
 
Toxo. 
 
- 
  
- 
 
5  (38.4) 
 
5 (5.3) 
 
Miscellaneous 
 
1     (2.7) 
 
1      (3.7) 
 
- 
 
- 
 
2 (2.1) 
 
Total  (%) 
 
7     (18.9) 
 
6      (22.2) 
 
6  (33.3) 
 
5 (38.4) 
 
24  (100) 
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Table 3.29  Eyes with BCVA ≤ 6/60 in children at presentation by uveitis types. 
Uveitis types↓                  N.eyes          % 
AU (n= 63)                         3            4.8 
IU  (n= 50)                         3      6 
Pan(n= 26)                        7       27 
Pu (n=16)                          3      19 
Total (n=155)                   16     10.3  
  
Ten percent of eyes had BCVA 6/60 or worse at presentation. When looking at different uveitis 
types, 27% of eyes with panuveitis and 19% of eyes with posterior uveitis presented with severe 
visual loss.             
Table 3.30  BCVA in different follow-up groups  in children.(Time from presentation to data collection in years.) 
Time line→ 
n.eyes (%) 
Baseline 
157(100%) 
1/2 -1year 
94 (59.8%) 
>1yr- 3years 
35(22.3%) 
>3yrs- 5yrs 
15 (9.6%) 
>5yrs- 10yrs 
13 (8.3%) 
6/12 or better 127 (80.9)      83 (88.3) 27 (77) 11 (73.3) 8 (61.5) 
6/18-6/36     20 (12.7)         8 (8.5)  6 (17) 1 (6.6) - 
≤ 6/60    10 (6.4) 3 (3.2) 2 (6) 3 (20) 5 (38.5) 
 
At presentation, 81% of eyes had BCVA of 6/12 or better. Thirteen percent and 6% of eyes had BCVA 
6/18-6/36 and ≤ 6/60 respectively. The proportion of eyes with visual impairment decreased with 
time. When it comes to eyes with severe visual loss, after an improvement at 1 year follow-up, the 
proportions increased with time. In the group of eyes followed up for 10 years or more, we found no 
eye with visual impairment. One third of eyes in this group developed vision loss to 6/60 or worse.  
                                    
The incidence rate for BCVA 6/18-6/36 was 0.10/EY, the incidence rate for severe visual loss was 
0.05/EY. 
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Table 3.31 Causes of BCVA 6/18-6/36 in children in different uveitis types. 
Uveitis types→ 
complications↓ 
AU  (%) IU (%) Pu (%) Panu (%) Total (%) 
CMO - 6 (86) - 5(83.3) 11  (73.3) 
Cataract - 1 (14) - - 1    (6.7) 
Chronic 
mac.damage 
 
- 
 
- 
 
2 (100) 
 
1 (16.7) 
 
3    (20) 
Total (%) - 7(100) 2 (100) 6(100) 15  (100) 
 
More than 2/3 of visual loss to 6/18-6/36 was caused by CMO. Seven eyes with IU, 2 eyes with 
posterior uveitis, and 6 eyes with panuveitis developed visual impairment. No eye with anterior 
uveitis had visual loss of 6/18-6/36.             
Table 3.32 Causes of BCVA ≤6/60 in children in different uveitis types. 
Uveitis types→ 
Complications↓ 
AU  (%) IU (%) Pu (%) Panu(%) Total  (%) 
CMO - -  1(12.5) 1  (7.7) 
Chr.mac damage. 2   (50) - 1 4(50) 7   (53.8) 
Hypotony  - - 1(12.5) 1   (7.7) 
Phthisis 1  (25) - - - 1   (7.7) 
Retinal detachment 1  (25) - - 2(25) 3  (23.1) 
Total (%) 4  (100) - 1  (100) 8(100) 13 (100) 
 
Chronic macular damage was the main cause of severe visual loss, accounting for 54%. 
No eye with IU developed severe vision loss. 
Of the children who developed IU aged </=7, none developed visual impairment at the end of the 
follow-up period. Only 22.2% of those aged > 7 at onset of IU developed visual impairment at the 
end of the follow- up period.  
3.2.15  Uveitis in patients aged ≥ 60. 
 
We identified 228 patients (392 eyes) aged ≥ 60, representing 14.3% of the whole uveitis population. 
Of these, 90 were males and 138 females.  
The mean age at first presentation was 68.1 years (range 60-92). 
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The types of uveitis developed were as followed: 176 eyes (45%) AU, 83 eyes (21%) IU, 45 eyes 
(11.5%) with posterior uveitis and 88 eyes(22.4%) with panuveitis. 
A systemic disease was identified in 158 patients (69.3%). Sarcoidosis accounted for 13.2%, diabetes 
mellitus for 8.3% and SLE for 1.3%. Two patients had AS, 1JIA, 1 MS, 1 toxoplasmosis. Miscellaneous 
diseases included 2 ulcerative colitis, 2 Waldestrom macroglobulinaemia, 1 HTLV1-Tcell lymphoma, 1 
Non-Hodgkin lymphoma, 2 Sjӧgren disease, 1 PMR and 2 Interstitial nephritis.                                
      
Table 3.33 Causes of BCVA 6/18-6/36 in patients aged ≥ 60. 
Types of uveitis→ 
Complications↓ 
AU (%) 
 
IU (%) Pu (%) Panu (%) Total (%) 
CMO 14 (54) 9 (56.2) 1(33) 2 (25) 26 (49) 
Chronic mac. 
Damage 
5  (19.2) 7 (43.8) 2 (67) 4 (50) 18 (34) 
Glaucoma 4 (15.3) - - 2 (25) 6  (11.3) 
Cataract 3 (11.5) - - - 3 (5.7) 
Total 26 (100) 16 (100) 3 (100) 8(100) 53 (100) 
 
CMO accounted for 49% of all causes of BCVA 6/18-6/36 in patients aged 60 or more, followed by 
chronic macular damage accounting for 34% and glaucoma 11%. When looking at different uveitis 
types, CMO was the leading cause of BCVA 6/18-6/36 in AU and IU with 54% and 56% respectively. 
Chronic macular damage occurred more in eyes with IU (44%). 
Table 3.34 Causes of BCVA ≤ 6/60 in patients aged ≥ 60. 
Types of uveitis → 
Complications↓ 
  AU (%) IU (%) Pu (%) Panu (%) Total  (%) 
CMO   - 4 (36.4) 1  (8.3) 2 (13.3) 7   (13.2) 
Chronic mac 
damage 
 7  (46.7) 4  (36.4) 7 (58.3) 4 (26.6) 22  (41.5) 
Glaucoma  8  (53.3) 3  (27.2) 1  (8.3) 4 (26.6) 16  (30.2) 
Mac ischemia  - - 2  (16.7) - 2   (3.8) 
Retinal detachment  - - 1 (8.3) 3 (20) 4   (7.6) 
Phthisis - - - 2 (13.3) 2   (3.8) 
Total 15  (100) 11  (100) 12 (100) 15(100)  53  (100) 
 
Chronic macular damage was the main cause of severe visual loss accounting for 41.5%, followed by 
glaucoma with 30% and CMO with 13%. In eyes with AU, glaucoma accounted for 53% of severe 
visual loss. Severe visual loss in eyes with IU was caused by CMO and chronic macular damage in the 
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ssame proportions (36.4%). In 58% of eyes with PU, chronic macular damage was the main cause of 
severe visual loss, whereas the latter accounted for 26.6%, the same proportion with glaucoma in 
eyes with panuveitis.                                     
 
    3.2.16  Treatment of uveitis. 
 
Table 3.35 Number of eyes treated with different regimen in different uveitis types. 
Treatment→ 
Uveitis type↓                      
Oral steroids 
 n.eyes   
Steroid sparing 
  n.eyes   
Biologic agents 
    n.eyes    
OFI 
 n.eyes   
IVTA 
n.eyes  
   Total 
 n.eyes  
AU n=1050(%)   76 (7.2)  22 (2.1)    2 (0.2) 4 (0.4)  4 (0.4) 108 (10.3) 
IU n= 666 (%)  196 (29.4) 72  (10.8)   13 (1.9) 20 (3.0) 33 (5) 334 (50.1) 
PU n=440(%)  263 (59.7)  69(15.7)   5  (1.1) 4 (0.9) 5 (1.1) 346 (78.6) 
Panu n=387(%)  255(65.9) 76(19.6)   3 (0.8) 13(3.4) 13(3.4) 360 (93) 
Total n=2543 (%) 790 (31) 239 (9.4)   23 (0.9) 41(1.6) 55 (2.2) 1148 (45.1) 
 
Fifty five percent of affected eyes were managed with topical treatment only. Oral steroids were 
used to treat 31% of eyes. For 9.4% of eyes, a steroid sparing agent drug was used, and biologic 
agents were used to control the inflammation in only 1% of eyes. Orbital floor and IVTA injections 
were used to treat 4% of eyes. 
Ninety percent of eyes with AU were managed with topical treatment alone. In 7.2% of AU, oral 
steroids were used. In most of these eyes which required a systemic treatment, an underlying 
systemic disease was present.  
Fifty percent of eyes with IU were treated with topical steroids alone. Twenty nine percent were 
managed with systemic steroids, and in 10.8% a steroid sparing agent was added. Biologic agents 
were used on 2% of eyes with IU, and OFI and IVTA were used in 3 and 5% respectively. The 
proportion of eyes treated with OFI and IVTA was higher in IU when compared with other uveitis 
types. 
Sixty percent and 66% of eyes with posterior and panuveitis respectively were treated with oral 
steroids. Sixteen percent of eyes with posterior uveitis and 20% of eyes with panuveitis were treated 
with a steroid sparing agent.  
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Chapter 4. Surgery in uveitis. 
4.1 Introduction. 
 
The sequelae of uveitis that may cause visual impairment are well known and include cataract, 
glaucoma, band keratopathy, vitreous opacities, retinal scars and ERMs, retinal detachment, retinal 
vascular abnormalities, CMO and optic atrophy. Several of these are surgically treatable, such as 
cataract, glaucoma, vitreous opacities, ERMs and retinal detachment [678].     
The risk factor for development of early cataract requiring surgery in children with JIA-associated 
uveitis is the presence of posterior synechia at the time of diagnosis of uveitis [679].  
Optimal treatment of cataract in the setting of uveitis requires optimal management of uveitis, 
including appropriate diagnostic workup and scrupulous attention to preoperative preparation, 
intraoperative technique, and postoperative management. Recent long-term outcome studies in 
cohorts of uveitis patients undergoing cataract surgery suggest very good outcomes in the majority 
of patients[403]. Using stringent perioperative and postoperative control of inflammation, patients 
with uveitis usually maintain high visual acuity over long-term follow-up[680]. Poor visual outcome 
after surgery is most commonly the result of preoperative vision-limiting conditions [411, 413].
 Secondary glaucoma is a difficult and frequent complication of uveitis[681]. Patients with 
uveitic glaucoma can have good outcomes after trabeculectomy with antiproliferative agents [682, 
683]. Deep sclerectomy with implant in uveitic glaucoma appear to be effective in controlling the 
IOP at short-term follow-up with no serious postoperative side-effects [684]. In children, reports 
on the use of trabeculectomy, goniosurgery, glaucoma drainage devices, and cyclodestructive 
procedures show higher failure rates than when used for primary open angle glaucoma in adults 
[685]. However, with good immunomodulatory control of their inflammation and appropriate 
follow-up, Ahmed valve implantation can be an effective and safe procedure for treating pediatric 
uveitic glaucoma[685].   With the advent of modern vitreoretinal surgical techniques, 
the spectrum for surgical interventions in various forms of uveitis has been notably expanded. 
Removal of optically relevant vitreous opacities, improvement of secondary macular edema, 
delamination of epiretinal membranes, and release of traction in the presence of abnormal 
vitreoretinal 
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adhesions represent indications for vitreoretinal procedures in uveitis patients [686]. ERM surgery 
appears to improve patients' subjective perception of visual function [687]. 
The major question addressed in this section is to establish whether uveitis patients who underwent 
cataract, glaucoma and vitreoretinal surgeries had their visual acuity improved. If vision did not 
improved, was this due to the surgery itself? 
4.2 Results. 
4.2.1 Demographics. 
 
From the whole uveitis population, 463 patients (696 eyes) representing 29% of patients underwent 
surgery.  Of these 197 were males and 266 females. 
Table 4.1 Number of eyes that underwent surgery by uveitis types. 
 
  
 
 
 
 
Twenty seven percent of all uveitic eyes were operated on. A quarter of eyes with AU and those 
with inermediate uveitis underwent surgery, while the proportion of eyes with panuveitis which 
underwent surgery was the highest (44%). Only 14% of eyes with posterior uveitis required 
surgery at some point.  
 
 
 
 
 
Types of uveitis Tot. N. Eyes Surgery/n.eyes  % eyes having surgery 
AU 1050 270 25.7 
IU  666 191 28.7 
Pu.  440 62 14 
Panu 387 171 44.2 
Total. 2543 696 27.4 
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Table 4.2 Systemic diseases associated with uveitis in patients who underwent surgery. 
Systemic d.           Tot. Patients         n. *Sx             % 
Sarcoidosis            170            41              24.1 
Behçet’s                  60             7               11.6 
Diabetes                  67            28              41.7 
JIA                           27            16              59.2 
VKH                        19             5               26.3 
MS                          13              3               23.0 
Toxo                        68             4               5.8 
Miscellaneous         40            27              67.5 
Total                      464            131             28.2             
                                                      *Sx= surgery  
Twenty eight percent of patients who underwent surgery had an underlying systemic condition. 
More than half the number of patients with JIA had surgery. Forty two percent of patients with 
diabetes had surgery, while 26% and 24% of those with VKH and sarcoidosis repectively underwent 
surgery.   
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Table 4.3 Surgery in different uveitis types. 
 
 
 
 
 
A quarter of all uveitis eyes underwent cataract surgery. Only 3% underwent glaucoma and 
vitreoreetinal surgeries. 
The same proportion (23%) of eyes with AU and IU underwent cataract surgery.  Only 8% of eyes 
with posterior uveitis had cataract surgery, and 45% of eyes with panuveitis underwent cataract 
extraction. Glaucoma surgery was performed on 4% of eyes with AU and panuveitis, on 3% and 
1.6% of eyes with IU and posterior uveitis respectively. Six percent of eyes with panuveitis 
underwent vitreoretinal surgery. This proportion was the double of that of eyes with IU and 
posterior uveitis, and the quadruple of eyes with AU on which vitreoretinal procedures were 
performed. 
4.2.2 Cataract surgery 
 
Table 4.4 Types of cataract surgery in different uveitis types. 
 
 
 
 
 
Phaco.=Phacoemulsification;ECCE.=Extracapsular cataract extraction ; ICCE.=Intracapsular cataracact extraction 
Phacoemulsification with intraocular lens implantation was the most common type of cataract 
surgery performed on uveitic eyes.  
Types of surgery 
Uveitis types. 
Cataract surgery 
n. eyes  
Glaucoma surgery 
n. eyes   
VR surgery 
n.eyes  
AU: 1050(%)      246 (23.4) 44  (4.2)      16  (1.5) 
IU : 666(%)      157 (23.6)            20 (3.0)      23  (3.4) 
Pu : 440(%)           37  (8.4)            7  (1.6)       14 (3.1) 
Panu :387(%)           175 (45.2)            16 (4.1)       23  (6) 
Total 2543           615 (24.1)              87 (3.4)      76 (3)  
Surgery→ 
 
Uveitis type↓ 
  Phaco.  
 
n.eyes 
 ECCE  
 
n.eyes  
ICCE 
 
n.eyes 
Lensectomy 
 
n. eyes 
 
AU n=246(%) 214 (87) 3 (1.2) 19 (7.7) 10 (4.1)  
IU  n=157(%) 153 (97.4) 2 (1.3) - 2 (1.3)  
Pu. n=37(%) 37 (100) - - -  
Panu n=175(%) 141(80.5) 5 (2.9) 5(2.9) 24(13.7)  
Total  n=615(%) 545 (88.6) 10 (1.6) 43 (7) 17 (2.8)  
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Ten eyes (1.6%) underwent ECCE, 43 eyes (7%) were aphakic following ICCE, 17eyes (2.8%) 
underwent lensectomy. The proportion of eyes on which the latter procedure was performed was 
higher in eyes with panuveitis than in other uveitis types. 
Table 4.5 Mean logMAR BCVA pre-cataract surgery. 
 
 
 
 
Eyes with panuveitis had the worse visual acuity pre cataract surgery. 
  Figure 4.1 Correlation between pre-cataract surgery visual acuity and post-cataract surgery. 
 
Although there was a positive correlation between visual acuity precataract surgery and post 
cataract surgery, this correlation was not statistically significant.(Pearson correlation =0.375). 
The overall mean preoperative logMAR BCVA was 0.88 ± 0.76 (0.74 – 0.93 95% CI). The mean 
logMAR BCVA after cataract surgery improved to 0.34 ± 0.64 (0.26 – 0.39 95% CI; p < 0.001). Most 
eyes achieved best vision at first post op follow-up visit (1 week). 
 
 
Uveitis types Log MAR BCVA 
AU 0.92 (SD± 0.78) 
IU 0.75 (SD± 0.62) 
Pu 0.79 (SD±0.63) 
Panu 0.99 (SD±0.73) 
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Table 4.6  Eyes with BCVA 6/18-6/36 and ≤ 6/60 post cataract surgery in different uveitis types. 
 
 
 
 
 
 
Of the 615 eyes, 66.5% attained BCVA 6/12 or better at final follow- up visit post cataract surgery. 
Seventeen percent of eyes developed visual loss to 6/18-6/36. Overall, 11% of eyes had severe visual 
loss after cataract surgery. Eyes with AU had vision loss to 6/18-6/36 and 6/60 or worse in 9.3% and 
11.8% respectively. A fifth of eyes with IU developed vision loss of 6/18-6/36 and 10% had severe 
visual loss after cataract surgery. Twenty seven percent and 22% of eyes with posterior uveitis and 
panuveitis respectively developed visual loss of 6/18-6/36, while the highest proportion of eyes with 
severe visual loss after cataract surgery was found in posterior uveitis (43%). 
Table 4.7 Types of cataract surgery and vision loss. 
 
Seventeen percent of eyes that underwent phacoemulsification with IOL insertion developed vision 
loss to 6/18-6/36 
Eyes which had lensectomy and ECCE developed BCVA 6/18-6/36 in 18% and 30% respectively. 
Sixteen percent of aphakic eyes following ICCE had vision loss to 6/18-6/36. 
In 13% of eyes that underwent phacoemulsification, severe vision loss occurred. Eyes in which 
lensectomy was performed had BCVA 6/60 or worse in 24%, while half and more than half the 
number of eyes that had ECCE and ICCE had severe vision loss. 
 
Uveitis types    BCVA 6/18-6/36 
     n.eyes  (%) 
BCVA ≤ 6/60 
     n.eyes (%) 
AU n.eyes=246       23  (9.3)      29  (11.8) 
IU n.eyes=157       34  (21.6)      15 (9.5)  
Pu n.eyes= 37       10  (27)      16  (43) 
Panu n.eyes=175       38(21.7)      41 (23.4) 
Total  n.eyes = 615      105 (17.1)      70 (11.4) 
Types of surgery BCVA  6/18-6/36  
 
n.eyes       (%) 
   BCVA≤ 6/60 
 
n.eyes    (%) 
Total n.eyes (%) 
 
Phaco  n.eyes = 545 
 
  92    (16.9) 
 
  68   (12.5) 
 
     160 (29.4) 
 
Lensectomy  n. eyes= 17 
 
   3      (17.6) 
 
   4     (23.5) 
 
      7  (41.1) 
 
ECCE  n.eyes = 10 
 
3      (30) 
 
5       (50) 
 
     8  (80) 
 
ICCE  n.eyes = 43 
 
  7    (16.3) 
 
   24     (55.8) 
 
      31 (72.1) 
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Univariate analysis of variance for factors predicting visual loss post cataract surgery show that 
gender and age at first diagnosis were not predictive of visual loss. However, associated systemic 
disease, presurgery macular damage and type of surgery influenced visual outcome. p values= 0.003 
for associated systemic disease, 0.027 for macular damage and <0.001 for type of surgery. 
In multivariate analysis, systemic disease did not appear to be an independent factor influencing 
visual outcome post cataract surgery (p= 0.22). Pre cataract surgery VA and type of surgery 
influenced visual outcome.(p= 0.030  and p< 0.001 respectively).                                   
 
Figure 4.2 Progression of visual acuity post cataract surgery in eyes with visual loss. 
 
Eyes which were visually impaired at final follow-up visit after cataract surgery had a slight 
improvement of visual acuity up to 6 months postop.   After 6 months, visual acuity declined. 
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Table 4.8  Causes of visual loss to 6/18-6/36 and ≤6/60 post cataract surgery. 
Complications BCVA 6/18-6/36  
n. eyes   (%) 
BCVA 6/60 or worse 
n.eyes  (%) 
CMO 20  (19.0) 17 (16.8) 
Glaucoma 21  (20) 36  (35.6) 
Mac. Damage 45  (42.9) 31  (30.6) 
Op. atrophy.  3   (2.9)  4   (4) 
Hypotony  2   (1.9)  3  (3) 
Retinal detachment 10  (9.5)  4  (4) 
Phthisis -  4  (4) 
Miscellaneous  4   (3.8)  2  (2) 
Total 105 (100) 101 (100) 
 
BCVA 6/18-6/36 was due to chronic macular damage in 43% of eyes, to glaucoma and chronic CMO 
in 20% and 19% respectively. Most of these complications were present prior to cataract surgery. In 
a further 18% of eyes, visual loss resulted from retinal detachment (9.5%), optic atrophy (2.9%), 
hypotony (1.9), corneal decompensation and PCO (3.8%).  
Glaucoma was the main cause of severe visual loss post cataract surgery accounting for 37%. 
Macular damage accounted for 31%, followed by refractory uveitic CMO which accounted for 17%. 
Optic atrophy and hypotony caused severe visual loss in 4% and 3 % respectively, and a further 10 % 
of eyes developed retinal detachment (4 eyes), phthisis (4 eyes), cyclitic membrane (2 eyes).   
Table 4.9  BCVA  6/18-6/36 after cataract surgery and visual acuity at presentation. 
BCVA at first visit BCVA post cataract surgery N.eyes (%) 
6/12 or better       6/18-6/36 35     (33.3) 
6/18-6/36       6/18-6/36 48     (45.7) 
≤6/60        6/18-6/36 22     (21) 
Total          - 105   (100) 
 
Vision loss to 6/18-6/36 developed in 105 eyes after cataract surgery. Of these, 33% had normal 
visual acuity at presentation, 46% had BCVA 6/18-6/36 at presentation and 21% had severe visual 
loss at first visit.  
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Table 4.10  BCVA ≤6/60  after cataract surgery and visual acuity at presentation. 
BCVA at first visit BCVA post cataract surgery N.eyes  (%) 
6/12 or better          ≤6/60  14  (13.9) 
6/18-6/36          ≤6/60  23  (22.8) 
≤6/60            ≤6/60  64  (63.3) 
Total             - 101 (100) 
 
Severe visual loss after cataract surgery occurred in 101 eyes. Of these eyes, only 14% had BCVA 
6/12 or better at presentation, 23% and 63% had BCVA 6/18-6/36 and 6/60 or worse respectively. 
Cataract surgery in JIA-associated uveitis.  
Of the 24 patients with JIA associated uveitis, 14 (58.3%), 21 eyes representing 80.8% of affected 
eyes underwent cataract surgery. Five eyes(23.8%) underwent phacoemulsification, 4 eyes(19.0%) 
underwent lensectomy. ICCE was performed on 12 eyes (57.1%).  
Table 4.11 Visual acuity in pre cataract surgery and post cataract surgery in JIA uveitis. 
BCVA Pre cataract surgery 
          n.eyes (%) 
Post cataract surgery 
        n.eyes (%)  
6/18-6/36           13 (61.9)          6(28.6) 
≤6/60            8(38.1)          8(38.1) 
 
Sixty two percent of eyes operated on had BCVA 6/18-6/36 pre- cataract surgery, 38% were 
severely visually impaired. At final post op follow up visit, 33.3% of eyes attained BCVA 6/12 or 
better. Twenty nine percent of eyes developed visual impairment, and 38% had BCVA 6/60 or 
worse. 
Table 4.12 Complications and visual loss post cataract surgery in JIA uveitis. 
 
 
 
 
 
Vision loss→ 
Complications↓ 
        BCVA   6/18-6/36      BCVA ≤ 6/60  
CMO 1 2 
Glaucoma 2 4 
Band keratopathy 2 - 
Hypotony 1 - 
Macular damage - 1 
Phthisis - 1 
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Glaucoma was the main cause of severe visual loss post cataract surgery in eyes with JIA-
associated uveitis.  CMO leading to severe vision loss developed in 2 eyes. Of eyes with severe 
visual loss one had chronic macular damage and one eye was phthisical. 
Table 4.13 Causes of visual loss in pseudophakic eyes and aphakic eyes with JIA-associated uveitis. 
 
 
 
 
 
Glaucoma was the main cause of visual loss and developed more frequently in aphakic eyes. Of 
the 3 eyes which developed CMO, 1 was aphakic and 2 were pseudophakic.  Two aphakic eyes 
developed hypotony. One aphakic eye developed chronic macular damage and another aphakic 
eye became phthisical at the final postop follow-up visit. 
4.2.3 Glaucoma surgery. 
 
Sixty eight patients (96 eyes) underwent glaucoma surgery. Of these, 34 were males and 34 
females.  
Table 4.14 Types of uveitis and glaucoma surgery. 
Uveitis types N.eyes        (%) 
AU  46               (47.9) 
IU 22               (22.9)      
Pu  8                (8.3) 
Pan 20               (20.8) 
Total 96              (100)  
 
Forty eight percent of eyes which underwent glaucoma surgery had AU. Intermediate uveitis and 
panuveitis accounted for 22.9% and 20.8% respectively. Eight percent had posterior uveitis.       
 
 
Complications Aphakic eyes 
n.eyes= 16 
Pseudophakic eyes 
   n.eyes= 5 
CMO       1         2 
Glaucoma       5         1  
Hypotony       2          - 
Mac. Damage       -         1 
Band keratopathy       -         1  
Phthisis       1         - 
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Table 4.15 Systemic disease and glaucoma surgery. 
Systemic disease N.patients    (%) 
Ankylosing spondylitis 4              (14.8) 
Behçet’s disease 3              (11.1) 
Diabetes 3              (11.1) 
JIA 8              (29.6)  
Sarcoidosis 6              (22.2) 
VKH 1              (3.8) 
Miscellaneous 2              (7.4) 
Total 27           (100) 
 
Twenty seven patients representing 39.7% of patients who underwent glaucoma surgery had a 
systemic disease. One third of these had JIA. Sarcoidosis the second most important systemic 
disease accounting for 22%, followed by AS with 14.5%. 
Table 4.16 Types of glaucoma surgery. 
 
 
 
 
                                
                                               *PI= Peripheral iridotomy 
Trabeculectomy with Mitomycin C was performed on 69.8% of eyes, tube insertion alone on 
20.8%. Five eyes had trabeculectomy first and tube insertion subsequently. On 4 eyes, PI was 
performed before trabeculectomy. 
The mean IOP preglaucoma surgery was 18 mmHg ± 10.5. 
Forty nine eyes (50%) had also cataract surgery. 
     The mean logMAR BCVA preglaucoma surgery was 0.57± 0.88 (0.30 – 0.73 95% CI). 
     The mean logMAR BCVA after glaucoma surgery was 0.52 ± 0.72 (0.29 – 0.65 95% CI),   
     p< 0.001. 
Types of surgery N.eyes    (%) 
Trabeculectomy 67       (69.8) 
Tubes 20       (20.8) 
Trabeculectomy+tubes 5         (5.2) 
*PI + Trabeculectomy 4         (4.2) 
Total 96       (100) 
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     At final follow up visit after glaucoma surgery, 19 eyes (19.8%) had BCVA 6/18-6/36, and    
    22 eyes (23%) had BCVA ≤6/60. No patient had lost vision from glaucoma surgery. 
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 4.2.4 Vitreo-retinal surgery. 
Sixty four patients (76 eyes) underwent vitreo retinal surgery. Of these, 26 were males, 38 females.  
The mean follow up post surgery was 3.8 years (SD ± 3). 
Table 4.17 Types of VR surgery in different uveitis types. 
 
Half the number of eyes which underwent vitrectomy had panuveitis. Eighteen percent and 21% had 
AU and IU respectively. Only 8.8 had posterior uveitis.  Forty percent of eyes which underwent 
epiretinal membrane peel had intermediate uveitis, 29% and 21% had posterior uveitis and 
panuveitis respectively. Two thirds of eyes on which retinal detachment surgery was performed had 
AU, and most eyes which underwent macular surgery had PU.      
Table 4.18  Eyes with BCVA 6/18-6/36 and ≤ 6/60 before and after VR surgery. 
Vision loss→ 
 
Time 
  BCVA  6/18-6/36 
    n.eyes  (%) 
 BCVA ≤ 6/60 
   n.eyes  (%) 
Pre VR surgery    25 (32.9)    40 (52.6) 
Post VR surgery    21 (27.6)    30 (39.5) 
 
Before surgery, 32.9% of eyes had BCVA 6/18-6/36, 52.6% had severe vision loss. 
After VR surgery, 27.6% of eyes had visual loss to 6/18-6/36, 39.5% had vision loss ≤ 6/60.  
The mean logMAR BCVA pre VR surgery was 1.14 ± 0.84 (0.81 - 1.37 95% CI). The mean logMAR 
BCVA post surgery improved to 0.62 ± 0.66 (0.57 – 0.37 95% CI); p < 0.001. 
 
 
 
VR surgery    AU 
n.eyes 
   IU 
n.eyes  
 Pu 
n.eyes) 
Pan 
n.eyes 
Total 
n.eyes) 
Vitrectomy n.eyes (%) 6 (18.2) 7 (21.2)  3(8.8) 18(52.9) 34 (100) 
ERM peel n.eyes (%) 1 (3.7) 11 (40.7)  7(29.1) 5(20.8) 24 (100) 
RD surgery n.eyes (%) 9 (60) 3 (20)  1(6.2) 3(18.7) 16 (100) 
Mac.surgery n.eyes (%) - -  5(83.3) 1(16.7)  6(100) 
Total (%) 16 (20) 21 (26.2) 16 (20) 27(33.8)  80 (100) 
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Figure 4.3 Visual acuity post VR surgery with time. 
 
Univariate analysis of variance shows a positive correlation between visual acuity and follow up time 
post surgery; Pearson correlation = 0.021(not statistically significant). 
 
Figure 4.4 Visual acuity with time in eyes which underwent membrane peel. 
 
Visual acuity of eyes which had undergone membrane peel declined with time (R2= 0.117). The 
Pearson correlation between follow up time and visual acuity was not statistically significant (0.05). 
However, the correlation between initial visual acuity and visual acuity post membrane peel was 
highly statistically significant (Pearson correlation = 0.00). 
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Table 4.19 Causes of visual loss after VR surgery. 
Vision loss→ 
Complications↓ 
  6/18-6/36 
  n.eyes (%) 
   ≤6/60  
  n.eyes (%) 
CMO   5  (23.8)   5 (16.7) 
Glaucoma   5  (23.8)   9  (30) 
Hypotony   1  (4.8)   1  (3.3) 
Mac ischemia   1  (4.8)   - 
Optic atrophy   -   1  (3.3) 
Chronic mac damage   6  (28.5)   11 (36.7) 
Retinal detachment   3  (14.3)   3  (10) 
Total  21 (100)   30 (100) 
 
Chronic macular damage accounted for 28.5% of causes of visual loss to 6/18-6/36, followed by 
glaucoma and CMO with 23.8% each.  
In the group of eyes with severe vision loss, chronic macular damage accounted for 36.7%, followed 
by glaucoma (30%) and CMO (16.7%).  
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Chapter 5. Ischemia. 
5.1 Introduction 
 
Patients with ischemic retinal vasculitis represent a major management problem. It is important to 
identify the presence of retinal ischemia in patients with retinal vasculitis because panretinal laser 
photocoagulation should be considered when angiographic evidence of widespread retinal 
nonperfusion is present, and before (or shortly after) the development of neovascularisation [517]. 
Ischemic retinal vasculitis may be secondary to Behçet’s disease where retinal vasculitis and 
recurrent vasoocclusive episodes are the major cause of visual morbidity. In addition, inflammatory 
retinal vein occlusions are strongly associated with Behçet’s disease [688-691].   
Retinal ischemia is frequently seen secondary to tuberculosis and retinal vasculitis   associated with 
tuberculoprotein hypersensitivity which is typically, an obliterative periphlebitis affecting the retina 
in multiple quadrants, starting at or anterior to the equator and progressing posteriorly. 
Occasionally, it can begin close to the optic nerve head, mimicking a vein occlusion. 
Ophthalmoscopic findings vary and depend on the stage of the disease. Initially, it presents as active 
retinal periphlebitis with thick exudates around the retinal veins associated with retinal 
haemorrhages, and haemorrhagic infarctions of the retina[517]. The periphlebitis may cause 
nonperfusion of a substantial portion of the retina that may lead to proliferative vascular 
retinopathy with sequelae such as recurrent vitreous haemorrhage, traction retinal detachment, 
rubeosis iridis, and neovascular glaucoma [223, 517, 692]. 
 Various ocular inflammatory changes have been described in patients with MS and may be 
the presenting sign of the disease.[579, 693-697]. Retinal periphlebitis has been described as a 
common manifestation of MS. It has been observed with an average frequency of 11.5% in more 
than 3,000 published cases of MS examined for sheathing [698]. The periphlebitis can progress to 
occlusive peripheral vasculitis, which results in peripheral retinal neovascularisation and tractional or 
rhegmatogenous retinal detachments or both [579, 696, 697].  
Retinal periphlebitis associated with sarcoidosis is usually nonocclusive, sometimes subclinical and 
only visible on fluorescein angiography, associated with typical segmental cuffing or more extensive 
sheathing and perivenous exudates, which are usually indicated as ‘‘candle wax drippings’’[699, 
700]. Development of capillary nonperfusion and subsequent neovascularisation as well as branch 
and central retinal vein occlusions have been described [701-704].  
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 The retina is a common site of ocular involvement in patients with lupus. The proportion of 
patients with SLE who manifest retinal involvement varies depending on the population studied and 
ranges from 3% in well controlled patients to 29% in patients with more active systemic disease 
[607, 608, 610-612, 705]. Retinal findings most commonly associated with lupus are cotton wool 
spots and intraretinal haemorrhages[609]. Other retinal manifestations may include 
microaneurysms, vascular tortuosity, arteriolar narrowing, retinal oedema, or exudates [610-612]. 
Most patients with mild retinopathy are at low risk for vision loss [611, 705]. In contrast, severe 
vaso-occlusive retinopathy is a rare but well described entity that is associated with widespread 
retinal capillary nonperfusion, multiple branch retinal artery occlusions, ocular neovascularisation, 
vitreous haemorrhage, and significant resultant visual loss [613, 614]. 
Severe retinal vaso-occlusive disease and CNS involvement have been associated with the presence 
of antiphospholipid antibodies in the antiphospholipid syndrome [706]. 
 Wegener’s disease may present with ocular symptoms in 8–16% of patients, but the eye 
becomes involved in up to 40% [707]. Involvement of the posterior segment is uncommon. It can 
manifest as an occlusive retinal vasculitis affecting either arteries or veins, retinitis or uveitis [708]. 
In polyarteritis nodosa (PAN), retinopathy is one of the most commonly seen ocular complications, 
with retinal vascular occlusions, oedema, cotton wool spots and retinal haemorrhages. These 
findings are secondary to hypertensive retinopathy, especially in patients with renal disease, or from 
primary retinal vasculitis[709]. 
 Occlusive retinal vasculitis, and subsequent retinal neovascularisation [710] and neovascular 
glaucoma[711] was also reported in patients with Crohn’s disease. 
The laboratory work-up of patients with retinal vasculitis has been described in chapter 2. 
The management of tuberculous retinal vasculitis or retinal vasculitis associated with 
tuberculoprotein hypersensitivity requires the use of systemic steroids and appropriate 
antituberculous therapy. New vessel formation associated with retinal vasculitis and capillary closure 
responds to panretinal photocoagulation.  
In case of peripheral capillary closure which results in peripheral retinal neovascularisation and 
tractional or rhegmatogenous retinal detachment or both, peripheral scatter photocoagulation and 
vitrectomy may be required to stabilise the proliferative retinopathy [579, 696, 697]. 
Early vitrectomy and adequate endolaser photocoagulation should be considered in eyes with 
nonresolving vitreous haemorrhage associated with active fibrovascular proliferation [712].   
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In this chapter I looked at eyes which have developed ischemia and see if their visual acuity had 
worsened with time. I also looked at the impact of different treatments on visual acuity. 
5.2 Methods. 
 
Fluorescein angiograms of patient who developed vasculitis were reviewed. Capillary non perfusion 
was identified as described in chapter 1. 
5.3 Results. 
5.3.1 Demographics. 
 
Sixty five patients (106) eyes were identified. Forty two were males and 23 females, a ratio of 1.8. 
The mean age at presentation was 40.2 years ± 11.3 for males and 43 ± 10.8 years for females. The 
difference was not statistically significant (p = 0.32). 
The mean follow up was 6.5 years (range 0.6 – 33). 
Table 5.1 Clinical entities in which ischemia developed. 
Clinical entities N.eyes    (%) 
Idiopathic retinal vasculitis 33       (31.1) 
Eale’s disease 20       (18.9) 
TB hypersensitivity 4         (3.8) 
Ischemic CRVO 7         (6.6) 
BRVO 20       (18.9) 
AU 4         (3.8) 
IU 2         (1.9) 
Pu 8         (7.5) 
Panu 8         (7.5) 
Total 106      (100) 
 
One third of all eyes which developed ischemia had idiopathic retinal vasculitis (IRV). Eale’s disease 
and BRVO accounted for 19% each. Eyes with posterior uveitis and panuveitis accounted for 7.5% 
each, and 7% had ischaemic CRVO. Four eyes and 2 eyes with AU and IU respectively developed 
ischaemia. A further 4 eyes had TB hypersensitivity. 
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Table 5.2 Systemic disease associated with ischemia. 
 
 
 
 
 
BD was the most common systemic disease associated with ischemia accounting for 45%, followed 
by TB with 15%. Sarcoidosis, MS and SLE accounted equally for 12% each. One patient had diabetes, 
but not ischemic retinopathy caused by diabetes. 
The mean logMAR BCVA at presentation was 0.47 (range 0.00 – 3). 
5.3.2 Visual loss in ischemia. 
 
Table 5.3  Eyes with BCVA  6/18-6/36  and ≤ 6/60 at presentation. 
 
 
 
At presentation, 24% of eyes had BCVA 6/18-6/36, and 23% were severely visually impaired. 
Figure 5.1 Visual acuity with time in eyes with ischemia.
 
Systemic disease Ischemia n.patients  (%)            
Behçet’s disease 15    (45.5) 
Sarcoidosis 4      (12.1) 
MS 4      (12.1) 
Diabetes 1      (3.0) 
SLE 4      (12.1) 
TB 5      (15.2) 
Total 33    (100) 
           BCVA 6/18-6/36 
                  N. eyes  (%) 
    BCVA ≤6/60  
      N.eyes  (%) 
                  25    (23.6)          24  (22.6) 
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Visual loss developed early in the first 5 years and does not worsen with time. A few number of eyes 
developed vision loss after 5 years. The correlation between time and visual acuity is not statistically 
significant (Pearson correlation =0.9)        
Table 5.4  Causes of visual loss in eyes with  ischemia. 
Vision loss→ 
Complications↓ 
 6/18-6/36 
N.eyes   (%) 
 ≤6/60  
N.eyes  (%) 
CMO 2   (11.1) - 
Neovasc. Glaucoma 2   (11.1) 3  (11.1) 
Mac. Ischemia 8   (44.4) 19  (70.4) 
Chronic macular damage 5   (27.8) 3   (11.1) 
Op.atrophy 1   (5.6) 1   (3.7) 
Phthisis - 1  (3.7) 
Total 18 (100) 27  (100) 
 
Macular ischemia was the main cause of both for visual impairment and severe visual loss 
accounting for 44% and 70% respectively. Chronic macular damage accounted for 28% of BCVA 6/18-
6/36 and 11% for BCVA 6/60 or worse. Two eyes developed neovascular glaucoma leading to BCVA 
6/18-6/36. Three other eyes with neovascular glaucoma had severe vision loss. Chronic CMO caused 
vision loss to 6/18-6/36 in 2 eyes. Two eyes developed optic atrophy. BCVA was 6/18-6/36 in one of 
these eyes and the other developed severe visual loss.  Of the 16 patients who developed macular 
ischemia, 3 had BD and 3 had SLE.  
With time, 20 eyes improved visual acuity by 3 Snellen lines or more, 15 eyes had visual acuity 
worsened by losing 3 Snellen lines or more. Eyes which developed macular ischemia did not improve 
visual acuity.             
At first presentation, 4 eyes out of 20 affected presented with BCVA 6/18-6/36, the same proportion 
presented with BCVA 6/60 or worse. 
At final follow up, 7 eyes had improved visual acuity, 3 eyes had worsened visual acuity. 
Causes of visual loss at final follow- up visit were macular ischemia in 1 eye leading to BCVA 6/18-
6/36, secondary glaucoma in 2 eyes and vitreal haemorrhage in 1 eye both leading to BCVA 6/60 or 
worse. 
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5.3.3 Treatment in ischemia. 
 
Table 5.5 Treatment of eyes which developed ischemia. 
Treatment regimen Ischemic eyes n=106 (%) 
Systemic steroids          39            (36.8) 
Systemic steroids+steroid sparing          23             (21.7) 
Anti TB agents+systemic steroids           6              (5.7) 
IVTA/OFI           7              (6.6) 
Vitrectomy           6              (5.7) 
Laser          48             (45.3)  
 
Systemic steroids were used to treat 68 eyes (64.1%). For 21.7% of eyes steroid sparing agents were 
associated. Mycophenolate Mofetil (Cellcept) was used in 6 patients, Cyclosporin A in 6 patients, 
Azathioprine in 4 patients, Methothrexate in 1 patient, and one patient was started on Infliximab. 
For 6 eyes, anti TB agents were used in combination with systemic steroids.  Intravitreal and/or 
orbital floor steroids injections were performed on 7 eyes. Six eyes underwent vitrectomy, and laser 
treatment (PRP or sectorial) was performed on 45% of eyes with ischemia.   
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Chapter 6. Discussion. 
6.1  Demographics 
 
The last big study on visual loss in uveitis was conducted by Rothova et al.[300] in 1996 and included 
585 patients. Durrani et al.[296] in 2004 conducted another observational study of 315 consecutive 
patients on degree, duration and causes of visual loss in uveitis. To my knowledge, this study is the 
largest to date on causes of visual loss in patients with uveitis. 
The mean age at presentation of patients in this series (Table 3.2) is similar to what reported in 
many other series on uveitis worldwide [290, 713, 714]. In two studies from Bogota and Iran, 
patients were much younger with mean ages of 31.7 and 32.2 respectively [715, 716]. 
As in other reports [279, 290, 717], the sex ratio in this study (1:1.2) is slightly in favour of 
females.(Table 3.3)  
Ratinham et al.[718] and Biswas et al.[717] reported lower incidences of 7.3% and 6.44% 
respectively in adults over 60 in this age group. The distribution of uveitis in different age groups in 
our series was similar to what many other studies have described. Eight percent of patients were 
aged between 3 and 16 years, 10% were in the age group older than 63. The majority of patients 
(82%) were aged between 25 and 63 years. 
In a review of 22 studies representative of Australia, North America, Europe, Asia and Africa, Chang 
et al.[274] concluded that there were similarities and distinct differences in the pattern of uveitis in 
the various geographic regions. Such patterns may be induced by combinations of geographical, 
environmental and genetic factors. 
 The incidence of anterior uveitis in our series (Table 3.3) was similar to that reported in 
China, Japan, and some European studies, especially in the Netherlands, Germany and Italy 
[304,315,416,458,461]. Two previous studies in the UK reported incidences of 63 and 87.5% [310, 
471]. Higher incidences of anterior uveitis were also reported in Finland, Australia and Turkey, 
respectively 87.5%, 76% and 52.5%.  
The high prevalence of anterior uveitis in Finland was in accordance with the high frequency of the 
histocompatibility antigen B27 among Finns [292, 302,467]. On the other hand, low prevalences 
ranging from 22% to 29.6% have been reported in the United States and Japan [293, 673, 719-721]. 
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In a population based study in India, Dandona et al.[271] reported an incidence of anterior uveitis as 
low as 13%. This could be due to the fact that cases of previous anterior uveitis which did not leave 
sequelae were overlooked.  Looking at the patterns of uveitis in patients admitted to a University 
hospital in Riyadh, Saudi Arabia, anterior uveitis was reported in 12%. This low prevalence was a 
referral bias as most cases of anterior uveitis were treated by local ophthalmologists. In addition, 
most cases of anterior uveitis were investigated and treated in the outpatients clinic and not 
admitted [722].  In a literature review covering a 37 years period, Chang et al reported a shift in the 
relative frequency of uveitis cases from anterior toward posterior and panuveitis in tertiary referral 
centres [274]. 
 Many reports have confirmed that chronic anterior uveitis tends to be more common in 
tertiary referral practices [226, 716, 721, 723, 724] The prevalence of chronic anterior uveitis 
reported in this study (Fig.3.1) was higher than that reported by Menezo and Lightman (64.7%) in 
the same hospital [723]. This could be a sample size effect; the Menezo series included only 68 
patients. 
Intermediate uveitis usually affects patients from 5 to 30 years old, without gender or racial 
preferences[131]. In this series, patients with IU were younger than those with AU or Pan and Pu 
(Table 3.2). The prevalence of IU reported in this study is similar to the report from the largest 
cohort so far in Germany and in India where intermediate uveitis was reported in 22.9% and 25% 
respectively [271, 725]. In many other series, the prevalence of intermediate uveitis was very low. 
Prevalences of 6.1% and 6.7% have been reported respectively in China and Turkey [714, 726], and 
2% in Sydney [287] . Two different studies 6 years apart in Japan reported 6.9% and 1.2% of 
intermediate uveitis [720, 721]. Rothova et al. [300] in the Netherland reported 13%. Looking at 
these discrepencies, a question as to whether the diagnosis of intermediate uveitis can be easily 
made needs to be asked. These conflicting results show that intermediate uveitis is not uncommon 
as previously thought. 
Posterior uveitis is reported in incidences varying from 6.8% in China to 31.2% in Japan[721, 726]. 
Incidences as high as 49.4% for panuveitis have been reported in Japan[720]. Jakob et al. [725] in 
Germany found 6.2%, and we report 33%.  
 A study in Canada revealed a striking difference in the subtypes of uveitis diagnosis by 
comparing ophthalmologist and non ophthalmologist referrals. In the non opththalmologist referral 
group, the authors found 92.8% AU, 5.4% IU, 1.8% Panuveitis, whereas in the ophthalmologist 
referral group, 67.4%, 14.0% and 18% we found respectively for AU, IU and Panu [727]. This 
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highlights the possibility of referral bias and the necessity of meticulous clinical examination in order 
to ascertain a definit line diagnosis. 
We found that 29% of patients in our cohort had a systemic disease associated with uveitis (Table 
3.4). Our findings are similar to what has been reported by Rothova et al. [228] in the Netherland 
reported (26%), and Boskovich et al.(31.3%) [728]. 
6.2 Vision loss in uveitis. 
 
 Although uveitis is a well known cause of blindness, there is only scant knowledge 
concerning the prevalence and incidence of uveitis among the blind. In most epidemiological studies 
dealing with blindness, uveitis was not considered a distinct entity [729-734]. The complications of 
uveitis, for example cataract, secondary glaucoma, and macular abnormalities, are included in many 
epidemiological studies about blindness, but how many of these are actually attributable to uveitis is 
not specified [730]. The largest population based study of the Western world, the Framingham Eye 
Study, illustrates this phenomenon: patients with blindness due to retinal toxoplasma lesions are 
classified as having macular degeneration; secondary cataract is indicated but carries no aetiological 
diagnosis for example, uveitis, trauma[730]. Blindness due to uveitis is usually not reflected in results 
reported on epidemiology of blindness and only few data are available about its incidence. It is 
estimated that it causes 10% to 15% of all cases of total blindness in the USA [2, 278]. The 
percentage of blindness in the Western world that was attributed to uveitis was similar in those 
studies where uveitis was reported, and varied from 3% to 7% of the total blindness [735-737]. 
Rothova et al.[300] reported that 35% of patients exhibited blindness or visual impairment; bilateral 
legal blindness developed in 4% patients, 4.5% had one blind eye with visual impairment of the 
other, 1.5% had bilateral visual impairment. Unilateral blindness developed 14% patients, whereas 
11% exhibited unilateral visual impairment. The authors did not report visual acuity at presentation. 
We report 23.7% of patients who developed irreversible visual loss. The proportion of patients who 
developed all types of visual loss is low in our series (Tables 3.7; 3.8; 3.9). This improvement is 
certainely the result of more efficient treatment options developed over the last decade.  
 The incidence rates for visual loss in AU in this study are 0.03/EY and 0.05/EY respectively for 
visual impairment and for BCVA 6/60 or worse. The proportion of patient with AU who developed 
unilateral visual impairment is extremely high (16.3%), when Rothova et al [300] reported only 5%. 
The incidence rates for visual loss in IU are 0.04/ EY and 0.02/EY for visual impairment and severe 
visual loss or blindness respectively. While in the Rothova cohort no patient with IU developed 
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bilateral severe visual loss[300], we report 4.7% of patients with IU who developed bilateral severe 
visual loss.  Jain et al [738] and Donaldson et al.[739] reported 3 eyes with IU which developed vsual 
loss of 6/60 or worse.  
There is a lack of data on visual outcome at different time points in the literature. Since the 
publication on standardisation of uveitis nomenclature for reporting clinical data by the SUN group 
in 2005[124], to the best of my knowledge, this is the first study reporting detailed visual outcome at 
different time points in different uveitis types on a large scale (Tables 3.9 and 3.10)  
Vidovic et al.[740] reporting on long-term course and visual outcome in IU found that the 
percentage of eyes with legal blindness and visual impairment gradually increased over time from 
17% at onset to 28% at 10-year follow-up. They also found that one-third of IU patients achieved a 
remission of their intraocular inflammation for longer than 1 year and had a mean time to remission 
of 8.6 years. Patients who were younger at onset of IU were more likely to achieve remission than 
those who were older at onset. This was not confirmed from our data. 
  Panuveitis yields the worse visual prognosis, with incidence rates of visual loss of 0.08/EY for 
visual to 6/18- 6/36 and 0.13/EY for severe vision loss or blindness. Our findings are in accordance 
with other studies where it was reported that panuveitis was associated with poor visual outcome 
compared with other anatomical types of uveitis [226, 296, 300, 341]. The proportion of patients 
with panuveitis who developed different types of visual loss in our series was very low when 
compared with the Rothova series[300]. However the prevalence of bilateral severe vision loss or 
blindness in this study was similar to that in the latter study.(Table 3.8) 
6.3 Causes of visual loss. 
 
 CMO regularly leads to a reduction in visual acuity and has been suggested to be a major 
cause of decreased visual acuity in patients with uveitis. Few data, however, are available on the 
impact of CMO on visual acuity for different uveitis entities [3, 226, 296, 300]. Rothova et al.[300] 
reported CMO as the main cause of blindness and visual impairment in 29% and 41% respectively. In 
the Durrani series[296], CMO accounted for 47% of causes of visual loss, 27% attributable to CMO 
solely, and 20% to the combination of CMO and cataract. In another study by Bodaghi el al [226], 
CMO was the main factor inﬂuencing visual outcome, with 18.3% of patients presenting the 
complication at the end of the observation period. Lardenoye et al.[341] reported that CMO caused 
visual loss in 44% of patients. In their series, patients with intermediate uveitis and panuveitis had 
the highest frequency of CMO 60% and 66% respectively, and a similar frequency of CMO leading to 
visual loss, respectively, 40% and 52% of patients. Except in the study by Rothova et al.[300], the 
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other studies did not specify the role of CMO in the two main categories of vision loss e.g visual 
impairment and severe visual loss or blindness. We report respectively 28.6% and 10.1% of visual 
impairment and severe vision loss caused by CMO, incidences by far lower than reported in previous 
studies. The incidence of CMO in eyes with IU in this study is higher than in AU or panuveitis or 
posterior uveitis. The incidence of CMO in IU reported in this study was similar to that reported in 
previous studies [300, 741]. We also report here that this complication decreased with time, from 
61.3% at 1 year follow-up to 8 % at 10 years follow up in the group of eyes that developed BCVA 
6/18- 6/36, and from 28% at 1 year follow up to only 1% at 10 years follow up in the group of eyes 
with severe visual loss or blindness.(Tables 3.11 and 3.12). The incidences of CMO in this study 
should be interpreted with caution because sequelae of CMO are reported separately. Moreover, we 
have reported only CMO causing visual loss.  
Previous studies documented various prognosticators of poor visual outcome in uveitic macular 
oedema, including prolonged duration of the uveitis and of CMO itself, a large foveal avascular zone, 
the presence of an incomplete vitreous detachment, and increased macular thickness on optical 
coherence tomography (OCT)[325, 341, 742]. The advanced age of patients was reported to be an 
independent factor for early development and poor outcome of CMO in uveitis [325, 677]. We did 
not report on macular thickness, foveal avascular zone, or vitreous detachment. These limitations 
were related to the design of our study. However, we found a significant correlation between CMO 
and the duration of intraocular inflammation (p=0.034). Age at onset did not influence CMO (p= 
0.68). 
Although CMO can resolve after treatment, its sequelae with macular scarring caused visual 
impairment and severe visual loss respectively in 41% and 36.4% and these sequelae increased with 
time,(p <0.001).   
 Glaucoma represents a severe complication of uveitis. Herbert et al.[743] reported a 41.8% 
prevalence of raised IOP in uveitic eyes and found that raised IOP was present in  26% of eyes with 
acute uveitis and 46.1% of eyes with chronic uveitis. The authors reported that active inflammation 
was significantly associated with raised IOP, and Steroid usage, increasing age as well as number of 
years since diagnosis were significantly correlated with raised IOP. In their series, 9.6% of eyes with 
raised IOP developed glaucoma. Heinz et al.[744] also reported that patients with chronic 
inﬂammatory eye disease had a substantial incidence of glaucoma, increasing with time up to 22.3% 
after 10 years of follow-up. In their report, 8.8% of patients developed secondary glaucoma. 
McCluskey et al.[745] reported that uveitis accounts for 10% of blindness in people aged under 65 
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and pointed out glaucoma as one of the most insidious and, unfortunately, often overlooked 
complications.  
Neri et al.[746] reported 16.6% of glaucoma in patients with chronic uveitis. They found an incidence 
of 6.5% at 1 year follow up, 11.2% after 4 years and 22.7% after 10 years. In their series, the 
probability of developing glaucoma in different topographic types of idiopathic uveitis was not 
different. Rothova et al.[300] found that 11% of uveitis patients developed visual impairment 
attributable to secondary glaucoma. Higher prevalence of glaucoma (23%) has been reported by 
Panek et al.[368]. Merayo et al.[349] reviewing the hospital records of patients with uveitis referred 
to the immunology Service of the Massachusetts Eye and Ear infirmary found that 9.6% of uveitis 
patients developed secondary glaucoma.  
In this study, 16.7% of eyes developed secondary glaucoma. The complication was predominant in 
eyes with AU (Table 3.13). This can be explained by the fact that there is more damage to the 
trabecular meshwork when the intraocular inflammation affects the anterior segment. In a study 
using UBM to characterize the inﬂammatory changes in the anterior segment in  patients with AAU, 
Yang et al.[185] showed severe changes in the anterior and posterior chambers, and in and around 
the ciliary body and anterior vitreous at the peak of the inﬂammation. Although the study assessed 
changes in acute inflammation, it can be extrapolated that when the inflammation lasts longer, 
more damage to the iridocorneal angle will occur. 
As in previous studies [744, 746], we find that glaucoma increased with time. In this study, 15% of 
visual impairment and 18.2% of severe visual loss or blindness was caused by secondary glaucoma. 
The main systemic disease associated with secondary glaucoma was sarcoidosis.(Table 3.16) 
 Hypotony from decreased production of aqueous humor is often due to inflammation, 
medications, or proliferative vitreoretinopathy[747]. Chronic hypotony may lead to visual loss and 
structural changes that alter the function and appearance of the eye [748]. There are very few 
reports in the literature on hypotony related to uveitis. The largest case series addressing hypotony 
related to uveitis was published recently by Kapur et al.[749]. Most reports on hypotony in uveitis 
are case series addressing the management aspect. The actual incidence of hypotony in the context 
of uveitis is not known. In this study, we report that 12 eyes (2%) developed vision loss due to 
hypotony secondary to uveitis. Of the 12 eyes which developed hypotony, 6 had CAU and 6 had 
panuveitis. When looking at the impact on visual acuity, 1% of visual impairment and 3% of severe 
visual loss or blindness were attributable to hypotony.   
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Twenty seven eyes (4.1%) developed vision loss attributable to macular ischemia. Of these, 70.3% 
developed severe visual loss or blindness. Results on ischemia will be discussed further in this 
section. 
 The frequency of retinal detachment (RD) among patients with uveitis is not known. In the 
general population, the incidence of rhegmatogenous retinal detachment (RRD) is approximately 
1:10,000 [750]. The frequency of RRD increases with age, the presence of myopia, and after 
intraocular surgery. It is not known whether the presence of uveitis forms an additional risk for the 
development of RRD.  Hagler et al found that among 2618 patients who underwent surgery for RRD, 
44 (1.7%) had previous uveitis[751].  Bosch-Driessen et al. [752] reported that in patients with ocular 
toxoplasmosis, the frequency of RRD was higher than that of the nonuveitis population, namely 6%. 
Kerkhoff et al[750] identiﬁed a prevalence of 3.1% for retinal detachment in a cohort of 1387 
patients with uveitis. RRD occurred predominantly in patients with panuveitis and in those with 
infectious uveitis, especially in HSV- and VZV-induced retinitis, and the visual outcome was 
poor[750]. So far, the presence of uveitis has not been associated with a high risk of developing RD, 
except for speciﬁc uveitis entities such as Vogt-Koyanagi-Harada syndrome, ARN, and more recently 
ocular toxoplasmosis [548, 752, 753]. Population based studies have reported the association 
between RRD and increasing age [754-756]. The peak incidence of RRD is in the seventh decade and 
was linked to the increasing prevalence of posterior vitreous detachment (PVD) also occurring in 
older age [757, 758]. In the Kerkhoff et al.[750] series the mean age of patients with RRD was 42 
years, which was signiﬁcantly lower than in the RRD controls. The authors hypothesized that RRD 
occurred early in uveitis patients because of the PVD occurence at an earlier age in uveitis [759]. 
Hikichi et al.[760] investigated the effect of intraocular inﬂammation on the vitreous and suggested 
that inﬂammation induced crosslinks in the collagen of the vitreous, which may damage the gel 
structure integrity and induces liquefaction of the gel, which is a mechanism that induces PVD. The 
frequency of RD in this study is in concordance with previous studies [750, 751]. We also find a high 
prevalence of RD in panuveitis as described in the literature. Kerkhoff et al. and Romero et al. 
reported that the ﬁnal visual prognosis for patients with RRD and uveitis was poor, most eyes ending 
up with BCVA 6/60 or worse[663, 750, 751]. In this study, 70% of eyes with RD and uveitis developed 
severe visual loss or blindness. 
 Phthisis bulbi is reported as a complication of severe ocular inflammation [761-765]. Atmaca 
et al.[766] reported 0.8% of phthisis in Eale’s disease. In a review of ocular complications in 
paediatric uveitis, Rosenberg et al.[767] found 4.1% of phthisis bulbi. The incidence of phthisis in this 
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study was similar to what reported in the literature. Seventy percent of phthisis developed in eyes 
with panuveitis, and the complication occurred from 5 years onwards (p=0.002) (Table 3.12). 
When looking at systemic diseases associated with different ocular complications, we found that 
sarcoidosis was the main condition associated with CMO, glaucoma and hypotony. BD was the main 
disease associated with optic atrophy. In patients who developed macular ischemia, BD and SLE 
were the most commonly found diseases (Tables 3.16). 
6.4 Systemic diseases. 
 
 Sarcoidosis occurs worldwide but is predominant in certain ethnic and racial groups (for 
example, US blacks, Scandinavian and Irish caucasians)[768]. The frequency of sarcoidosis is 
reported to be low in various parts of the world [769, 770]; it is not known whether this low 
frequency of sarcoidosis is genuine or whether it represents an underdiagnosis owing to the 
frequent occurrence of subclinical course, similarity with other diseases, or absence of firm 
diagnostic criteria. The first international workshop on ocular sarcoidosis (IWOS) proposed 
diagnostic criteria based on ocular signs, laboratory investigations, and biopsy results [565]. Ocular 
involvement manifests in 25%–60% of patients with systemic sarcoidosis[700]. This percentage 
depends on the population studied and the extent of ocular examinations. Japanese sarcoidosis 
patients develop ocular disease in more than 70% of cases [771].  
 The most common ocular manifestations are uveitis (30%–70%) and conjunctival nodules 
(40%) [609, 772]. In large surveys of uveitis patients, the frequency of sarcoidosis was about 
5%[700]. Sarcoidosis is one of the most common systemic disease associations with uveitis in the 
USA and Europe accounting for 3-7% of non infectious uveitis cases [226, 773]. Traditionally, the 
most common type of sarcoid associated uveitis was attributed to anterior uveitis. It is noteworthy 
that the high frequency of sarcoid associated anterior uveitis (70%–75%) was noted mainly in the 
studies where the majority of patients were black [300, 774-776]. Black patients present typically 
with more severe and acute disease whereas Caucasians usually have asymptomatic and chronic 
disease [770]. Ocular disease may be the initial manifestation in sarcoidosis and may progress to 
severe visual impairment or even blindness. Two peaks of incidence were reported for ocular 
sarcoidosis, the first at ages 20–30 years and the second at ages 50–60 years[777]. Rothova et 
al.[777] evaluating the risk of developing ocular involvement in patients with biopsy proven 
sarcoidosis reported that 58% developed uveitis, and that 43% of patients who developed uveitis 
were black. The authors also found that black patients tend to develop AU, whereas caucasians 
develop PU.  Birnbaum et al.[778] reported that African American patients were more likely to be 
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diagnosed as having uveitic sarcoidosis and to present with uveitis if they were younger than 50 
years, while caucasians were more likely to present when they were older than 50 years. Adan et 
al.[779] found uveitis as the presenting manifestation of sarcoidosis, especially in women over 60 
years of age, with bilateral panuveitis and chronic bilateral anterior uveitis being the most common 
clinical presentations. In a recent study, Gregoire et al.[780] found Sarcoidosis in 37.4% of patients 
aged 60 and over who developed uveitis.  
Rothova et al.[777] reported that uveitis preceded the non-ocular signs of sarcoidosis in about 30%. 
In a study by Lobo et al.[781], it was reported that posterior uveitis was evenly distributed between 
black and white patients. It is noteworthy to mention that in their series like in our own, it was not 
possible to identify the race of all patients.    
In another study, Rothova reported that the visual impact of sarcoid associated uveitis was severe, 
about 10% of patients developed blindness in at least one eye[300]. Stavrou et al.[782, 783] found 
that the main cause of visual loss in sarcoidosis related uveitis was cystoid macular oedema. The 
poor visual prognosis was associated with the advanced age of patients, black race, female sex, 
chronic systemic disease, and also with posterior segment involvement, peripheral punched out 
lesions, and the presence of cystoid macular oedema and glaucoma. Chronic anterior uveitis may 
lead to secondary cataract, glaucoma, and cystoid macular oedema; corneal band keratopathy may 
also develop [300]. Jabs et al. [775] reported that chronic uveitis and secondary glaucoma were poor 
prognostic signs, as 73% of patients with uveitis and glaucoma suffered severe visual loss. In a series 
by Lobo et al., 32% of patients had AU, 21% IU and 46% Pan/Pu. Bilateral disease was seen in 86% 
and it was not always symmetrical at presentation [781]. The authors reported that 11% of eyes 
developed visual impairment, 9% developed severe visual loss and found greater age as a risk factor 
for visual loss. The main causes of visual loss in their study were cataract, glaucoma, macular 
oedema, vitreous haemorrhage and retinal detachment. 
 In this study, the proportion of patients who had sarcoidosis associated with uveitis was 
similar to that reported in previous studies.(Tables 3.14 and 3.15). The prevalence of sarcoidosis in 
patients aged 60 or more was higher when compared with young patients and similar to that 
reported in studies by Gregoire et al.[780] and Birnbaum et al.[778].  
As in many other reports, females were more affected than males. The majority of patients in our 
series developed AU. 
The prevalence of vision loss with time in this study was lower than that reported by Lobo et al[781] 
in the same institution. One explanation to this difference could be found in the fact that in the 
latter study, the cut- off for vision loss was 6/12, while in this study we considered  6/18 as 
recommended by the SUN group. The proportion of eyes which developed severe visual loss in this 
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study was similar to that reported by Rothova et al. [300] in sarcoidosis associated uveitis (Table 
3.17). We did not find any incidence rates reported in the literature, therefore could not make any 
comparison.  
As in previous studies, we found that the increased risk of a poor outcome is confounded by the 
adverse influence of increased age at presentation on the visual acuity at follow up. Rothova et 
al.[700] reported that visual loss was associated with posterior segment involvement and was 
caused by cystoid macular oedema in the majority of cases. The prevalence of glaucoma was low in 
the study by Lobo [781], probably because of the lower prevalence of chronic anterior uveitis and 
the small size of their sample.  
In this study where AU was predominant, glaucoma was the most important cause of visual loss, 
followed by chronic macular damage.(Tables 3.18 and 3.19). Our findings were in concordance with 
reports by Jones et al[784] and Jabs et al[775]. Although cataract surgery has been shown to be 
highly successful[785], glaucoma still appears to carry a poor visual prognosis in patients with 
chronic ocular sarcoidosis, presumably related to a greater inflammatory insult [775, 776] (Tables 
3.18 and 3.19). 
  Behçet’s disease (BD) is a multisystem disorder that was described in 1937 by the Turkish 
dermatologist, Hulusi Behçet (1889-1948) as consisting of the triad of ocular inflammation and oral 
and genital ulcers. Other systemic manifestations include erythema nodosum, cutaneous 
thrombophlebitis, arthropathy, gastrointestinal disturbances, and, less commonly, central nervous 
system involvement and major vessel thrombosis. BD is prevalent in countries lying along the 
ancient Silk Road, a route of travel and commerce from the eastern Mediterranean to East Asia. 
Epidemiologic studies have shown that Turkey has the highest prevalence with 20-420 cases per 
100,000 [786-788], followed by Japan, Korea, China, Iran, and Saudi Arabia, where the frequency has 
been reported to range from 13.5 to 22 cases per 100,000 [787, 789]. On the other hand, the 
prevalence is much lower in Western countries: 0.64 cases per 100,000 in the United Kingdom and 
0.12-0.33 per 100,000 in the United States[789]. In a population-based study covering a 45 years 
period, Calamia et al.[790] recently reported an overall incidence estimate of 0.38 per 100,000 
population in the USA. BD is slightly more frequent and has a worse clinical course in men (they have 
a higher risk of eye involvement and of visual loss, cardiovascular and neurological involvement, a 
younger age of disease onset and worse evolution of clinical features) [791, 792]. It usually develops 
between the third and fourth decades of life, rarely appearing before puberty and after the age of 
50 [793-796]. The disease generally is more severe in patients with a younger onset age. However, 
recent studies, one from Korea and one from Turkey, suggested that late-onset BD (age of onset at 
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or after 40 years) may not be associated with a milder evolution [794, 797].    
   This study is in agreement with previous reports[794, 798] where males 
predominated in both centres, in contrast to studies which suggested a more even distribution of 
disease between the sexes [799] and a predominance of females[790]. The mean age of patients at 
presentation in this series was similar to what reported in many other studies [556, 790, 800]. In 
reports from Iran and Turkey [791, 798], patients were younger than in reports from the western 
world. Similarly to many data in the literature, we did not find a difference in age at first 
presentation between males and females. In our cohort, only 6 patients were aged below 25, and 
none were 16 or younger. This confirms the fact that childhood BD is rare in the UK.                
 The pattern of types of uveitis reported in this study (Table 3.20) is in agreement with most 
reports Panuveitis or posterior uveitis occur in the majority of patients, while AU has been reported 
in proportions of 5- 10% [801, 802].   
 Reports published prior to 1992 indicated that long-term visual prognosis for ocular BD 
patients was generally poor, and in 60–80% of these cases, visual acuity deteriorated to less than 
useful levels (worse than 6/60) during the 10-year period following initial diagnosis[561, 803, 804]. 
However, recent reports have shown some improvements in the visual prognosis for these patients 
[791, 801, 805, 806]. Notably, reports published after 2004 indicated obvious improvements in 21–
34% of patients [805, 806]. Yoshida et al.[806] comparing clinical findings in patients with BD seen in 
2 different decades (1980s and 1990s) in Japan reported that 37% of the patients seen in the 1980s 
had poor VA (6/60 or worse) at the first visit, and this decreased significantly in the 1990s. Tugal-
Tutkun et al.[791] reported that at the beginning of the follow-up, potential visual acuity was 6/60 or 
worse in 30.9% of eyes in males and 24.2% of eyes in females. The Kaplan-Meier survival analysis in 
their study estimated the risks of losing useful vision (>6/60) at 5 and 10 years for males and females 
as 21% vs 10% and 30% vs 17%, respectively and found that male patients who presented in the 
1990s had a significantly lower risk of losing vision compared with male patients who presented in 
the 1980s. The incidence of severe visual loss or blindness in this study(Table 3.22) was similar to 
that reported by Muhaya et al [556] in a comparative study between patients with BD in Japan and 
in Great Britain. Kaçmaz et al.[801] reported incidence rates of 0.12/EY and 0.09/EY for BCVA 6/15 or 
worse and 6/60 respectively. The incidence rates reported in the present study were low for both 
visual impairment and severe visual loss or blindness when compared with the latter study. Kaburaki 
et al.[807] recently reported that uveitis related BD is particularly aggressive during the first 3 years 
after its onset, and clinicians should take particular caution during that period. Demiroglu et al. [808] 
also suggested that treatment of ocular BD within 2 years of disease onset is very important. 
Another study reported that the number of ocular attacks per year was higher in cases of BD with 
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poor visual prognosis (6/60 or worse) than in those with good visual prognosis (better than 
6/60)[805]. Kaçmaz et al.[801] also suggested the significant relationship between the loss of VA to 
the 6/60 or worse level and activity of ocular inflammation. In this series it was not possible to 
establish the frequency and the severity of attacks because of the retrospective nature of the study 
with no standardization of records, and we could not determine with certainty whether patients 
with ocular inflammation were seen at this tertiary referral centre within the critical period of 2 
years from disease onset. Cho et al. [809] reported that while the long-term visual prognosis for BD 
uveitis may be affected by many factors, the initial visual acuity appears to be the most significant. 
Similarly, we found a highly statistically significant correlation between visual acuity at presentation 
and at final floolw- up visit (p<0.001). (Fig.3.3)  
 Recurrent attacks of inﬂammation lead to secondary complications namely, posterior and/or 
peripheral anterior synechiae, iris atrophy, cataract due to inﬂammation and/or medication, 
secondary glaucoma (sometimes neovascular), atrophic retina, optic atrophy, macular oedema, 
macular degeneration, retinal veins occlusion, sheathed vessels, chorioretinal scars and/or 
proliferative vitreoretinopathy, phthisis bulbi [691, 810, 811]. Repeated ocular attacks result in 
limited visual recovery and in irreversible alterations of the sensory retina even after the 
inflammation is under control, which is not typical in the eyes with other types of uveitis[789]. Yu et 
al.[812]reporting on fluorescein angiography and visual acuity in active uveitis with BD found that 
diffuse vascular leakage and diffuse macular leakage were the predominant angiographic findings, 
followed by disc leakage, CMO, peripheral capillary nonperfusion, macular window defect, macular 
ischemia, and disc neovascularisation in eyes from BD patients and that the main destructive 
mechanism of BD was vasculitis.           
The vasculitic and vasoocclusive episodes in BD uveitis can cause capillary dropout resulting in 
capillary nonperfusion or macular ischemia[424]. Retinal atrophy, retinal exudates, haemorrhage 
and retinal–choroidal degeneration may collectively form a macular window defect [813]. These FA 
characteristics were identified in eyes with chronic and irreversible cases that may not respond to 
immunosuppressive treatment [812]. In the series by Kaburaki et al.[807], chronic macular damage 
accounted for 80% of severe visual loss or blindness, optic atrophy and phthisis for 14.3% and 2.4% 
respectively. Kaçmaz et al.[801] found that 13% and 6.4% of eyes with severe visual loss had chronic 
macular damage and CME respectively while 4.3% developed optic atrophy and 1.4% had glaucoma. 
Benchekroun et al.[814] reported 24% of severe visual loss caused by chronic macular damage and 
17% by CMO. In this study, we report a higher incidence of optic atrophy and glaucoma than that 
reported in previous studies. The prevalence of CMO as a cause of severe visual loss in the present 
study is similar to that reported by Kaçmaz et al.[801] (Tables 3.21 and 3.22). When looking at 
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different data in the literature, it is surprising that macular ischemia is rarely mentioned. We report 
16.7% of severe visual loss or blindness due to macular ischemia. In this study, the patients’ profile 
corresponds to that reported in the literature.  In Turkey, the mean age for patients with BD who 
develop uveitis is 28.5 years and 30 years for males and females respectively [791]. In a series from 
Taiwan, the male-to-female ratio was 1:6 [815].  Panuveitis is the most common ocular 
manifestation associated with BD reported in most studies [802, 816]. Our findings are consistent 
with this pattern. (Table 3.20) 
A study from 25 eye centres in 14 countries emphasised that Behçet’s disease is still a blinding 
disorder despite modern treatments, with one quarter of the patients becoming blind [817]. Kump 
et al.[818] analyzing differences in response to the treatment of ocular Behçet’s disease (BD) in the 
1960s, 1980s, 1990s found a definitive trend towards improvement in clinical outcome from the 
1960s to 1990s. Statistical analysis showed that the mean logMAR score decreased with each decade 
as a result of newer and more potent corticosteroid-sparing agents being used. However, Kaçmaz et 
al[801] found that loss of visual acuity and occurrence of ocular complications were common in 
patients with ocular inflammation associated with Behçet’s disease, even with aggressive therapy, 
persistent inflammatory activity being one of the risk factors for visual impairment. A recent study 
by Takeuchi et al.[819] demonstrated that visual acuity, sensitivity and retinal thickness decrease 
with the duration of uveitis in Behçet’s disease. This suggests that ocular inflammation in patients 
with Behçet’s can cause severe visual impairment. In the present study, after an improvement at the 
end of the first year, visual acuity continued to decrease as a result of subsequent ischemic 
events.(Fig.3.3)  
 The association between anterior uveitis and diabetes is well known. Despite DM being 
implicated as a cause of uveitis, little is known about  the clinical features of uveitis occurring in 
patients with preexisting DM[618]. Data on diabetes and uveitis are scarce in the literature. Brewitt 
at al.[820] found that out of 103 patients with uveitis, 14.5% cases showed pre-clinical diabetes, 
outnumbering by far the average frequency of approximately 6% of pre-clinical diabetes and 
concluded that diabetes mellitus was assumed to be a co-factor of the development of uveitis.  
Rothova et al.[616] reported a prevalence of 6% of patients with AU associated with diabetes. We 
found diabetes mellitus associated with intraocular inflammation in 4.2%, and the prevalence of 
diabetes in AU that we report is similar to that reported by Rothova in the latter study (Table 3.24). 
In an immunological study, Castagna et al.[615] underlined the correlation between AU and type I 
diabetes. They suggested that the high level of CD8+ T cells found could be an expression of unstable 
lymphocytic equilibrium. Most of our patients were Type 2 and not induced by the steroid drugs, 
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few were type I. Looking at clinical features of patients with diabetes mellitus presenting with their 
first episode of uveitis, Oswal et al.[618] reported that patient may present with severe intraocular 
inflammation, and found in their series that 31% had the BCVA between 6/18 and 6/60, 22% had 
BCVA= 6/60 or worse. Probst et al. [821] found elevated intraocular cellular fibronectin (cFN) levels 
in eyes with uveitis and DM, especially in those with active disease, intraocular vascular damage, and 
macular edema. Their findings suggested that locally produced cFN levels reflect intraocular vascular 
damage. It is noteworthy that visual loss in the Oswal  series[618] was not merely caused by ocular 
inflammation and its complications, but 42% of eyes had diabetic retinopathy. We found in this 
study that diabetic males tend to develop uveitis earlier than females. In our cohort, diabetic 
patients with uveitis and diabetic retinopathy affecting their visual acuity were not included. We 
report here incidence rates of 0.036/EY and 0.026/EY for visual loss to 6/18-6/36 and 6/60 or worse 
respectively. There are no reports on incidence rates in diabetes associated uveitis in the literature 
to allow any comparison with our findings.  
 Birnbaum et al.[822] reporting on etiologies of AU at a tertiary referral centre over 35 years 
found that Multiple sclerosis (MS) showed an increase of approximately 1% in the latest decade 
(1995–2004) when compared to the earlier decade (1975–1984). The diagnosis of MS has increased 
in recent years, perhaps related to the increased use of neuroimaging and/or the increased lifespan 
of patients diagnosed with MS [823]. MS is reported to be associated with uveitis in 1-2% [226, 577]. 
MS and uveitis are associated with immune dysregulation and the diagnosis of MS is more likely to 
precede that of uveitis[576]. Biousse et al.[575] reported a 9 years delay between the onset of 
neurologic and ocular symptoms, emphasising the importance of a sequential diagnostic search 
throughout the patient's course. Looking at the frequency of uveitis among MS patients, Le Scanff et 
al. [572] reported that uveitis preceded the onset of MS in 46% of the patients; it occurred 
simultaneously or after MS, in 18% and 36% of the cases, respectively. Edwards et al.[576] 
investigated 658 consecutive outpatients attending a specialist MS clinic and found that 2.28% had 
the association of symptomatic uveitis and MS. In another series, Zein et al.[577] reported that the 
diagnosis of MS preceded the onset of uveitis in 56%, followed it in 25%, and was made concurrently 
in 19% of the cases. In a series by Towler et al.[579] the majority of patients had documented MS at 
the time of presentation of their uveitis, three did not and there was a considerable time-lag before 
the onset of their neurological disease.  
 The prevalence of MS and the female predominance in this study was in concordance with 
most data in the literature. We found that 69% of patients had the diagnosis of MS before they 
develop uveitis, and the mean time interval between the diagnosis of MS and intraocular 
inflammation was 8 years. The clinical pattern of uveitis occurring in multiple sclerosis is wide-
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ranging and may cover the full range of clinical manifestations [575, 577, 579, 824]. The features of 
uveitis in the series by Towler were non-specific in that they could occur in association with other 
disorders, and were of no value in predicting the subsequent development, clinical type or course of 
MS, unlike the known association of asymptomatic peripheral periphlebitis with optic neuritis and its 
predictive value for a subsequent diagnosis of MS. They reported intermediate and posterior as the 
commonest types of uveitis[825]. Granulomatous uveitis has been noted to occur in MS 
patients[577] and attributed to MS when the typical diseases associated with granulomatous uveitis 
(tuberculosis, sarcoidosis and syphilis) have been excluded [826], and this has been hypothesised to 
be at least partly due to the disordered immunity occurring in MS [827].  Boskovich et al. [728] 
identifying the clinical features of intermediate uveitis and assessing its association with systemic 
diseases found that 7% of patients with IU had MS associated. Khairallah et al.[828] reported 2.3% of 
MS associated with IU. Following Rucker’s first report of the association of retinal periphlebitis with 
multiple sclerosis (MS) in 1944[829, 830], the observation has been confirmed by many other studies 
[831-833]. The reported incidence of retinal vascular sheathing has varied considerably in different 
series, from as low as 2% to 44%, but with an average of around 20%[834]. In the majority of 
patients the retinal vascular changes are not associated with symptoms and are not a threat to 
vision. In addition, the presence of peripheral retinal venous sheathing in individuals presenting with 
isolated optic neuritis has been shown to be predictive of the subsequent development of MS, with 
a relative risk of 14.4[825]. In this series, we report IU in 83% and the prevalence of MS among all 
cases of IU was similar to what reported in other series. Over the follow-up period, visual outcome 
was very satisfactory as only 1 eye developed visual loss of 6/18-6/36 due to macular damage and 1 
eye developed severe visual loss due to optic atrophy. CMO was the main cause of visual loss in the 
Towler series. Better management options of this complication have been developed over the last 
decade, and this explains its absence from our study. 
 Vogt-Koyanagi-Harada (VKH) disease is a chronic, bilateral, granulomatous panuveitis and 
exudative retinal detachment associated with poliosis, vitiligo, alopecia, and central nervous system 
and auditory signs[548]. Exudative retinal detachment during acute disease and sunset glow fundus 
during the chronic are highly specific to this entity [551]. Results from previous studies have shown 
that, worldwide, VKH disease is slightly more common in Japan (10.1% of all uveitis referrals) and 
less common in the USA (1–4%)[548], India (2%) [835] and Brazil (2.5%) [550]. Prevalences as high as 
18 to 35% associated with panuveitis were reported in Los Angeles [280], and up to 38% in one study 
in Argentina [836]. Most studies have reported a female predominance. 
 Ocular complications of VKH syndrome include cataract, glaucoma, serous retinal 
detachment, subretinal fibrosis, subretinal neovascularisation, epiretinal membrane formation, 
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macular atrophy or pigmentary degeneration [837, 838]. In the series by Moorthy et al.[548], 
cataract developed in 25%, glaucoma in 33% and subretinal neovascularisation in 10%. Khairallah et 
al [839] reported cataract in 33.9%, glaucoma in 16.9% and subretinal neovascularisation in 1%. In 
their series 40.8% of eyes had BCVA 6/60 or worse at presentation. In another series by Al-Karashi et 
al.[840], 31.6% of eyes had severe visual loss.  A similar proportion of eyes with BCVA 6/60 or worse 
at presentation was reported by Chee et al.[841]. Initial visual acuity was also shown to be 
significantly associated with final visual acuity by Read et al. [842] and Ohno et al. [843] with those 
eyes possessing better visual acuity at presentation more likely to have better final visual acuity and 
conversely those eyes with poor acuity at presentation more likely to have poor final visual acuity. If 
initial presenting VA has been found to correlate well with final visual outcome in most studies, Chee 
et al.[841] found that the VA at one month after starting treatment was an important prognostic 
factor. They reported that eyes that had good VA at one month were more likely to have good VA at 
three years, and were less likely to develop persistent/recurrent inflammation, cataract, or CR 
degeneration. This was consistent with the finding of better outcomes in eyes that had received 
early and adequate immunosuppressive therapy [844-846]. Hence, the response to treatment is the 
main prognostic indicator for a good outcome and VA at one month is a useful early indicator of the 
adequacy of treatment. Therefore, patients who have not achieved a VA of better than 6/60 at one 
month after starting treatment should be considered for more aggressive immunosuppression[841]. 
Rubsamen and Gass [847], however, found no correlation between visual acuity at presentation and 
final visual acuity.  
 The prevalence of VKH in our cohort was similar to that reported in other studies in Western 
countries. We also report a predominance of female (sex ratio 3:1). The proportion of eyes with 
vision loss at presentation was lowerr than that reported in previous studies. We found a strong 
correlation between visual acuity at initial presentation and visual acuity at final follow-up visit (P = 
0.003). Chronic macular damage was the main cause of visual impairment, and 2 eyes developed 
glaucoma leading to severe vision loss. Noteworthy, our sample of VKH patients was very small, so 
we could not draw more on statiscal analysis. However, visual outcome was overall satisfactory. 
 JIA is the most common rheumatic disease in childhood, occurring in approximately 1:500 
children[848]. Pauciarticular JIA is associated with intraocular inflammation (uveitis) early during the 
arthritic disease course[589]. The mean age at the uveitis diagnosis was 4.5 years in the Marvillet’s 
series [588]. In their cohort, uveitis antedated joint manifestations in 13% of patients; in 24.7% both 
were diagnosed simultaneously; and in 62.3% arthritis antedated uveitis. It was not possible for us to 
determine which between uveitis and arthritis preceded. Sixty percent of patients with JIA related 
uveitis in the present study were females. The female predominance reported in this study is in 
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agreement with the literature.  Saurenmann et al [584] reported that among girls, the risk was 
maximal (47%) in those who were ANA positive and were ages 1-2 years at the time of the onset of 
JIA; this risk decreased to <10% in those in whom the age at onset was >7 years.  AU is the most 
common uveitis reported. It accounted for 60% in this study. Patients considered at higher risk of 
developing JIA related uveitis are those with an age of onset of arthritis under 7 years, pauciarticular 
involvement and positive ANA titers. Ophthalmological examinations of these patients are 
recommended every 3 months. Medium risk patients include those with an age of onset under 7 
years, polyarticular or pauciarticular involvement, and negative ANA titers. All pauciarticular patients 
with onset after age 7 are also considered at medium risk. Ophthalmological examinations are 
recommended for medium risk patients every 6 months. All patients with systemic JIA are 
considered low risk, and ophthalmologic examinations are recommended annually [588]. Marvillet 
et al.[588] recommended ophthalmological follow-up at regular intervals, even if their joint disease 
is quiescent. In a study covering an eight years period, Bolt et al.[849] reported that uveitis occurred 
in 35/265 patients (13.2%) of their JIA cohort. In a series by BenEzra et al.[589], uveitis was detected 
in 9.2% of children with JIA during the first ophthalmic examination and in an additional 11.2% 
during the follow up period of up to 15 years. Twelve percent in their study presented initially with 
uveitis. The authors reported that in children developing uveitis before or along with arthritic 
manifestations, the ocular disease was chronic with a high rate of secondary complications (band 
keratopathy, glaucoma, posterior synechiae and cataract). In all affected eyes the initial ocular 
inflammation was typically confined to the anterior segment. On longer follow up however, most 
children developed binocular disease and posterior segment involvement [589]. In a cohort of 55 
consecutive patients with JIA associated uveitis, Skarin et al.[850] found that uveitis was still active 
24 years after onset. They reported that cataract developed in 42% at 7 years, and in 51% at 21 
years, uveitic glaucoma developed in 5% at 7 years and in 22% at 24 years. Looking at visual 
outcome of children with JIA associated uveitis, Kump et al.[851] found that 64% developed 
cataracts, 20% developed increased intraocular pressure, and 46% developed band keratopathy.  
 JIA-associated uveitis has been reported to result in significant impairment of visual acuity as 
a consequence of structural ocular complications such as cataract, band keratopathy within the 
macular axis, glaucoma, and macular pathology [852]. The same was reported by Thorne et 
al.[853]in a recent study. In their series, Woreta et al[585]also reported 67% of ocular complications 
at presentation. They found that 36% and 24% of eyes had respectively BCVA 6/15 or worse and 
6/60 at presentation. Thorne et al. [853] reported incidence rates of 0.10/EY and 0.08/EY for BCVA 
6/15 or worse and 6/60 or worse respectively. They reported incidence rate of 0.04/EY for cataract. 
The proportion of eyes with BCVA 6/18-6/18 at presentation in this study was inferior to that 
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reported by Woreta et al. [585], but we report a higher proportion of eyes with severe visual loss or 
blindness at first visit. Incidence rate for cataract in our study was similar to that reported by Thorne 
et al [854], but rates for vision loss were by far lower than that reported by the same authors in  
another study [853].          
 While male gender has been reported as an independent risk factor for poor visual outcome 
in previous studies [376, 855], we did not find a gender influence on visual outcome. This could be a 
sample size effect.        
 When we consider the high proportion of patients who presented with severe visual loss or 
blindness and the mean age at first visit in our series, there could be a referral bias in that only the 
most severe cases of JIA-associated uveitis were referred. The delay in referring to a tertiary care 
centre or uveitis specialist has been reported to be a risk factor for poor clinical and visual outcomes 
in patients with JIA associated uveitis, presumably because of the delay in aggressive management 
of the inflammation [856]. While it is generally accepted that JIA related uveitis bears a reserved 
visual prognosis, Sabri et al.[857] and Bolt et al.[849] reported good visual outcome in JIA-associated 
uveitis despite uveitic complications. Heilingenhaus et al.[858] suggested that in order to reduce 
severe disease at presentation and achieve an excellent long term visual outcome, earlier 
ophthalmological screening should be initiated after arthritis onset and the intervals be related to 
the JIA subgroup. 
6.4 Idiopathic uveitis. 
 
 Birdshot chorioretinopathy (BSCR) is a chronic intraocular inflammatory disease of unknown 
origin that is responsible for 1% to 2% of all uveitis cases [229, 290, 300, 478]. It occurs in the early 
to mid fifties [482]. BSCR is predominantly considered to be an ocular disorder without systemic 
manifestations [477]. Occasionally, systemic hypertension has been noted, and a small number of 
patients complained of hearing loss, vitiligo, and mood disorders[859]. Rothova et al. [860] found 
the prevalence of systemic hypertension as high as 46%. This high prevalence of hypertension could 
be explained by the fact that in the Dutch population older than 55 years, 31% to 39% suffer from 
systemic hypertension [860]. The course of BSCR is, in the majority of patients, chronic and 
progressive. Various studies have shown that BSCR usually remains active for approximately 10 to 12 
years, and after that the active inflammation slowly declines, resulting in atrophic changes of the 
retina and optic disc [861, 862]. One study reported a self-limiting course in 20%[861]. Although 
some authors argued that BSCR is most severe during the first 2 to 4 years of activity and, in 
consequence, requires most aggressive treatment in this initial period of the disease, others report 
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on a prolonged course with frequent remissions[863]. In a literature review, Shah et al.[479] 
reported that Birdshot choroidopathy is a slowly progressive disease with profound dysfunction of 
vision that may not be reflected in Snellen visual acuity, and CMO is the main cause of visual loss. Oh 
et al.[864] looking at the long-term course of BSCR at the University of Iowa found that the retinal 
function in this inflammatory ocular condition deteriorated progressively over a period of years 
despite stable visual acuity. In their study, they reported that late in the course of the disease, visual 
acuity may be lost due to chorioretinal atrophy in the posterior pole, and that visual acuity alone was 
not an adequate parameter with which to monitor disease activity as it may falsely suggest that the 
patient is stable or well. Rothova et al.[860] reported a gradual loss of VA, and a long association 
between VA at onset and visual outcome after 5 and 10 years. In their series, 8% of eyes had BCVA 
6/60 or worse at presentation, proportions increased to 30% at 5 years follow-up and to 39% at 10 
years follow-up.They did not find any difference in annual loss of VA between patients on standard 
treatment and untreated patients. They concluded that the visual prognosis of BSCR was poor in the 
spectrum of uveitis. Thorne et al.[865] reported that in affected eyes, the frequencies of vision loss 
to 6/15 or worse and to 6/60 or worse and of CMO at presentation were 33%, 13%, and 20%, 
respectively. They found that patients who presented with a duration of disease of > or = 30 months 
had higher frequencies of visual impairment to 6/15 or worse (68% vs 32%; P = 0.004) and to 6/60 or 
worse (32% vs 9%; P = 0.01), and had a higher frequency of CMO (38% vs 14%; P = 0.02) than 
patients who presented with a duration of disease <30 months. They also reported on incidence 
rates on follow-up, 0.13/EY and 0.04/EY for 6/15 or worse and 6/60 or worse respectively. Long-
term visual prognosis of BSCR was repeatedly reported to be poor: 16% of BCR patients in Europe 
and 22% of BSCR patients in the United States developed a VA of 6/60[477, 482, 861].   
 In this series the prevalence of BSCR in this study (1.5%) was similar to that reported in many 
studies [290, 291, 300, 478]. In our cohort, 2 patients had diabetes; this association was thought to 
be coincidental. The female preponderance and the age at onset was in concordance with the 
literature, and the proportions of eyes with vision loss at presentation were similar to that reported 
by Rothova et al.[860]. Although we found the same proportion of eyes with BCVA 6/60 at 
presentation as in the latter study, we did not find an increase in the number of severely impaired 
eyes with time (Fig.3.4). The proportion of eyes with 6/60 vision or worse and 6/15 or worse at 
presentation and the incidence rate for vision loss to 6/15 or worse in the series by Thorne [865] was 
very high. Rothova et al.[860]  found that patients who had cardiovascular risks/disease were prone 
to developing severe visual loss. They suggested that hypertension might negatively influence visual 
prognosis in BSCR patients. Whether this hypothesis could explain the difference in visual outcome 
between  their study and our own remains a question to answer. As in most studies, CMO and its 
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sequelae was the main cause of visual loss, accounting for 82.3%. This high incidence of CMO was 
similar to that reported in the cohort by Rothova et al.[860]. In their cohort, CMO accounted for 
84%, vs 30% in the uveitis population. Thorne et al[865] reported that patients who presented at a 
later date after the onset of the disease were more likely to have visual impairment and CMO. A 
prevalence of subretinal neovascularisation was previously reported in approximately 6% to 
14%[482, 860, 861, 866]. In our series, this complication was not found, but again, this could be a 
sampling effect. Our findings confirm the fact that the disease is very active during the first 3 years 
during which vision was severely impaired. The rise in the number of eyes with BCVA 6/18-6/36 from 
10% at presentation to 50% after 10 years reflects the effect of macular chronic inflammatory insults 
over a long term (Fig. 3.4). Macular and chorioretinal atrophy in long-standing birdshot 
retinochoroidopathy has been mentioned in the literature [860, 864, 867]. Birch et al.[487] 
corroborated the long-term visual prognosis in patients with BSCR and provided further evidence 
that the decline is because of progressive deterioration of function of photoreceptors, RPE, and 
choroid. Kiss et al.[868] reported that long-term preservation of visual function is attainable with 
systemic corticosteroid-sparing immunomodulatory therapy (IMT) for patients with BSRC. Prompt 
treatment with systemic IMT may offer the best hope of maintaining retinal function in what is often 
thought of as a chronically progressive disease resistant to treatment. 
  Birdshot chorioretinopathy patients complain frequently of having problematic vision 
outside, abnormal color vision, and reading difficulties. Therefore, central VA alone is not the only 
parameter for treatment efficacy; VF examinations and electroretinogram might be extremely 
helpful parameters when assessing the degree of visual impairment and progression of the disease. 
Visual fields and electroretinograms were abnormal even in BSCR patients with full central acuity 
[861, 864, 869, 870].  
 Multifocal choroiditis (MFC) is thought to be an autoimmune inflammatory condition 
affecting one or both eyes characteristically with a chronic relapsing course. The first description of 
MFC with panuveitis as a distinct clinical entity is attributed to Dreyer and Gass in 1984 [871].  It is a 
chronic progressive inflammatory disease which is more common in young to middle-aged myopic 
women. MFC frequently is complicated by structural ocular complications involving the posterior 
pole which can result in loss of central VA over time [871-874]. Pathologically MFC represents a non-
granulomatous choroiditis with a predominantly B-cell infiltrate and can be associated with 
choroidal neovascularisation (CNV)[875].  Acutely the foci may show chorioretinal inflammation that 
leads to destruction of Bruch’s membrane, retinal pigment epithelium and the outer neural retina 
[876]. It has been shown that despite steroid treatment, MCP progresses to significant permanent 
visual loss in 60% to 75% of reported cases [871, 872, 877]. The vision loss occurs as a consequence 
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of chronic or recurrent inflammation [871, 872, 877](CMO, ERM, other maculopathy, optic 
neuropathy, subretinal fibrosis, and subretinal neovascular membrane) and/or from steroid 
complications (glaucoma)[873]. It has been reported that CNV occurs in 32%–46% of MCP cases 
[872, 878]. Palestine et al.[877] found that only 25% of their cases had some benefit from steroid 
therapy, whereas Cantrill and Folk[879] reported that 40% responded and 60% progressed despite 
steroid treatment. Brown and associates[872] found that more than half their patients progressed to 
vision of 6/60 or less despite steroid treatment. And Nӧlle et al.[880] reported their patients to be 
refractory to local and systemic steroid therapy, with deterioration in vision during steroid 
treatment. In the largest series of MFC to date, Thorne et al[881] reported repectively 55% and 38% 
of vision loss to 6/15 or worse and 6/60 or worse at presentation. In their series, 20% and 15% of 
patients respectively presented with bilateral visual loss to 6/15 or worse and 6/60 or worse. They 
reported incidence rates of vision loss to 6/15 or worse and 6/60 or worse of 0.19/EY and 0.12/EY 
respectively.  
The mean age at diagnosis of MFC and the female preponderance in this study is in concordance 
with the literature [882, 883]. In our series, the proportion of patients who presented with bilateral 
vision loss was five times less than reported in the latter study. We also report a low incidence of 
visual loss at presentation and very low incidence rates of visual loss. The incidences of visual loss to 
6/60 or worse at presentation and at five years follow-up in the present study (Fig.3.5) were similar 
to that reported by Vianna and MacLaren[874, 884]. We do not have a plausible explanation as to 
why patients in our series presented with better visual acuities when compared with the series by 
Thorne. In this study, chronic macular damage was the most common cause of visual loss. The 
incidence of CNVM in affected eyes was similar to that reported in most studies [871, 872, 878]. Low 
incidences of CNVM have been reported by Vianna et al[885] and by Michel et al[873].  Unlike the 
study by Michel et al[873] who found a high incidence of glaucoma, we did not find any glaucoma in 
our series (Table 3.26). The paper by Michel et al[873] does not make it clear as to whether the 
authors considered transient ocular hypertension secondary to corticosteroid therapy as glaucoma. 
Our findings corroborate the fact that visual acuity in eyes with MFC decreases with time (Fig.3.5). 
 Punctate inner choroidopathy has classically been described as an idiopathic ocular 
condition that presents as a single episode with rare recurrences [452, 872]. Usually it is an 
incidental finding of scars on routine refraction, or sudden onset of visual loss. The visual prognosis 
is usually favorable if CNVM does not develop. In addition, the majority of patients with PIC have 
been reported to be young, myopic, otherwise healthy women [452, 872, 882, 886]. In the biggest 
series to date, Essex et al. [451] reported that the condtion was unilateral in 47% at baseline. The 
rate of CNVM occurrence has been reported between 27%–77%[452, 872, 882]. In a series by Bouzas 
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et al.[887], 44.4% of affected eyes had BCVA 6/15 or worse and 33.3% had BCVA 6/60 or worse at 
presentation. Patel et al.[888] reported an equal proportion (10.5%) of visual loss to 6/15 or worse 
and 6/60 or worse in eyes with PIC at presentation. The demographics of patients who developed 
PIC in our series were similar to many previous reports [882, 888, 889]. Patients were in their early 
thirties, and 88% were females. Visual loss to 6/18-6/36 at presentation in this study was similar to 
that reported by  Patel et al.[888]. The proportion of CNVM reported in this study was on the lower 
end of the range of proportions reported in the literature. 
 When comparing the clinical characteristics of MCF and PIC at presentation, Kedhar et 
al.[882] found that patients with PIC were much younger than those with MFC, with mean ages of 29 
years and 49 years respectively. They also reported a higher frequency of structural complications 
and a higher tendency to develop bilateral visual impairment in MFC. In their series, no patient with 
PIC had bilateral visual loss despite the fact that CNVM was more common (76.9%) than in MFC 
(27.7%).  In our cohort, 2 patients developed bilateral vision loss, one of them having bilateral severe 
visual loss and 1 having BCVA 6/18-6/36 in his better eye. As in most series, CNVM was the main 
cause of visual loss in this study accounting for 87.5%. 
 Acute posterior multifocal placoid pigment epitheliopathy (AMPPE) is a chorioretinal 
inflammatory disease, first described in 1968 by Gass[453]. The condition has been described as an 
acute self-limiting inflammatory disorder [890-892]. Characteristically, patients with AMPPE 
experience sudden loss of vision, followed by a rapid recovery, with resolution of the acute lesions, 
leaving a permanently altered retinal pigment epithelium [890-894]. Although most patients 
ultimately have good visual acuity [891, 892, 894, 895],  some authors have reported persistent 
troubling symptoms such as blurred vision, metamorphopsia, and scotoma [896, 897]. Furthermore, 
to the best of my knowledge, there are only two reports in the literature examining the long-term 
visual outcome of AMPPE [896, 897]. The long-term visual outcome after an acute episode of AMPPE 
does not appear as favorable as initially reported [891, 892, 894, 895]. There is general agreement 
regarding the poor initial visual acuity.         
 Many authors remarked that patients with AMPPE have good visual recovery with an 
excellent prognosis [891, 892, 894, 895]. Other reports [896-898] however, show that nearly 50% of 
eyes reached incomplete recovery of visual acuity (6/9) and that approximately 25% of the eyes 
have a more limited visual recovery (6/12). The visual prognosis of the disease is strongly affected by 
the presence of initial foveal involvement. In fact, the percentage of eyes with full visual recovery is 
88% and 53%, respectively, in the eyes without and with initial foveal involvement. Although initial 
foveal involvement does not preclude good recovery, eyes with poor visual recovery are usually 
those ones with initial foveal involvement and poor visual acuity at presentation [898]. Fiore et 
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al.[898] reported 23% of vision loss to 6/15 or worse and 30.7% of vision loss to 6/60 or worse at 
presentation. In another study by O’Halloran et al. [454], visual loss to 6/15 or worse and 6/60 or 
worse at presentation were reported in 31.2% and 6.2% respectively. Williams et al.[895] reported 
22% of visual loss to 6/15 or worse and 16.6% of visual loss to 6/60 or worse at initial presentation 
and demonstrated a favourable long-term visual prognosis. The demographics of patients who 
developed AMPPE in our series were in concordance with the literature. The trend of visual loss at 
presentation in our cohort was similar to that reported by O’Halloran et al.[454] and Williams et 
al.[895].  Our findings were in agreement with previous reports in that a guarded visual prognosis 
should be considered in cases with initial foveal involvement [898-900]. The main cause of visual loss 
at the end of the follow-up period was macular damage/scarring. Although not commonly reported, 
SRF may occur in AMPPE and should not decrease the suspicion of this diagnosis [901]. Noteworthy, 
1 patient in our series developed SRF in both eyes causing vision loss to visual impairment in one eye 
and severe visual loss in the other.  
 
 Fuchs’ Heterochromic uveitis (FHU) is a chronic, low-grade, typically unilateral anterior 
segment inflammation. About 5-10% of cases are bilateral. It is an important and often overlooked 
cause of uveitis. Failure to make this diagnosis occurs because the hetrochromia may be subtle or 
absent, especially in those with brown irides[374, 902]. The aetiology of FHU is still unknown. 
Schwab[903] found an epidemiological association between FHU and toxoplasmosis. He presented 
the idea that toxoplasmosis might create a chronic condition resembling FHU. A case report 
supporting this concept was  presented by Ganesh et al [904].  By contrast, La Hey et al.[905]  
claimed that there is no association between FHU and toxoplasmosis. In another study, intraocular 
synthesis of rubella antibodies was found in 52 eyes of 52 patients with FHU [906]. The rubella 
genome was detected in the aqueous humour in some younger patients and the authors concluded 
that FHU is a virus-driven disease. Some of their results were reproduced by de Groot-Mijnes et 
al.[907]. In an epidemiological study, Birnbaum et al. reported a decrease in the proportion of 
patients developing FHU after the introduction of rubella vaccination in the US with a corresponding 
increase in percentage of foreign-born cases[908]. 
  Previous series have reported cataract in 23–90.7% of eyes [909]. The most serious problem 
with FHU is glaucoma. The prevalences of glaucoma reported in earlier studies vary markedly. In 13 
reported series of FHU cited in a review by Jones [910], the incidence of glaucoma varied between 
6.3% and 59%. The mean incidence of all patients in these series was about 20%[910]. La Hey et 
al.[911] reported a prevalence of 27%, including glaucoma suspects. In our study, glaucoma 
developed in 4 eyes (7.7%). The large variations in reported incidences of glaucoma probably result 
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from differing deﬁnitions of glaucoma. In concordance with the literature, in the present study the 
condition was mainly unilateral with no gender preponderance. The prevalence of cataract reported 
here was on the lower side of the range of incidences reported in previous reports.  
 The diagnosis of FHU is important to make for the following reasons: (1) patients with FHU 
are at a significant risk for developing secondary glaucoma and need to be monitored for life for 
early glaucoma detection; (2) corticosteroids do not reduce the inflammatory activity in FHU 
patients, do not produce any long-term change in the clinical course, and on a long-term basis can 
hasten the formation of cataract and induce glaucoma, and should therefore not be used. (3) FHU 
has a fairly good prognosis for the patient. Unilateral cases of FHU have not been reported to 
become bilateral; (4) cataract extractions are generally tolerated well by FHU patients and result in 
the restoration of good vision. Only glaucoma, is difficult to control therapeutically [374, 912]. Our 
data corroborate the favourable visual prognosis in FHU.     
 The true incidence of sympathetic ophthalmia has been hard to establish due to its rare 
occurrence and its diagnosis based on clinical findings. In 1979, sympathetic ophthalmia following 
intraocular surgery was reported to have an incidence of 0.1%, while open globe injuries had an 
incidence of 0.2% to 0.5% [913]. Kilmartin et al. [499] conducted a prospective study in England and 
Ireland with a surveillance of 59 million citizens, where 23 patients with a new diagnosis of SO were 
reported in a 15-month period. The resulting incidence was estimated to be 0.03 in 100,000. The 
study also demonstrated ocular surgeries as the most common cause of SO. Most of the newly 
diagnosed cases occurred in patients with multiple ocular trauma incidents, suggesting a possible 
additive risk [914]. Surgical interventions noted to be associated with sympathetic ophthalmia 
include glaucoma surgery, cataract extraction, scleral buckling, pars plana vitrectomy and 
cyclodestructive procedures that affect the integrity of uveo-retinal tissue[915]. In the year 2000, 
the calculated risk of SO was estimated to be 1 in 1152 retinal surgical procedures[499]. In a review 
of 32 patients with SO at the National Eye Institute Bethesda during a 10 year period, 1.4% of 2287 
of patients who presented with uveitis had SO. The age range was from 3 to 80 years old, affecting 
all age groups with no racial predilection noted [916].  The incidence of SO in our uveitis 
population and the patients profile were similar to that reported in previous studies[916, 917]. 
Although earlier studies found traumatic SO to be more common, Kilmartin and associates 
demonstrated ocular surgery to be the most common cause[499, 502, 916, 918, 919]. In a study in 
the same institution as us 20 years ago, Hakin et al.[502] reported that 83% of patients developed 
SO following trauma in the inciting eye, only 17% of eyes sympathised after repeated retinal 
detachment surgery in the inciting eye. The type of trauma in the inciting eye was not established in 
the present study. 
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 Sympathetic ophthalmia in itself is a sight-threatening disease with a high rate of visual loss; 
approximately half of patients experience 6/12 or worse vision, and one-third of 
patients become legally blind[916]. Although improved immunosuppressive therapy may reduce 
chronic inflammation, there is still a risk of visual loss from complications such as chorioretinal scars, 
macular edema, and choroidal neovascularisation[490]. In this study, 47.4% of eyes maintained 
visual acuity of 6/12 or better. A quater of patients had worsened visual acuity at the end of the 
follow up period, while only 10% improved visual acuity in the sympathizing eye. Parikh et 
al[74]recently reported that in SO, photoreceptor mitochondrial oxidative stress occurs in the 
absence of leukocytic infiltration of the retina and may lead to photoreceptor apoptosis and 
subsequent vision loss. The current anti-inflammatory therapy combined with agents that could 
prevent oxidative stress may prevent photoreceptor damage in SO and may preserve vision. Sen et 
al.[920] emphasised the significant vision loss associated with SO and highlighted the importance of 
early diagnosis and prompt, aggressive treatment. 
6.5 Uveitis in children. 
 
 Children with uveitis present a number of unique diagnostic and therapeutic challenges 
[921-923]. Uveitis in childhood differs in various noteworthy aspects from uveitis in adulthood. 
Firstly, the association with systemic diseases is different in children and ANA positive oligoarticular 
juvenile idiopathic arthritis (JIA) presents as the most common systemic disorder (41.5%) [377, 924]. 
Secondly, the use of standard systemic medications such as corticosteroids and immunosuppressive 
drugs for non-infectious uveitis in childhood has an impact on the immature immune system and 
developing bones. A growing body of evidence suggests that prolonged administration of 
corticosteroids is associated with a significant number of permanent adverse effects and steroid 
sparing drugs are recommended [925-929]. Thirdly, the onset of ocular inflammation in children is 
often asymptomatic despite severe ocular inflammation and with decreased visual acuity already 
present. Hence, the ocular inflammation is often discovered by routine screening only in the 
advanced stages of the disease. At the time the child is first seen by an ophthalmologist, ocular 
complications with negative effects on visual prognosis are regularly detected [856, 930]. In addition, 
in children younger than 7 years, the risk of amblyopia must be considered. Finally, the results of 
surgical procedures for the various complications of uveitis (for example, cataract, glaucoma) in 
children are often discouraging [931, 932].  
 Children account for only 2.2% to 13.8% of patients in many uveitis clinics, and most 
published series of pediatric uveitis are limited to a small number of patients [281, 314, 933]. 
Cunningham et al[127] reported that children constituted only 5% to 10% of patients with uveitis. 
           Discussion 
 
200 
Biswas et al[717] found 3.6% of uveitis in children below 10 years of age. Narayana et al.[934] 
reported 6% of uveitis in children in a referral eye care centre in India. In a population-based study, 
Paivonsalo[935] identified 4.9% of uveitis in children. Some authors have proposed that uveitis in 
children has a relatively severe course and is more likely to lead to vision loss[127]. Delayed 
diagnosis, extended burden of disease over a lifetime, limited treatment options in children, difficult 
examinations, and the risk of amblyopia are all challenges specific to childhood uveitis[310, 311]. 
The age range is often a problem in comparing different studies: recent series about pediatric uveitis 
generally involved patients <16 years old, one even 18, while in reports from some decades ago the 
upper age limit was 14[281, 936, 937]. Moreover, conclusions from children eye hospitals or from 
referral centres not always fit together [937]. The mean age at presentation of children who 
developed uveitis in our series was in agreement with many previous reports, and we did not find 
any gender predominance.  
 
Table 6.1 Comparison of distributions of uveitis etiology and anatomic location in studies of pediatric uveitis published after 2000. 
Study Curren
t 
Smith[309] BenEzra[281] deBoer[308] Kadayifcilar[938] Edelsten[314] Rosenberg[767] Kump[312
] 
Year 2011 2007 2005 2003 2003 2003 2004 2004 
n.patients. 95 527 276 123 219 249 148 269 
AU 40% 44.6% 13.4% 36% 43.4% 70% 30.4% 56.9% 
IU 32% 28% 41.7% 24% 11.9% - 27.8% 20.8% 
Pan/PU 28% 27.3% 14.9% 40% 44% 30% 41.9% 22% 
JIA 8.4% 21% 14.9% 20% 13.2% 47% 23% 33% 
Toxo. 5.3% 5% 7.2% 10% 21% 2% 7.4% 3.3% 
Idiopathic 74.7% 29% 25.4% 53.7% 36% 44% 26.4% 51.7% 
 
The present study confirms the lower incidence of paediatric uveitis compared to adult uveitis. In 
the 1950s and 1960s anterior uveitis accounted for 11–49% and posterior uveitis for 22–67.7% of all 
pediatric uveitis[127]. In our study, anterior uveitis was the largest group(Fig.3.2.14.1), in agreement 
with many other reports about pediatric uveitis from North America and Europe [308, 312, 314, 933, 
935, 937]. The higher incidence of IU was reported by BenEzra et al[281]. Edelsten et al[314] 
reported the higher incidence of AU, and no IU was reported in their cohort. Their study was 
conducted in district hospitals, and it is possible that there is a referral bias, more complex cases 
being referred to tertiary referral centres. Also, some cases require an examination under general 
anaesthesia(EUA). The incidence of posterior uveitis was similar to the findings by many authors 
[127, 312, 933, 937]. Children under eight to ten years of age with uveitis are at risk of developing 
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amblyopia. Furthermore, surgery carries added risks in children compared to adults[922, 923], both 
because children tend generally to mount more inflammation following surgical procedures than 
adults and because one of the most common causes of uveitic cataract in children is juvenile 
idiopathic arthritis, a condition in which intraocular surgery is generally associated with a more 
guarded prognosis[127].          
  The causes of uveitis in children differ somewhat from the causes of uveitis in adults 
[921, 922, 939, 940]. The most frequent form of endogenous uveitis in children is JIA. Other less 
frequent causes of endogenous causes of uveitis include HLA-B27-associated uveitis, which may 
occur in the setting of ankylosing spondylitis, Reiter’s syndrome, inflammatory bowel disease, or 
psoriatic arthritis, Fuchs’ uveitis syndrome, Behçet’s disease, VKH, ocular sarcoidosis, and 
sympathetic ophthalmia [127]. In a review of different studies reporting on the prevalence and 
patterns of uveitis in children, prevalences of JIA were reported to vary between 5.6% and 41%, and 
Toxoplasmosis between 7% and 39% [127]. In one study, the prevalence of JIA was reported to be as 
high as 81.5%[377]. The proportion of children who developed uveitis with an underlying condition 
in this study was similar to that reported in the literature (Fig.3.7). The prevalence of idiopathic cases 
in this study was similar to that reported by Azar et al.[933] in Australia, and by Cunningham et al 
[127] in the US. This is in contrast to most studies where the proportions of idiopathic uveitis have 
been reported to be as low as 25%. One explanation of this difference is that our selection criteria 
excluded infective cases excepting Toxoplasmosis.  
 
Table 6.2 Comparison of visual acuities in children at different time points between this study and the study by Smith et al[309]. 
Time pointS→ 
BCVA↓ 
 Baseline 
S*.          C** 
   1 year 
S.          C. 
 3 years 
S.         C. 
  5 years 
 S.          C. 
  10 years 
S.           C. 
> 6/18 (%) 80.2      80.9 84.1      88.3 80.9      77 72.3        73.3 69.2      61.5 
</=6/18 (%) 39.7      12.7 27.5      8.5 28.5      17 51.4        6.6 46.1       - 
</= 6/60 (%) 9.2         6.4 6.5        3.2 3.2         6 15.1        20 7.7         38.5 
S*= Smith et al., C**= current study 
 A  review of the literature indicated that up to one third of all children with uveitis ended 
with severe visual impairment[127]. The trend of visual outcome over time was similar to that 
reported by Smith et al[309]. However, the proportion of eyes with visual impairment reported by 
Smith and associates was very high throughout the follow-up period when compared with our own 
data. In both studies, we note an improvement in visual acuity at one year follow-up. Afterwards, 
the proportions of eyes with visual impairment and those with severe vision loss increased. This 
demonstrates that most cases of vision loss at presentation are reversible. The prevalence of 
baseline legal blindness in this study was similar to what reported by Smith et al.[309] , but lower 
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when compared with 18% and 53% reported by Rosenberg et al[767] and Edelsten et al[314]. As in 
most series, we found that posterior uveitis is a major risk factor for poor visual outcome.  
 The course of IU in children can be worsened by many sight-threatening complications [740, 
941]. Nevertheless in many children and young adults IU can reach remission with maintained good 
visual acuity in the absence of ongoing therapy; their disease can resolve and ‘burn itself out’ [132, 
739, 740]. In a series by de Boer et al. [132] 9.4% of patients developed unilateral legal blindness. 
One of the major questions in IU is whether it is possible to predict which patients are at greater risk 
of developing severe course of IU with visual loss before the sight-threatening complications actually 
occur[942]. It has been reported that children with IU might have a more severe disease and worse 
outcome than patients with onset at older age [943, 944]. Visual prognosis in IU in this study was 
favourable as no eye developed legal blindness(Tables 3.30). In a recent study, Ayuso et al.[945] 
showed a negative effect of young age at onset of IU on the clinical course and visual outcome up to 
3 years’ follow-up. We did not find a difference in BCVA at presentation between children who were 
aged </=7 at onset of IU and those who were aged > 7 years. Contrary to the report by Ayuso et al., 
young age at onset of IU was not an independant risk factor for poor visual outcome in our series. 
Interestingly, children who developed visual impairment in our cohort were aged >7 at onset of IU. 
Our findings are in agreement with previous studies [660, 740] where young age at onset of IU was 
not found to be a negative factor on visual oucome. 
 A  review of the literature indicated that up to one third of all children with uveitis ended up 
with severe visual impairment[127]. De Boer et al.[308] reported that 2% of children became legally 
blind and an additional 17% had one legally blind eye caused by uveitis. The most frequent causes of 
blindness in their study were chorioretinal scars in the macular area and glaucoma. In our cohort, 
22% of children developed vision loss in at least one eye at the end of the follow-up period. Ten 
percent developed severe visual loss in at least one eye, one child (1%) developed bilateral legal 
blindness. The pattern of causes of severe vision loss was similar to that reported in the latter 
study.(Table 3.32) 
 JIA has been reported to be the most common underlying disease in paediatric uveitis in 
most series [308, 312, 314, 933, 935]. A deﬁnite association exists between the articular and ocular 
manifestations in children with JIA. The prevalence of uveitis in JIA varies widely across case series, 
from 11.4% to 20.1% [582, 946]. The cumulative incidence of uveitis was found to vary depending on 
the country of origin of the study, being significantly greater in Scandinavian series, followed by 
series from the US, East Asia and finally India[947]. Factors that may explain this variability include 
changes in the classification scheme for JIA, small sample sizes, and differences in populations 
recruited at rheumatology departments compared to ophthalmology departments. There is general 
           Discussion 
 
203 
agreement, however, that the risk of ocular involvement is highest in pauciarticular JIA, which 
predominantly affects girls before 5 years of age. The risk of uveitis persists for years after arthritis 
onset, extending into adulthood [586, 948]. Less severe ocular disease has been reported in some 
series [946, 949-951]. A minority of studies provided data for visual outcome [947]. Bolt et al.[952] 
reported an excellent longterm visual outcome despite a relatively high complication rate. They 
found that 90.6% of patients in their cohort had normal visual acuity,1 patient (3.1%) had impaired 
visual acuity in 1 eye, and 2 patients (6.25%) had legal blindness in 1 eye each at last ophthalmologic 
follow-up. None of their patients had developed bilateral reduced visual acuity at last follow-up. This 
rate was much lower than in the majority of other studies [953, 954]. Cassidy et al.[955] reported 
that 16% of the afflicted children experienced either unilateral or bilateral blindness. In a study by 
Wolf et al.[932] 22% of eyes had visual loss to 6/60 or worse. The authors reported that severity of 
visual loss and complications correlated with the degree of inflammation found on initial ocular 
examination. In their series, Azar et al.[933] found that 33.3% of eyes with JIA-associated uveitis 
developed visual loss to 6/18 or worse, and 28.7% of eyes had severe vision loss or blindness. The 
proportion of eyes in the group of JIA-associated uveitis which developed severe visual loss (33.3%) 
in this series was similar to that reported in the latter study. One patient in our cohort developed 
bilateral legal blindness (Table 3.31). Woreta et al [585] reporting on the frequencies and risk 
factors for ocular complications and poor visual acuity at presentation in a cohort of patients with 
JIA-associated uveitis found that 36% and 24% of eyes had BCVA 6/18 or worse and 6/60 or worse 
respectively. We found a similar incidence of vision loss to 6/60 or worse at presentation, but none 
of the children with JIA-associated uveitis presented with vision loss to < 6/12. Thorne et al [853] 
reported incidence rates of 0.10/EY and 0.08/EY for vision loss to 6/18 or worse and 6/60 or worse 
respectively. In this study incidence rates for vision loss were higher than those reported by Thorne. 
Despite the fact that girls are at higher risk to be affected by anterior uveitis [950, 956, 957], many 
studies have demonstrated that male gender is an independent baseline risk factor associated with 
multiple ocular complications of JIA-associated uveitis [376, 958-960].  
 The big limitation of our study as far as JIA-associated uveitis in children is concerned is that 
we had a very small sample (8 children). Hence, we could not perform more statistical analysis. 
However our data conﬁrm, as reported by others [406, 585, 932, 961] that severe complications with 
loss of vision are still to be feared in children with JIA who develop uveitis, particularly if there is a 
long delay in referral to a tertiary care center. Prompt referral of these patients to a uveitis specialist 
and early aggressive therapy with immunosuppressive agents may decrease the odds of poor vision 
[585]. 
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 Toxoplasmic retinochoroiditis appears to be more common in Brazil than in Europe or North 
America and more severe. It is a leading cause of blindness in Brazil[962] but not in Europe or North 
America[3, 308]. The estimated incidence of acute symptomatic chorioretinitis for all people born in 
Britain was 0.4/100,000/year and for black people born in West Africa 57/100,000/year[963]. The 
exact contribution of congenital and postnatal infection to OT is not known because the ocular 
involvement occurs predominantly during the chronic phase of infection and because, to date, no 
laboratory tests discriminate between the prior congenital and postnatal acquisition of 
infection[508]. Many studies have reported that postnatal acquisition of toxoplasmosis might also be 
an important cause of ocular disease [510, 964-967]. Most infected newborns have no clinical signs 
but are at risk of developing visual impairment as a result of retinochoroiditis in childhood or 
adolescence [968]. Gilbert et al.[969] compared ocular sequelae of congenital toxoplasmosis in Brazil 
and in Europe and found that children with congenital toxoplasmosis in Brazil developed 
retinochoroiditis earlier than children in Europe. They reported that affected children tend to have 
multiple lesions more frequently, and the lesions were larger and more likely to affect the posterior 
pole and hence to threaten vision.        Tan et 
al.[970] reported that severe bilateral impairment occurred in 9% of children with congenital 
toxoplasmic retinochoroiditis. Half the children with a posterior pole lesion and one in six of those 
with peripheral lesions alone were visually impaired in the affected eye. Wallon et al.[971] reporting 
on the clinical evolution of ocular lesions and the final visual function in a prospective cohort of 327 
congenitally infected children found that none of the children had bilateral visual impairment. In the 
24 children with known unilateral visual impairment, 1 patient developed vision loss to 6/15 or 
worse and 5 patients (20.8%) developed severe visual loss or blindness. In this study, all children had 
unilateral lesions of ocular toxoplasmosis. Severe visual loss or blindness due to toxoplasmosis did 
not occur in our cohort. A better visual oucome in ocular toxoplasmosis had also been reported by 
Koppe et al.[972]and Mets et al.[973] in children who were treated at birth or perinatally with 
pyrimethamine and sulfadiazine for 1 year.       
 Clinicians and parents should be informed that, despite early diagnosis of congenital 
toxoplasmosis and treatment, relapses and late-onset ocular lesions can occur late after birth. They 
cannot be predicted at the present time but fortunately do not lead to severe visual 
impairment[971]. Reactivation is uncommon under 16. 
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6.6 Uveitis in patients aged > 60. 
 
 Uveitis in patients older than 60 years has been considered uncommon, but two recent 
epidemiologic studies showed that the burden of uveitis in elderly population is significant [279, 
974]. Little is known about the epidemiology of uveitis in the elderly population over the age of 60 
years as there is a paucity of population-based epidemiology data for this age. Only 7 studies have 
specifically evaluated the clinical characteristics of uveitis de novo in the elderly [283, 316, 975-978]. 
All these studies were retrospective and all but two were published more than 10 years ago. First, 
Gritz and Wong reported a cross-sectional study of 2070 people within 6 Northern Californian 
medical center communities[279]. They observed that the incidence of uveitis rose with age, peaking 
at 102.7/100,000 in subjects aged 65 years and older. Prevalence findings were similar, rising up to a 
high of 234.6/100,000 in patients at the age of 60 or more years. Reeves et al.[974] used longitudinal 
Medicare claims data to estimate the annual incidence and prevalence of uveitis in the U.S. elderly 
population. They found an average cumulative incidence of 340.9/100,000 persons per year and a 
doubling of the cumulative incidence from 511/100,000 in 1991 to 1231/100,000 in 1999.  
 The prevalence of uveitis in this age group reported in this series was similar to that 
reported by Chatzistefanou et al.[979]. Higher prevalences of uveitis in the elderly have been 
reported in many other studies [284, 976, 977]. Our data confirm the female preponderance found 
in pevious reports [976, 979]. In an epidemiological study calculating the incidence and prevalence 
of uveitis by anatomic location in the elderly, Reeves et al.[974]reported that AU was the most 
common incident diagnosis for all locations from 1993 through 1999, with a mean of 243.6/100 000, 
and ranged from 171/100 000 (1997) to 304/100 000 (1996). The mean incidence of PU was 
76.6/100 000. Intermediate uveitis was almost nonexistent in their population. Overall prevalence of 
uveitis more than doubled during the 9 years of the study, from 511/100 000 in 1991 to 1231/100 
000 in 1999. They found that AU increased almost 3-fold from 338/100 000 in 1991 to 935/100 000 
in 1999 and the prevalence of PU doubled from 108/100 000 in 1991 to 286/100 000 in 1999. As in 
most studies, we found that AU was the most common uveitis type. The anatomic distribution of 
uveitis in Gregoire’s series[976] of elderly patients differed from younger patients. The authors 
reported that Panuveitis was statistically more common in the first group and the percentage of 
older patients with AU was much lower than those reported by most of authors in previous studies. 
We found similarities in the trend of uveitis types in the elderly and in children in our cohort, and the 
prevalence of IU is the highest reported to date.    
 The proportion of idiopathic cases found in this study (31%) was close to that reported by 
many authors [284, 976, 979]. The highest proportion of idiopathic cases (68%)was reported by 
Barton et al.[316]in the same institution as us more than fifteen years ago. In their series, diabetes 
           Discussion 
 
206 
was the most common systemic associated with uveitis in the elderly (7%). We found a similar 
proportion of diabetes (8.3%) which was not exceptionally high when compared with the whole 
uveitis population. In our series, sarcoidosis was the most common systemic condition(13.7%). The 
proportion of sarcoidosis reported here was close to that reported by Favre et al.[284] and by 
Bouillet et al.[975].  
 Ocular neoplasia, especially lymphoma has been a major concern. Ocular lymphoma has 
been described most commonly in patients over 60 years of age[980] and is characterized by a 
chronic uveitis which responds poorly to corticosteroids. The anterior segment signs are usually 
discrete, although a hypopion may appear during evolution. The vitreous is often markedly involved. 
The chorioretinal lesions are variable in aspect. Subretinal infiltrates or solid retinal pigment 
epithelial detachments are the most characteristic fundus signs of the disease. Other fundus signs 
may be present, such as retinal vascular occlusions, perivasculitis, macular oedema, optic disc 
oedema or ischaemic optic neuropathy[981].        
  Vitreous biopsy is recommended only in patients with abnormal-looking vitreous 
cells, a poor response to steroid treatment, or classical chorioretinal lesions in the presence of 
vitritis, when a definitive diagnosis has not been made and progressive posterior segment 
inflammatory disease threatens vision[316]. As reported by other authors, intraocular lymphomas 
represent a small proportion of our population of elderly patients. Our 1% prevalence of intraocular 
lymphoma among elderly patients was similar to that reported by many authors [295, 673, 975]. 
Chatzistefanou et al.[979] reported 3.4% of intraocular lymphoma. In spite of these low prevalences, 
it is important to keep this diagnosis in mind because of its sinister implications. Since PIOL is a 
potentially fatal malignancy, early and accurate diagnosis is critical for the initiation of appropriate 
therapy [982].  
 Reports on visual outcome in the elderly are scarce. Chatzistefanou et al.[979]  reported that 
35.6% of affected eyes presented with BCVA 6/12 or better, 31% were visually impaired and 32.6% 
had severe visual loss or blindness. A comparison of visual outcome in children and in the elderly 
showed that patients who developed uveitis after 60 years presented with poor visual acuity. 
Incidence rates for visual impairment in children was higher than in the elderly (0.10/EY vs 0.05/EY 
respectively), and incidence rate for severe visual loss in the elderly was higher than in children 
(0.06/EY vs 0.05/EY respectively). The prevalence of CMO in the elderly reported in this series was 
similar to that reported by Chatzistefanou et al.[979]. The 21.9% of glaucoma could be an 
underestimation as we only reported glaucoma affecting visual acuity. Some cases of glaucoma with 
preserved visual acuity may have been overlooked. 
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6.7 Treatment of uveitis. 
 
 Although some disorders such as acute anterior uveitis may be either monophasic or 
episodic and recurrent, most types of non-infectious uveitis are chronic and typically require chronic 
suppressive therapy [983]. Furthermore, those types of uveitis requiring treatment beyond topical 
corticosteroids (intermediate uveitis, posterior uveitis, and panuveitis) are associated with a 
frequency of visual loss ranging from 28% to 59% respectively[300]. As such, appropriate 
management of these disorders is critical in minimizing visual loss and preserving visual function 
[983]. 
  Topical corticosteroids have provided the mainstay of treatment for anterior uveitis since 
the 1950s, but do not penetrate far enough into the eye to control intermediate or posterior 
disease[984]. Most cases of AU in this study were managed successfully with topical corticosteroids 
alone (Table 3.36). 
 Systemic corticosteroids are generally advocated for intermediate and posterior uveitis that 
requires treatment that is either bilateral or associated with systemic disease [985-987]. They are 
the standard treatment in patients with anterior uveitis and visually significant cystoid macular 
oedema and those with sight-threatening complications of posterior uveitis[986]. Most eyes with 
Panuveitis and poaterior uveitis and one third of eyes with IU in this study were treated with oral 
steroids (Table 3.36). 
 In patients with unilateral or asymmetric disease, or in whom systemic administration of 
medication is less desirable, e.g. during pregnancy or in patients with a history of gastric ulceration, 
periocular injection can be useful to provide a depot of corticosteroid that successfully reaches the 
posterior segment to control inflammation[985, 988-992]. Periocular corticosteroid injections are a 
valuable therapy for intermediate uveitis which needs only an occasional injection in order to control 
the process and as adjunctive therapy for CMO.[993] Although repetitive periocular corticosteroid 
injections also are used for more severe forms of uveitis, such as posterior uveitis and panuveitis, 
this approach appears to be more problematic in the long run. Typically these patients require 
chronic suppressive therapy and 
control of the inflammation to prevent long-term visual loss[993].  
In our cohort, orbital floor injection was used on 2% of eyes, mainly eyes with IU which have 
developed CMO (Table 3.36). 
The use of intravitreal injections of triamcinolone acetate (IVTA) in the treatment of uveitis is now 
commonplace, and involves the injection of corticosteroid directly into the vitreous body, thus 
achieving a higher concentration of intraocular corticosteroid [994]. The dose most commonly used 
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is 4 mg, and the typical duration of the effect is 4–5 months, with the maximum effect on visual 
acuity occurring at 1–6 months after injection [995, 996]. It tends to be most effective in younger 
patients with a limited duration of macular oedema, and can allow the cessation and/or reduction of 
immunosuppressive therapy [997].  
 The fact that both OFTA and IVTA were mostly used in eyes with IU in this study is 
understandable. The frequency of CMO was higher in this type of uveitis when compared with 
others. It has previously been shown that uveitic CMO may resolve completely with repeated IVTA 
injection[998], but that the improvement in BCVA and reduction of CMO after a single TA injection is 
mostly transient [999-1001]. 
 Previous studies have demonstrated that a single IVTA injection is more effective than a single OFTA 
injection for improving uveitic macular oedema and this favors its use [992, 997]. The better efficacy 
of IVTA may be attributed to the higher intravitreal concentrations of TA that were detected after 
intravitreal drug injection as compared to a posterior periocular injection [994]. Kok et al[997] 
reported that eyes with most visual improvement had CMO for less than a year. They also found that 
in some eyes, there was subjective clinical improvement in CMO by biomicroscopy and FA that was 
not accompanied by improvement in vision, and eyes of younger patients attained better vision after 
treatment. This is not surprising, as chronic CMO results in ultrastructural changes in both the retina 
and the retinal pigment epithelium (RPE), some of which can be observed clinically[220, 1002]. The 
ability of photoreceptors and the RPE to recover from insult declines with age, as is also observed in 
central serous chorioretinopathy [1003]. 
 Indications for immunosuppressive drugs are: 1) failure of the disease to respond to oral 
corticosteroid therapy, 2) serious side effects of oral corticosteroids, 3) requirement for a chronic 
dose of oral corticosteroids likely to result in serious side effects (e.g. >10 mg daily), and 4) a disease 
known to be poorly responsive to corticosteroid therapy alone [1004]. 
The comparative efficacy of different treatments modalities was not the aim of the present study. 
6.8 Surgery in uveitis. 
 
 Cataract surgery in uveitic eyes is more complex than in healthy eyes and has a considerable 
potential for an unfavorable postoperative outcome mainly due to worsening or relapsing of 
intraocular inflammation [1005, 1006]. The uveitic cataract poses for the surgeon special challenges 
given the commonly encountered consequences of chronic inflammation, which include a miotic 
pupil, iris atrophy, posterior synechiae, pupillary membrane, band keratopathy, and bleeding from 
abnormal fragile iris vessels[1007]. Previously, cataract surgery in eyes with intraocular inflammation 
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was considered a high-risk procedure or a contraindication because of the high number of 
postoperative complications such as severe inflammatory reaction, IOP elevation, or 
glaucoma[1008]. These complications can lead to poor visual outcome. Intracapsular cataract 
extraction, a surgical method in which the cortical material is completely removed within the 
capsular bag, was the preferred method many years ago because it was thought to reduce the risk 
for postoperative inflammatory response[1008]. Cataract surgery in patients with uveitis is indicated 
in four settings: active inflammation secondary to leakage of lens proteins (i.e. phacoantigenic 
uveitis); visually significant cataract with preoperatively controlled inflammation and expected good 
visual prognosis; cataract impairing proper assessment and treatment of possible retinal 
inflammation; and cataract impeding posterior segment visualization in a patient requiring posterior 
segment surgery (e.g. pars plana vitrectomy)[401]. 
  Apart from the recommendation to perform cataract surgery during a quiescent interval 
three months with little or no inflammation, supplementary antiinflammatory treatment prior to 
cataract surgery has been advocated in several studies [1009]. The improved visual prognosis after 
cataract surgery in eyes with uveitis in recent years seems to be related to the more consistent use 
of perioperative antiinflammatory and immunosuppressive treatment regimens [1010]. New 
technologies, including phacoemulsification, modern equipment for irrigation and aspiration, and 
foldable acrylic IOLs, have been introduced. As a result, phacoemulsification and IOL implantation 
are now the most common type of cataract surgery procedures in patients with uveitis [1011-1014]; 
however, the outcomes have been evaluated in small groups of patients only. We report in this 
series on the largest number of eyes (615) which underwent cataract surgery. We indentified only 
7% of eyes which underwent intracapsular extraction vs 89% which underwent phacoemulsification 
and IOL implantation, 1.6% underwent ECCE (Table 4.4). 
 In this study, we found that phacoemulsification in patients with uveitis led to a significant 
improvement in BCVA immediately after cataract surgery and this vision  remained stable during 
follow-up(Table 4.7). This is in agreement with several other studies that reported short- and long-
term visual improvement in up to 93% of patients [413, 680, 1015-1018]. Kawaguchi et al.[1019] 
reported that the overall visual prognosis in eyes that had undergone phacoemulsification was 
favorable in 84.7%, with 74% of eyes attaining a final visual acuity of 6/12 or better. In a recent 
study, Ram et al.[1020] found that 71% of eyes had a BCVA 6/12 or better at the final postop follow-
up visit. In their series, 16% of eyes were visually impaired and 13% developed severe vision loss. In 
another series, Estafanou et al.[1016] reported that 87% of eyes which underwent 
phacoemulsification improved VA to 6/12 or better at final follow-up visit. Kang and Lee [1021] and 
Harada and associates[1022] reported visual improvement in 89% and 96% of eyes, with final visual 
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acuities of 6/12 or better in 64% and 82% of eyes, respectively. In this study, 66% of eyes had BCVA 
6/12 or better at final follow-up postsurgery (Table 4.5). This proportion was inferior to that 
reported by Okhravi et al.[1018](90%) in the same institution a decade ago. However, proportions of 
eyes with visual impairment and those with severe visual loss after cataract surgery were similar in 
the two studies and in agreement with the study by Ram et al.[1020] 
 As in many other reported data, we found that eyes with Panuveitis and posterior uveitis 
bore the poorest visual prognosis post cataract surgery. Yoeruek et al. [1009] reported that eyes 
with preoperative macular lesions were likely to have a poorer visual outcome. They found that 
aetiology of uveitis, gender of patients, age at cataract surgery (<30 years), and anterior segment 
pathology, such as anterior synechiae, were not predictive for poor visual outcome after cataract 
surgery. Our data corroborate preoperative macular lesions as a predictive factor for poor visual 
outcome. Moreover, in a multivariate model analysis, we found that the type of cataract surgery 
influenced visual outcome (p< 0.001). Eyes which underwent ECCE and ICCE had the worse visual 
outcome as compared to phaco (Table 4.7). 
 In our series, CMO was the third most common postoperative complication (Table 4.8). The 
incidence reported in this study was close to that reported in previous studies [413, 1020]. A lower 
incidence (2.3%) has also been reported  by Suresh et al [1023] in a cohort of 86 eyes with uveitis 
undergoing phacoemulsification. 
Cataract surgery in a patient with uveitis warrants thorough diagnostic evaluation, diligent pre, peri 
and postoperative control of inflammation, and meticulous surgery[1007]. Identifying patients who 
are at risk for poor visual outcome is of importance for preoperative counseling and postoperative 
care [1009]. 
 Historically, experts have cautioned against primary placement of intraocular lens (IOLs) in 
patients with JIA because of the risk of secondary cyclitic membranes and development of hypotony 
[406, 1024, 1025]. With more widespread practice of strict control of uveitis at least 3 months prior 
to surgery and using systemic immunomodulatory therapy, good postoperative results can be 
achieved[414]. Even so, the presence of an IOL can still incite recalcitrant inflammation necessitating 
removal of the implant [1026]. Alternatively, pars plana lensectomy with anterior vitrectomy and 
subsequent aphakia can be an effective way to manage uveitic cataract [1027]. Pars plana 
vitrectomy (PPV) in combination with phacoemulsification has been reported to successfully 
improve vision in adults and children with chronic uveitis [1028-1030]. 
 A recent retrospective study by Sijssens et al [1031] examined long-term complications after 
cataract surgery in aphakic and pseudophakic eyes of children with JIA-associated uveitis. They 
found no statistically significant difference in complications between the two groups. Cystoid 
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macular oedema was higher in the aphakic group, but did not achieve statistical significance. Visual 
acuity was significantly better in pseudophakic eyes than in aphakic eyes up to 7 years after cataract 
extraction. The authors did not report any hypotony, perilenticular membranes or phthisis in the 
pseudophakic group. In our series, all cases of secondary glaucoma and hypotony developed in 
aphakic eyes and visual outcome was worse in this group. The number of pseudophakic eyes in our 
cohort was too small for us to do any statistical calculations and compare the two groups. Recent 
studies have reported that implantation of an intraocular lens in selected cases of JIA-associated 
uveitis was associated with good visual results [1032-1034]. The poor visual outcome post cataract 
surgery in JIA associated uveitis in our series is explained by the fact that more than half the number 
of affected eyes underwent ICCE and this was done a long time ago.                   In a 
comparative study between children with JIA-associated uveitis and those with non JIA-associated 
uveitis, Nemet et al[1033] recently reported that those with JIA-associated uveitis tend to have more 
severe manifestations of disease when first seen and after surgery, but they found no significant 
difference in postoperative course or complications. The authors concluded that intraocular lens 
implantation, including small-incision, foldable intraocular lenses, is well tolerated when combined 
with aggressive medical treatment for controlling inflammation [1033]. This was confirmed by most 
recent studies [1031, 1034, 1035]. Sijssens et al[1031]suggested the following relative 
contraindications for IOL placement in patients with JIA-associted uveitis: age less than 4 years, 
hypotony, fellow eye IOL-related complication and shallow anterior chamber. 
 The management of uveitic glaucoma may be difficult because of the numerous mechanisms 
involved in the pathogenesis[368]. The condition becomes more challenging when the elevated 
intraocular pressure (IOP) is unresponsive to medical treatment. To improve the surgical outcome of 
these cases, alternative approaches such as trabeculectomy with antiproliferative agents[1036-
1038], aqueous drainage devices with or without trabeculectomy, trabeculodialysis[1039, 1040], and 
transscleral diode laser  cyclophotocoagulation[1041] have been proposed. Most studies suggest 
using antiproliferative agents in terms of long-term IOP control in those patients [1036, 1038]. 
Stavrou and Murray[1038] observed a high rate of trabeculectomy survival (53%) after 5 years 
without antiproliferatives. A higher success rate (67%) at 5 years was obtained by Towler et 
al.[1042]by using intraoperative 5-fluorouracil. However, even with adjunctive antiproliferative use, 
increased inflammatory cells and fibroblasts in uveitic patients result in significant inflammatory 
response and excessive fibrosis. Furthermore, antiproliferative agents have potential complications 
such as corneal epithelial defects, increased incidence of bleb rupture, late bleb leak, bleb-related 
endophthalmitis, and chronic hypotony[1043]. To minimize these complications and the risk of 
trabeculectomy failure due to excessive scarring and fibrosis, shunting devices may be considered as 
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a primary surgical procedure for IOP control in uveitic patients [1044]. Aqueous shunts traditionally 
have been reserved for treatment of the most refractory glaucomas. However, more recent studies 
have suggested that aqueous shunts offer similar outcomes to trabeculectomy with mitomycin C in 
eyes that are at a lower risk of failure, that is, in patients with primary glaucomas who are 
pseudophakic or who have had 1 failed trabeculectomy[1045-1049]. Consequently, aqueous shunts 
have been used increasingly in the management of medically uncontrolled glaucoma[1050]. 
 The aim of this study was not to report on the efficacy of different filtering procedures.  
Hence we did not report on IOP control, but the impact on visual acuity. We report that 
trabeculectomy with mitomycin C was the most common surgical procedure (70%). Clinical trials 
[1051-1053] have shown that the lowering of intraocular pressure (IOP) is associated with reduced 
progression of glaucomatous visual field (VF) loss. Francis et al.[1054] have recently reported that 
unexplained permanent vision loss (or snuff-out) can occur after trabeculectomy with mitomycin C 
treatment. Risk factors for long-term vision loss are preoperative split fixation on VFs, preoperative 
number of quadrants with split fixation, and postoperative choroidal effusion with eventual 
resolution. They concluded that transient vision loss after trabeculectomy is common and may take 
up to 2 years for recovery. 
 In a recent study, Malone et al.[1055] reported that visual acuity improved in every eye after 
a combined Fluocinolone Acetonide Intravitreal Insertion and Glaucoma Drainage Device Placement 
for chronic uveitic glaucoma. They attributed improved visual acuity to excellent postoperative 
inflammation control, cataract extraction in eyes with pre-existing cataract, and decreased macular 
oedema in eyes with pre-existing macular thickening. In this study, we found a slight, but statistically 
significant improvement in visual acuity post glaucoma surgery. Fifty percent of eyes which 
underwent glaucoma surgery in our cohort had also cataract surgery. When comparing visual 
outcome in eyes which underwent glaucoma surgery only with those that underwent cataract and 
glaucoma surgery, we did not find any statistically significant difference. The mechanism behind 
visual improvement post glaucoma surgery needs to be elucidated. 
 Vitrectomy has been advocated for management of complications of uveitis, including 
vitreous hemorrhage, persistent dense vitreous inflammation, persistent cystoid macular edema, 
and epiretinal membrane formation [1056-1058]. The possible efficacy of pars plana vitrectomy 
(PPV) in inflammatory macular oedema has been studied for many years[1059], but randomized 
trials are lacking, except for one: a beneficial effect on visual function and angiographic findings is 
reported in a randomized controlled pilot study compared to a slighter effect of systemic treatment 
with steroids and immunosuppressants[1060]. Theoretically, the value of PPV for inflammatory 
macular oedema might be even better than in macular oedema of other origins since many 
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inflammatory mediators accumulate in the vitreous and a removal of these mediators may have a 
good effect on macular oedema; in addition, an enhanced fibrosis of the vitreoretinal interface 
occurs often and may result in the formation of epiretinal membranes and subsequent macular 
oedema. A review of studies on vitrectomy in the treatment of uveitis shows that conclusive 
evidence for a benefit of PPV in improving visual or disease outcomes in uveitis does not exist, but 
there is suggestive evidence [1059]. The presence of an epiretinal membrane has been proven to be 
a significant factor associated with medical treatment failure [1061] and a removal of this membrane 
can help to reduce macular oedema. Gutfleisch et al.[1062] performed a PPV with ILM peeling and 
injection of 4 mg triamcinolone in 19 patients with refractory macular oedema and found in 44% of 
the eyes a decrease of macular oedema on FA, but in 22% of all eyes a worsening of visual acuity. 
Schaal et al.[1063] reported a positive effect of a surgical posterior vitreous detachment on retinal 
thickness and visual acuity. In this sudy refractory macular oedema was not an indication for 
vitrectomy. Epiretinal membranes (ERM) have been removed by pars plana vitrectomy for decades 
[396, 397, 1064, 1065] but visual outcomes vary considerably. Membrane peeling has resulted in a 
favorable outcome in the management of idiopathic epiretinal membranes,[396, 1066, 1067] but 
epiretinal membranes associated with chronic uveitis reportedly have a poorer visual prognosis after 
vitrectomy[396]. Michels et al.[1067] reported postoperative visual acuities ranging from 6/7.5 to 
6/12 in 28% of eyes, from 6/15 to 6/30 in 52% of eyes, and from 6/60 or worse in 20% of operated 
eyes. In a series by Kiryu et al.[1068], 82% of eyes gained two or more lines of visual acuity within 12 
months after vitreous surgery, but after 24 months of mean follow-up, only 45% retained at least 
two lines of visual improvement. Ghazi-Nouri et al[1069] found that visual acuity improvement post 
epiretinal membrane peel was not statistically significant. Our data confirm the poor visual prognosis 
post membrane peel and the strong correlation between postop and preop visual acuities as 
reported in previous studies [397, 1070, 1071]. We found that only 3% of eyes that underwent 
membrane peel gained 3 Snellen lines or more, while 12% had lost 3 Snellen lines or more at the 
final postop follow-up visit (Fig.4.2.4.2). Suh et al.[1072] demonstrated that once photoreceptor cells 
have been impaired attributable to macular traction by ERM, they hardly recover with time after 
surgery. In their series, only 5 of 22 eyes with preoperative photoreceptor disruption showed 
recovery at 3 months after surgery, and only 2 eyes at 6 months, suggesting that prompt surgery is 
beneficial to prevent irreversible photoreceptor impairment. On the other hand, they found a 
relatively large number of eyes (12eyes)  with newly developed photoreceptor disruption after 
surgery, and this was confirmed in 8 eyes by Cirrus HD OCT, while only 5 eyes showed photoreceptor 
recovery. This finding suggests that surgery can lead to the new development of photoreceptor 
disruption. Shimada et al.[1073] recently suggested that the central retinal thickness (CRT) to 
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amplitude macular ERG (amERG) ratio could be used in predicting the post-operative visual function 
along with the pre-VA and the duration of symptoms in eyes with ERM. 
 
6.9 Ischemia. 
 Patients with ischemic retinal vasculitis characterised by a posterior uveitis and capillary 
closure on fluorescein angiography are rare but represent a major management problem [443]. Such 
patients generally do not respond well to immunosuppressive drugs, several of which have the 
potential to exacerbate disease because they are prothrombotic at high dosage (corticosteroids, 
cyclosporine). Furthermore, these patients usually present with the complications of retinal ischemia 
(i.e. poor vision resulting from macula ischemia or vitreous haemorrhage secondary to 
neovascularisation), and primary medical treatment is unlikely to reverse the situation in these 
circumstances[524]. The vasculitic and vaso-occlusive episodes in BD can cause capillary dropout 
resulting in capillary nonperfusion or macula ischemia [1074]. Macular ischemia secondary to 
occlusive parafoveal vasculitis has previously been described in cases of BD[203, 525, 1075], 
sarcoidosis and idiopathic retinal vasculitis[525]. Forooghian et al.[1076] observed macular ischemia 
in eyes with these syndromes as well as in eyes with idiopathic intermediate uveitis, idiopathic 
granulomatous panuveitis, sympathetic ophthalmia, and lupus vasculitis. Furthermore, they 
observed angiographic evidence of active occlusive parafoveal vasculitis in eyes with idiopathic 
intermediate uveitis, BD, and lupus vasculitis. In active phase of BD, drastic macular changes such as 
macular oedema or retinal ischemia could lead to the direct and persistent damage of the fovea 
[203, 1077, 1078].  
 Although all macular aspects of visual morbidity have been reported, macular ischemia has 
not been well documented[203]. Garcher et al.[1075] have reported a case of bilateral visual loss 
and macular ischemia related to BD and Bentley et al.[525] have reported macular ischemia in 12 
patients with posterior uveitis, of whom 4 were diagnosed with BD. Behçet’s disease was the 
commonest systemic disease associated with retinal ischemia in this study. Little attention has been 
paid to macular ischemia in the past; it is a rare finding in BD and there are no established criteria 
concerning its treatment in these patients[1079]. However, Yilmaz et al.[1079] reported that when 
inflammation is brought under control, macular ischemia may also improve. They suggested that 
every effort should be made to control ocular inflammation in BD. Garcher et al.[1080] reported a 
case of recovery of macular ischaemia and visual acuity with high dose corticosteroid treatment. Out 
of 16 patients who developed macular ischemia in our series, 3 had BD and 3 had SLE.   
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 Vascular occlusion in the antiphospholipid syndrome can occur in vessels of all sizes; 
histologically the lesion is one of (non-inflammatory) bland thrombosis[1081]. Antiphospholipid 
antibodies are found in approximately 30% of patients with SLE.  
The antiphospholipid syndrome may develop in 50–70% of patients with both SLE and 
antiphospholipid antibodies after 20 years of follow up[1082, 1083]. Important risk factors for a 
thrombotic event are a history of thrombosis, the presence of lupus anticoagulant antibodies, a high 
titre of IgG anticardiolipin antibodies and persistence of antiphospholipid antibodies. However, once 
a thrombotic event occurs, the risk of further thrombosis is lifelong, irrespective of the presence or 
disappearance of these antiphospholipid antibodies[1084]. Asherson et al.[1085] showed a four-fold 
increase in the prevalence of ocular vaso-occlusive disease in the presence of antiphospholipid 
antibodies. Jabs et al.[609] in their case series of patients with this form of severe retinal vaso-
occlusion described very poor visual outcomes despite the use of different regiments of 
immunosuppression. Visual acuity was worse than 6/60 in 55% cases.  
In a literature review, Au et al[1086] reported that patients developed visual loss in 80% of cases 
with visual acuity being 6/18 or worse at follow up or at presentation in 40% of these patients. A 
significant factor affecting visual outcome was the high rate of neovascularisation and/or vitreous 
haemorrhage arising from the retinal ischemic events.  
Our study is in concordance with previous reports with regards to the poor visual outcome in 
ischemia, particularly in eyes with macular ischemia (Table 5.3 and Fig.5.1). 
 Clinical manifestation of Eales’ disease is due to three basic pathological changes: 
inflammation (peripheral retinal perivasculitis); ischemic changes (peripheral retinal capillary non-
perfusion); and neovascularisation of the retina or disk, which often leads to vitreous 
haemorrhage[692]. Vision in these patients can be normal to hand movements or light perception 
only. Bilaterality is quite common (50–90% of the patients)[766, 1087]. Although the disease may 
proceed to its full-blown picture, visual prognosis in these patients is not totally hopeless[766]. 
Elliot,[1088] for example, reported that 25 of the 46 eyes he followed for an average of six years had 
a visual acuity of 6/18 or better, whereas 26% had a vision of 6/60 or worse. Atmaca et al. reported 
that 47.5% of eyes had a visual acuity of 6/12 or better  at the final examination, after a mean 
followup of 142.4 months[766]. The prognosis for visual acuity improvement is good after 
vitrectomy, because the patients tend to have relatively little coexisting structural retinal damage 
[1089]. Another study reported that the final visual acuities improved in all eyes after 
vitrectomy[1090]. Severe visual loss in Eales’ disease usually results from complications of 
neovascularisation, such as persistent vitreous haemorrhage, retinal detachment, and anterior 
segment neovascularisation with secondary glaucoma[766]. Visual outcome of Eales’ disease in our 
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cohort was favourable and in line with previous studies. We report 3 eyes out of 20 with severe 
visual loss due to neovascular glaucoma in 2 eyes and vitreous haemorrhage in 1 eye. 
 Bentley et al.[202] suggested that all patients with posterior uveitis should have a 
fluorescein angiogram before systemic treatment, when special attention should be given to the 
early venous phase to detect signs of macular ischemia. If visualisation is not sufficiently clear the 
angiogram should be repeated after or during treatment when the ocular media clears. The authors 
advised that full immunosuppression should be given to all patients at the start, but if macular 
ischemia is demonstrated and the vision fails to improve, the rationale for treatment should be 
revised. Some patients may still require high dose treatment for either their systemic disease or to 
control frequent relapses of acute uveitis, but in many the dose of these toxic drugs may be 
reduced[202].  
 A literature review suggests that treatment outcomes with immunosuppression in the case 
of retinal vaso-occlusions in SLE have been largely disappointing [613]. Although it has been shown 
that corticosteroids may result in the reduction or disappearance of lupus anticoagulant activity; and 
that immunosuppression can decrease anticardiolipin antibody titres (independent of its effect on 
disease activity in SLE), the role of immunosuppression in preventing thrombosis remains unclear 
[1091-1093].  
There are only two reports where immunosuppression and treatment of the underlying systemic 
disease resulted in some opening of previously occluded retinal vessels [613]. In only one of these 
was immunosuppression used alone. In the first case described by Pfaffenbach et al.[1094], where 
heparin was used in combination with corticosteroids, some reperfusion of previously occluded 
vessels was noted but in other areas of the retina progressive occlusions of the retinal arterioles 
were also present. Gold et al.[1095] described a patient with bilateral extensive arterial occlusions 
treated with prednisolone and azathioprine. On follow-up examination gradual disappearance of the 
area of retinal infarction and reperfusion of a previously occluded branch retinal artery were noted, 
but this was in the setting of extensive neovascularisation. Montehermoso et al[608] reported 
improvements in the ‘retinal lesions’ in all five of their patients with retinal arterial occlusion in the 
setting of SLE treated with immunosuppression and anticoagulation, although it is unclear if 
revascularisation of previously occluded vessels occurred. Only small improvements in visual acuity 
occurred in three of these patients, with visual acuity worse in two patients following treatment. 
There is one anecdotal report to show that treatment with anticoagulation, despite the tapering of 
immunosuppression, resulted in the stabilisation of the retinal vaso-occlusive disease[1096].  
However, with the exception of the case described by Pfaffenbach et al.[1094], it appears that once 
established the retinal vaso-occlusions do not resolve with anticoagulation. Therefore, treatment 
           Discussion 
 
217 
should be aimed at halting the progression of this microthrombotic disease and should include 
anticoagulation [613]. Panretinal photocoagulation and vitrectomy have been found to be useful in 
preserving vision[1097]. 
 The management of Eales’ disease depends on the stage of the disease[1098]. It includes 
non-treatment with periodic evaluation in the regressed stage of periphlebitis or fresh vitreous 
haemorrhage, treatment with oral or periocular steroid in the active perivasculitis stage, and laser 
photocogulation in case of neovascularisation of retina or optic disk, or gross capillary nonperfusion. 
Vitreous surgery is indicated in nonresolving vitreous haemorrhage (usually more than 3 months). 
Any associated retinal detachment will, however, warrant early vitreoretinal surgery[1098]. The role 
of anticoagulant hyperbaric oxygen [1099]  and anti-tubercular therapy remains controversial[1098]. 
Several studies regarding the management of Eales disease in various stages have been reported. 
Yet, in the absence of a randomised controlled clinical trial, a definite guideline is not available. 
Management options include the following: observation, medical, photocoagulation, and 
vitreoretinal surgery. A particular patient may require one or more of the above modalities of 
treatment, as quite frequently the other eye has a different stage of the disease[1098]. 
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Chapter 7  Conclusion 
 
 Uveitis is a potentially blinding condition in the active population and should be cited among 
causes of blindness. Amongst different uveitis types, Panuveitis yields the worse visual prognosis. 
The main causes of visual loss are glaucoma in AU, CMO in IU and chronic macular damage in 
panuveitis and posterior uveitis. The proportion of CMO reported in this study is lower than that 
reported by Rothova et al.[300]more than a decade ago. This illustrates the effect of different 
treatment options developed over the past decade. Causes of visual loss within the first year of 
intraocular inflammation are reversible. Hence, it is important to initiate early and aggresive 
treatment to avoid irreversible macular damage. We also report in the present study a high 
prevalence of glaucoma, especially in eyes with chronic anterior uveitis.  
Visual outcome after cataract surgery in uveitic eyes is favourable. Careful selection of cases, pre, 
peri and post cataract control of inflammation are important. Pre-op macular lesion is the main risk 
factor for visual loss post cataract surgery. Glaucoma surgery stabilizes visual acuity over time. We 
found no evidence of visual acuity improvement after membrane peel. 
Visual loss in eyes with ischemia develops within the first five years and does not worsen with time. 
It is important to identify macular ischemia; when present, patients should be spared from 
aggressive immunosuppresion as this will have no impact on vision.  
We could not determine the patients’ ethnicity in this study. This information could have helped to 
determine whether race has any influence on visual prognosis in different types of uveitis.  
Clinicians should familiarize with the SUN standardisation of criteria on reporting clinical data in 
uveitis to allow comparison with further studies. 
This study was conducted in a tertiary referral centre. There is a selection bias inherent to the 
retrospective nature of this study, and the severity of cases attending this tertiary referral centre. 
The results cannot be therefore extrapolated to the general population. Population-based studies 
are needed. 
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CAUSES  OF  VISUAL  LOSS  IN  UVEITIS/ MEH 
 
Study Number: .........................  Hospital Number: .................. 
 
DOB. 
        
       
Gender: 1=M,  2=F 
  
Ethnic origin: 1= Caucasian 
         2= Afro-carribean 
                                                        3= Asian 
                                  4= Indian 
            5= Mixed  
Systemic/ Ocular co-morbidity:  (1= YES, 0= NO) 
 
     - Diabetes:  1/ 0 
 
     - HTN   :     1/0 
 
     - Others( Specify)........................................................................... 
    ……………………………………………………. 
                                                      
Medications: ................................................................................................................................... 
                     .................................................................................................................................... 
 
Studied eye:  R L BOTH 
 
 
VA @ 1ST VISIT..............................................    /......./......./........     IOP: ...................mmHg.                                                             
 
 
VA< 6/12..1 / 0............. …………………….    /....../....../..........       IOP……….......mmHg                                    
 
    
VA @ LAST VISIT........................................./......../....../......... 
 
 
Uveitis site: Anterior/ Intermediate/Posterior         Diagnosis............................................... 
                     Panuveitis/ Scleritis                                                  
        
BCVA: .......................................................      /......../......../..........          
 
Worse VA: ..........................    /......./......./........... Cause of worse VA.................  
 
Lens:       Cataract  1 / 0  Type :…………………………                  
 
 
Fundoscopy: ............... (1=normal, 2= CMO, 3=CNVM, 4=ERM, 5= RD , 6=scar, 7= atrophy  
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               8=optic neuropathy, 9= Ischaemia)                                          
                            
 Other( specify)..................................................                                         
 
OCT:  ..................  (1=normal, 2=CMO, 3=CNVM, 4=ERM, 5=PED, 6=CSR)                                         
 
FFA  : ............( 1=normal, 2= CMO, 3= Closure,  4=  Leakage, )                           
. 
BScan:…………( 1= normal, 2= Sclera thickening, 3= subtenon fluid, 4= RD) 
 
Ishihara:…………( 1=normal, 2= abnormal)….. 
 
Electrophysiology:…………(1=normal, 2 abnormal)                                                                       
 
Other Investigations:……………………………………………..      
  
TREATMENT:( 1= YES, 0= NO)  
 
Steroids: 1 / 0  Topic steroids/ Systemic steroids/.........................................  
 
IMMT: 1 / 0................................................................................................... 
......................................................................................................................... 
 
OFI : 1 /  0 ................. /....../......./................... 
                        
 IVTA :   1 / 0 ……… /……/……/………. 
 
Surgery: 1 / 0        What for? ...............................................   /....../......./....... 
                                
 
VA Post: Surgery / IVTA/  ORFI/  LASER 
 
2weeks     1month   2months 3months        6months         1year              18 months     2 years 
  
 
Other( Specify)................................................................................................... 
 
 
 
COMPLICATIONS DEVELOPPED : (1= YES,  0=NO)  
 
Cataract:  1/ 0               /……/……/…… 
    
-Type: .............................................................. 
 
Raised IOP: 1/ 0           /......../......./........ 
 
-Highest IOP..................   
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-Glaucoma:  1/ 0           
 
Ischaemia : 1 / 0              
 
  -Affected area................................................      
 
RD : 1 / 0                           
 
  -Macula affected?  1 / 0      
 
CMO :  1 / 0                 Present at baseline: 1  /  0       
 
Was it adequately treated?  1 / 0.    
  
Macula ....................(1=scarring, 2= atrophy,2=ERM, 3= Hole)  ..................  
 
Other (Specify)………………...........................................................................        
 
IOP Rx  1 /  0 ................................. With what? ......................................... ......   
       
Laser:  1  /  0............................../......./......./................  
 
Further IVTA: 1 / 0............... How many: .....      
 
Further OFI:  1 /  0 ............... How many: ......                                       
 
Are the complications refractor to treatment? 1 / 0 .. ……………………(1=yes, 0=no)  
        
 
